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a  b  s  t  r  a  c  t
Attention-deﬁcit/hyperactivity  disorder  (ADHD)  is  a common  and  often  persistent neurodevelopmental
disorder.  Beyond  gene-ﬁnding,  neurobiological  parameters,  such  as  brain  structure,  connectivity,  and
function,  have  been  used  to link  genetic  variation  to  ADHD  symptomatology.  We  performed  a  systematic
review  of  brain  imaging  genetics  studies  involving  62 ADHD  candidate  genes in  childhood  and  adult
ADHD  cohorts.  Fifty-one  eligible  research  articles  described  studies  of  13  ADHD  candidate  genes.  Almost
exclusively,  single  genetic  variants  were  studied,  mostly  focussing  on  dopamine-related  genes.  While
promising  results  have  been  reported,  imaging  genetics  studies  are  thus  far hampered  by methodological
differences  in  study  design  and  analysis  methodology,  as  well  as limited  sample  sizes.  Beyond  reviewing
imaging  genetics  studies,  we  also discuss  the  need  for complementary  approaches  at  multiple  levels  of
biological  complexity  and  emphasize  the  importance  of  combining  and  integrating  ﬁndings  across  levels
for a  better  understanding  of  biological  pathways  from  gene  to  disease.  These  may  include  multi-modal
imaging  genetics  studies,  bioinformatic  analyses,  and  functional  analyses  of  cell  and  animal  models.
© 2017  The  Authors.  Published  by  Elsevier  Ltd.  This  is  an  open  access  article  under the  CC  BY license
(http://creativecommons.org/licenses/by/4.0/).
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1. Introduction
Attention-deﬁcit/hyperactivity disorder (ADHD) is a common
neurodevelopmental disorder (Faraone et al., 2015). The world-
wide prevalence has been estimated at 5% in children and between
2.5 and 4.9% in adults (Polanczyk and Rohde, 2007; Simon et al.,
2009). Approximately 55–75% still carry the diagnosis in adult-
hood or remit only partially displaying several impairments also
in adulthood (Faraone et al., 2006). ADHD is characterized by
age-inappropriate levels of inattention and/or hyperactivity and
impulsivity (Frances, 2000), but the clinical phenotype is hetero-
geneous (Frances, 2000; American Psychiatric Association, 2013).
Severity level and presentation of ADHD can change during a
person’s lifetime, with adult patients displaying less obvious symp-
toms of hyperactivity and impulsivity (Buitelaar et al., 2011; Haavik
et al., 2010). The phenotypic heterogeneity of the disorder is appar-
ent from a large diversity of psychiatric co-morbidities, frequently
seen both in children (Biederman and Faraone, 2005; Gillberg et al.,
2004; Lycett et al., 2015; Rappley, 2005; Reinhardt and Reinhardt,
2013) and in adults (Mcgough et al., 2005; Miller et al., 2007;
Ollendick et al., 2008; Sobanski et al., 2007; Wilens et al., 2009).
1.1. Identiﬁcation of ADHD candidate genes
The etiology of ADHD is strongly inﬂuenced by genetic factors,
as demonstrated by twin and adoption studies (Faraone and Mick,
2010; Kotte et al., 2013; Thapar et al., 2013; Burt, 2009). Heritabil-
ity estimates range between 70 and 90% (Faraone and Mick, 2010;
Larsson et al., 2013b). Despite this substantial heritability, iden-
tiﬁcation of ADHD risk genes has been challenging (Franke et al.,
2009; Gizer et al., 2009). One reason for this may  be that ADHD
has a complex, polygenic genetic background, in which multiple
genetic variants (many of them with small effects) contribute to
the etiology of the disorder in most patients. Although a substan-
tial fraction of ADHD etiology is due to genes, many environmental
risk factors and potential gene-environment interactions are also
linked with an increased risk for the disorder (Banerjee et al., 2007;
Han et al., 2015). Furthermore, it has been shown that persistent
ADHD and its paediatric form are genetically linked, but overlap
only partially (Chang et al., 2013).
Multiple molecular genetic studies, employing mostly
hypothesis-driven and some hypothesis-free approaches, have
been used to identify ADHD risk genes. Because of the high preva-
lence of ADHD in the population, the search for genetic factors has
mainly focused on common genetic variants, which generally have
small effect sizes (Li et al., 2014; Neale et al., 2010b).
While many of the individual hypothesis-driven, candidate
gene-based association studies have been underpowered, meta-
analysis of those studies identiﬁed signiﬁcant associations for
common genetic variants in several candidate genes (Gizer et al.,
2009; Faraone et al., 2005; Li et al., 2006a). Those are the
dopamine and serotonin transporter encoding genes, SLC6A3/DAT1
and SLC6A4/5HTT, genes coding for the D4 and D5 dopamine recep-
tors, DRD4 and DRD5, a serotonin receptor, HTR1B,  and the gene for
the synaptosomal-associated protein 25, SNAP25. Some additional
genes (encoding dopamine beta-hydroxylase [DBH], adrenocep-
tor alpha 2A [ADRA2A], tryptophan hydroxylase 2 [TPH2], and
monoamine oxidase A [MAOA]) were found suggestively associated
with ADHD in meta-analyses (Gizer et al., 2009; Li et al., 2006a;
Faraone et al., 2005). In addition, an in depth analysis of 51 genes in
a European multisite sample of 674 families with ADHD combined
type probands, collected for the International Multisite ADHD Gene
project (the IMAGE project), identiﬁed associations with ADHD
candidate genes, such as ADRAB2, DAT1, DRD4, TPH2, and MAOA
(Brookes et al., 2006). For more extensive reviews of ADHD candi-
date genes see references (Li et al., 2014; Faraone and Mick, 2010;
Banaschewski et al., 2010; Franke et al., 2012; Hawi et al., 2015).
Genetic linkage studies provided a ﬁrst possibility to per-
form hypothesis-free genetic studies in the early 2000s. However,
gene identiﬁcation through linkage analysis has been limited
(Banaschewski et al., 2010). A meta-analysis of seven linkage
studies revealed a locus on the short arm of chromosome 16 to
be relevant for ADHD etiology (Zhou et al., 2008). An interest-
ing candidate gene in the locus is cadherin 13 (CDH13), a gene
also found in the top-ranks of several genome-wide association
studies (Rivero et al., 2015). Linkage analysis also identiﬁed the lat-
rophilin 3 (LPHN3) gene on chromosome 4, which was  subsequently
conﬁrmed through association testing (Arcos-Burgos et al., 2010;
Ribases et al., 2011). Genome-wide association studies (GWAS) of
common single nucleotide polymorphisms (SNPs) have been the
main hypothesis-free approach to studying the genetics of ADHD
during the last ten years. However, with nine GWASs on ADHD and
ADHD-symptoms published to date (Hinney et al., 2011; Lasky-
Su et al., 2008; Lesch et al., 2008; Mick et al., 2010; Neale et al.,
2008; Neale et al., 2010a; Stergiakouli et al., 2012; Yang et al., 2013;
Sanchez-Mora et al., 2014), no locus has yet been identiﬁed that
meets genome-wide levels of signiﬁcance (Li et al., 2014; Neale
et al., 2010b), nor has meta-analysis of these studies provided one
(van Hulzen et al., 2016). An interesting genome-wide approach
to identify ADHD genes has been the analysis of overlap with other
psychiatric disorders. A cross-disorder GWAS across ﬁve main neu-
ropsychiatric disorders (schizophrenia [SCZ], bipolar disorder [BD],
autism spectrum disorder [ASD], major depressive disorder [MDD],
and ADHD) identiﬁed ﬁve genome-wide signiﬁcant ﬁndings, four
of which – in/near the genes ITIH3, AS3MT,  CACNA1C,  and CACNB2 –
were shared with ADHD (Cross-Disorder Group of The Psychiatric
Genomics Consortium, 2013).
Following promising results in other psychiatric disorders
(Purcell et al., 2014; Cukier et al., 2014; Cruceanu et al., 2013;
Kerner et al., 2013), studies of rare variants were also performed
for ADHD and were successful in identifying genetic variants
related to the disorder (Elia et al., 2010; Williams et al., 2010;
2012; Ramos-Quiroga et al., 2014; Lesch et al., 2011; Yang et al.,
2013). Genome-wide analysis of (rare) copy number variants
(CNVs) showed an enrichment of rare CNVs in patients with ADHD
(Williams et al., 2010), and implicated the genes CHRNA7 and NPY
in ADHD etiology (Williams et al., 2012; Lesch et al., 2011), as
well as genes encoding several glutamate receptors (Akutagava-
Martins et al., 2014; Elia et al., 2012), and regions on 15q11-15q13
(Valbonesi et al., 2015) and 16p13.11 (Williams et al., 2010). The
picture emerging from those initial studies is that the rare vari-
ant contribution of ADHD genetics is highly heterogeneous, similar
to the common variant contribution. Nevertheless, given the suc-
cess of CNV studies, exome and whole-genome sequencing are now
being used, allowing the identiﬁcation of rare single nucleotide
variants and small insertions/deletions contributing to ADHD eti-
ology. A ﬁrst study indeed found enrichment of rare variants in a
predeﬁned set of 51 candidate genes in adult patients with persis-
tent ADHD (Demontis et al., 2016).
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The genetic factors associated with ADHD are distributed across
the genome, but tend to be enriched within speciﬁc functional
categories. By clustering ADHD-related genes within functional
networks or pathways, several biological processes have been
shown to be involved in the etiology of the disorder. Top-ﬁndings of
ﬁve GWASs in ADHD showed convergence on the biological process
of neurite outgrowth (Poelmans et al., 2011). Comparable enrich-
ment analyses revealed that most signiﬁcantly enriched functions
for the ADHD-GWAS association signals were related to nervous
system development, neuron projection morphogenesis, oxoge-
nesis, cell–cell communication, glutamatergic synapse/receptor
signalling, and multicellular organismal development (Hawi et al.,
2015) or neuron projections and synaptic components (Yang et al.,
2013), which is consistent with a neurodevelopmental pathophys-
iology of ADHD. These ﬁndings were strengthened by results from
a recent study, that used two GWAS datasets to identify pathways
associated with ADHD by applying six pathway analysis methods
(Mooney et al., 2016). Cross-method convergent results revealed
a number of brain-relevant pathways, such as RhoA signaling,
glycosaminoglycan biosynthesis, ﬁbroblast growth factor recep-
tor activity, and pathways containing potassium channel genes
(Mooney et al., 2016). Another study revealed that CNVs involved
in ADHD converge on biologically meaningful gene clusters related
to ion channel pathways, organonitrogen compound catabolic pro-
cesses, and transmembrane transport (Thapar et al., 2015). A
combined analysis of ADHD candidate genes, derived both from
SNP-based and CNV-based studies, showed that genes involved in
biological processes, such as synaptic transmission, catecholamine
metabolic processes, G-protein signalling pathways, and cell migra-
tion were over-represented among the top-ﬁndings of such studies
(Cristino et al., 2014). More generally, the genome-wide analysis of
ﬁve major psychiatric disorders (also including ADHD), supported
a role for calcium channel signalling genes for all ﬁve disorders,
suggesting that genetic variation in calcium-channel activity genes
can have pleiotropic effects in the development of psychopathology
(Cross-Disorder Group of The Psychiatric Genomics Consortium,
2013).
1.2. Brain correlates of ADHD
The effects of ADHD genetic risk factors on (aberrant) behaviour
are likely to be mediated through effects on cell biology and
brain system development and functioning. Several aspects of
brain development, structure, function, and connectivity have been
found altered in ADHD (Cortese et al., 2012; Greven et al., 2015;
Shaw et al., 2007b; Shaw et al., 2012; van Ewijk et al., 2012; Glahn
et al., 2010; Onnink et al., 2015; Mostert et al., 2016; Hoogman et al.,
epub head of print).
Two indirect neuroimaging techniques that have been used in
imaging (genetics) studies in ADHD are positron emission tomog-
raphy (PET) and single photon emission computed tomography
(SPECT). Both are based on the measurement of a radionuclide’s
decay, during which a positron or a -ray is emitted, generat-
ing photons. The high sensitivity and limitless penetration depth
of PET and SPECT enable imaging to examine metabolic activ-
ity, cerebral perfusion, neurotransmitter turnover, and receptor
binding potentials within examined brain regions or receptor sys-
tems (Rahmim and Zaidi, 2008). Until now, the majority of recent
PET studies using ADHD samples have focused on examining dif-
ferences and changes in neurotransmitter binding and receptor
density (Zimmer, 2009). In vivo imaging of the dopamine trans-
porter (DAT) is particularly relevant for ADHD, given that DAT
is the target of stimulant medications and, subsequently, a tar-
get protein for studies of pathophysiology. PET and SPECT studies
have been useful in comparing striatal DAT availability between
ADHD patients and controls (Jucaite et al., 2005; Spencer et al.,
2005; Ludolph et al., 2008). A meta-analysis of nine PET stud-
ies revealed that striatal DAT density was 14% higher in patients
with ADHD compared to healthy controls (Fusar-Poli et al., 2012).
Besides that, striatal density in people with ADHD seems to depend
on previous psychostimulant exposure, with lower density in drug-
naive subjects and higher density in previously medicated patients
(Fusar-Poli et al., 2012). In addition to studies exploring DAT den-
sity and binding, Volkow and co-workers examined postsynaptic
dopamine receptor availability and found that medication-naïve
adults with ADHD showed decreased dopamine D2/D3 recep-
tor availability in the left caudate compared to healthy controls.
Following administration of methylphenidate (MPH), the ADHD
group demonstrated decreased dopamine activity in the caudate
compared with controls (Volkow et al., 2007). One SPECT study
investigated D2 receptor availability as a function of MPH  therapy
in ADHD and concluded that D2 receptor availability is signiﬁcantly
reduced in patients with ADHD in all four regions of the striatum
(Ilgin et al., 2001).
Structural magnetic resonance imaging (sMRI) allows to nonin-
vasively characterize the structure of the human brain. With the
help of sMRI, the different magnetic properties of brain tissues are
used to non-invasively map  the spatial distribution of these struc-
tural properties of the human brain. Thereby, the different brain
tissues (grey and white matter) and cortical and subcortical struc-
tures of the brain can be accurately mapped, and different aspects
of brain structure can be quantiﬁed and compared. In general, sMRI
has pointed to total brain volume and total grey matter reductions
up to 3–5% in ADHD patients compared to controls (Castellanos
et al., 2002; Valera et al., 2007; Greven et al., 2015). To inves-
tigate, whether these reductions are global or regional, several
brain regions of interest (ROIs) have been studied. A meta-analysis
reported signiﬁcant volume differences in cerebellar regions, total
and right cerebral volume, right caudate, and frontal brain areas
(Valera et al., 2007). To investigate the most prominent changes in
grey matter intensity, detected by using voxel-based morphom-
etry (VBM) analyses, four meta-analyses have been performed
to date (Ellison-Wright et al., 2008; Frodl and Skokauskas, 2012;
Nakao et al., 2011). Most consistently, grey matter reductions in
the ventrolateral prefrontal/insular-striatal regions, such as the
right insula, putamen, globus pallidus, and caudate nucleus have
been described in ADHD patients (Ellison-Wright et al., 2008; Frodl
and Skokauskas, 2012; Nakao et al., 2011; Norman et al., 2016).
A recent study could also show that participants with ADHD had
signiﬁcantly smaller grey matter volume in ﬁve clusters located
in the precentral gyrus, medial and orbital frontal cortex, and
(para)cingulate cortices (Bralten et al., 2015). Unaffected siblings
of patients with ADHD showed intermediate volumes, signiﬁcantly
different from controls in four of these ﬁve clusters (all except
the precentral gyrus), suggesting that the volume reductions are
unlikely to be a consequence of disease, but may rather contribute
to ADHD etiology (Bralten et al., 2015).
Brain differences observed in ADHD have been hypothesized
to be partly attributable to a delay in maturational processes
(Castellanos et al., 2002). Indeed, the few longitudinal imaging
studies of ADHD patients support this hypothesis: for CT measures,
Shaw and co-workers investigated growth trajectories of different
points of the cortex and reported that cortical thickness maturation
in participants with ADHD lagged behind that of healthy controls
of approximately three years throughout the cerebrum, but most
prominent in the PFC (Shaw et al., 2007a). In addition, also the
SA developmental trajectory was found to be delayed in ADHD,
especially in the right PFC (Shaw et al., 2012). Support for the devel-
opmental delay hypothesis in ADHD also came from cross-sectional
meta-analyses of VBM studies, which found increasing age associ-
ated with more normal grey matter values in affected brain areas
(Frodl and Skokauskas, 2012). The recent large mega-analysis of
118 M. Klein et al. / Neuroscience and Biobehavioral Reviews 80 (2017) 115–155
subcortical regions across 60 years of the lifespan by the Enhancing
NeuroImaging Genetics Through Meta Analysis (ENIGMA) ADHD
Working Group extended the delayed maturation theory also to the
volumes of most subcortical regions (Hoogman et al., epub head of
print). First of all, they observed signiﬁcant smaller volumes for the
nucleus accumbens, amygdala, caudate, hippocampus, putamen,
and intracranial volume (ICV) in ADHD cases relative to controls
(Hoogman et al., epub head of print). Age analyses suggested differ-
ent brain volume trajectories across age for patients and controls.
These results from the cross-sectional lifespan analyses were con-
sistent with the early maturation delay hypotheses of ADHD and
hint at delays in brain growth and degeneration across the lifespan
(Hoogman et al., epub head of print; Rubia, 2007).
Next to volumetric differences observed in grey matter, white
matter structure has also been found to be altered in ADHD, leading
to a potential disorganization of the brain’s connectivity. Diffu-
sion tensor imaging (DTI) enables non-invasive investigations of
the macrostructural integrity and orientation of white matter ﬁbre
bundles. DTI measures the directional diffusion of water molecules
along neuronal membranes, allowing to map  white matter path-
ways within the brain. One measure frequently derived from DTI
is fractional anisotropy (FA). Anisotropy indicates that diffusion
occurs in a directional manner, whereas isotropy indicates diffusion
in all directions. Other measures derived from DTI include mean
diffusivity (MD), which is an average of axial diffusivity (AD) and
the perpendicular diffusivities, and radial diffusivity (RD), which is
the average of perpendicular diffusivities, the mode of anisotropy,
which is sensitive to crossing ﬁbres, and the apparent diffusion
coefﬁcient, which indicates the magnitude of diffusion (Le Bihan,
2003; Le Bihan et al., 2001; Yoncheva et al., 2016). In a meta-
analysis, comparing DTI ﬁndings between patients with ADHD and
healthy controls, ﬁve areas with disturbed microstructural integrity
in people with ADHD were highlighted, located in white matter
tracts subserving the fronto-striatal-cerebellar neurocircuitry (van
Ewijk et al., 2012). Most consistently, studies reported white mat-
ter anomalies in the corpus callosum in childhood ADHD (van Ewijk
et al., 2014) and adult ADHD (Dramsdahl et al., 2012; Onnink et al.,
2015). Although the exact neurobiological meaning is not fully
understood, reduced FA in the corpus callosum of adult patients
with ADHD was driven by changes in RD rather than AD, suggest-
ing that aberrant myelination is a pathophysiological factor in adult
ADHD (Onnink et al., 2015). However, replication from longitudi-
nal studies is still lacking, and the differences between patients and
controls seem to be widespread and heterogeneous across studies
(van Ewijk et al., 2012).
A method to investigate potential changes in brain activity
is functional magnetic resonance imaging (fMRI). FMRI is pri-
marily sensitive to the oxygenation of the blood, the so-called
blood-oxygen-level-dependent (BOLD) signal. It measures brain
function based on the premise that active cells consume oxygen,
thereby causing changes in blood oxygenation and subsequently
leading to increased blood ﬂow, although the exact link between
cell activation, oxygen saturation, and blood ﬂow is still under
debate; for review see (Hillman, 2014). Generally in fMRI, alter-
ations in blood ﬂow after a stimulus (e.g. a certain task) or during
a resting state are measured. Comparing anatomical or functional
brain measures in individuals with ADHD, their unaffected sib-
lings, and healthy comparison subjects, is one of the best ways
to examine the suitability of these neural markers as endopheno-
types. With respect to functional brain studies, van Rooij et al.,
(2015c) recently reported a distinction in hemodynamic patters
during a stop-signal task between patients with ADHD, their
unaffected siblings, and control subjects, suggesting the familial
nature of these activation patterns. Thus, inhibition-related neu-
ral activation could be considered as a valuable endophenotype
for ADHD. Several reviews have provided excellent overviews of
cognitive and brain (candidate) endophenotypes for ADHD (del
Campo et al., 2012; Gallo and Posner, 2016; Rommelse et al.,
2011). In accordance with those reports, dysregulation of struc-
ture and function of the fronto-subcortical-cerebellar pathways
that control attention, response to reward, salience thresholds,
inhibitory control, and motor behaviour are among the most
promising endophenotype candidates, and task-based functional
MRI  studies in ADHD have largely focused on these neurocognitive
domains. More speciﬁcally, fMRI studies using inhibitory control,
working memory, and attentional tasks in patients with ADHD
and healthy comparison subjects have shown underactivation of
fronto-striatal, fronto-parietal, and ventral attention networks in
the patients (Cortese et al., 2012). The fronto-parietal network
mediates goal-directed executive processes, whereas the ventral
attention network facilitates reorientation of attention towards
salient and behaviourally relevant external stimuli. Meta-analyses
of fMRI studies of inhibition and attention revealed that patients
with ADHD have consistent functional abnormalities in two  distinct
domain-dissociated fronto-basal ganglia networks. These include
the inferior frontal cortex, supplementary motor areas, and anterior
cingulate cortex (ACC) for inhibition and the dorsolateral prefrontal
cortex (PFC), parietal, and cerebellar areas for attention processes
(Hart et al., 2013). Studies using reward-processing paradigms
reported reduced activation of the ventral striatum of participants
with ADHD in the anticipation phase of reward relative to controls
(Plichta and Scheres, 2014), and differences between patients and
controls have also been observed during reward receipt (von Rhein
et al., 2015). Additionally, a meta-analysis of fMRI studies of timing
reported consistent reductions in activation in typical areas of tim-
ing, such as the left inferior frontal gyrus (IFG)/insula, cerebellum,
and the left parietal lobe in ADHD patients relative to controls (Hart
et al., 2012).
In resting state MRI  (rs-fMRI), the temporal correlations in neu-
ral activity across anatomically disparate brain regions are analysed
to examine functional connectivity based on spontaneous brain
activity, neural organization, and circuit architecture. Rs-fMRI stud-
ies of ADHD have mainly focused on neural circuits implicated
in the disorder, especially the default-mode network (DMN), cog-
nitive control network, and cortico-striato-thalamo-cortical loops
(Posner et al., 2014). It was shown that ADHD is associated with
less-pronounced or absent anti-correlations between the DMN  and
the cognitive control network, lower connectivity within the DMN
itself, and lower connectivity within the cognitive and motivational
loops of fronto-striatal circuits (Posner et al., 2014). A recent study
in a large sample of adult participants with ADHD and healthy con-
trols, showed that functional connectivity in the executive control
network, and to a lesser extent also the cerebellum network, was
stronger in the ADHD group (Mostert et al., 2016). Additionally,
hyperactivity/impulsivity symptoms were positively correlated
with the connectivity strength in these networks (Mostert et al.,
2016).
Functional near-infrared spectroscopy (fNIRS) measures con-
centration changes of oxygenated, deoxygenated, and total
haemoglobin in brain haemodynamics by measuring the absorp-
tion of near-infrared light projected through the scalp (Gervain
et al., 2011). Thereby, fNIRS provides an indirect measure of neural
activity based on changes in blood oxygenation due to metabolic
processes within the cortex. Compared to fMRI, fNIRS is less sen-
sitive to movement artefacts, and since the emitters and detectors
can be worn in a cap, functional neural activity can be studied, while
the participant is interacting with its environment. This makes
fNIRS an ideal tool to study brain development, e.g. in children
with ADHD (Vanderwert and Nelson, 2014). FNIRS has greater
spatial resolution compared to event-related potential (ERP) or
EEG techniques, however, since it is dependent on light penetra-
tion and reﬂection, fNIRS can only examine the cortical surface
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within 2–3 cm of the scalp (Vanderwert and Nelson, 2014). The
majority of fNIRS studies on ADHD investigated children with the
disorder. These studies particularly focused on alterations in PFC
activity during different experimental paradigms, such as Stroop
tasks (Negoro et al., 2010; Xiao et al., 2012), working memory
tasks (Schecklmann et al., 2010), the Trail Making Test (Weber
et al., 2005), or Go/NoGo paradigms (Xiao et al., 2012; Inoue et al.,
2012); they consistently pointed towards an attenuated oxygen
metabolism within the frontal lobe (Ehlis et al., 2014). Studies in
adult ADHD patients suggest that this hypofunctionality is per-
sistently observed throughout development (Schecklmann et al.,
2013; Ehlis et al., 2008).
The functional brain imaging techniques electroencephalogra-
phy (EEG) and magnetoencephalography (MEG) have also been
used for the study of ADHD (genetics). EEG directly measures
electrical activity from large populations of cells and therefore
offers a very good temporal resolution, far superior to fMRI. How-
ever, it has a poor spatial resolution, as electric ﬁelds smear as
they pass through the skull (Ahmad et al., 2016). Every electric
ﬁeld also has a magnetic ﬁeld, which can be detected by MEG.
The spatial resolution of MEG  is slightly better compared to EEG,
but MEG  only measures information strictly from the sulci, thus
it is more limited and misses information (van Diessen et al.,
2015). The frequency bands mostly studied in ADHD are theta (),
alpha (), and beta (), either individually, or compared to each
other (such as theta/beta power or amplitude ratio). In a resting
state, (lower frequency)  band activity can reﬂect drowsiness or
“cortical slowing”. The  band activity is usually observed dur-
ing eyes closed conditions at rest, particularly in posterior brain
regions, and it is negatively associated with central nervous sys-
tem arousal. In contrast,  band activity generally accompanies
mental activity and concentration. The / power ratio has been
proposed to capture the relative contributions of two relevant
frequency bands for ADHD; however, the true functional signiﬁ-
cance of this measure remains unknown (Loo and Makeig, 2012).
It has been reported that patients with ADHD exhibit increased
fronto-central theta () band activity and increased theta-to-beta
(/) power ratio during rest compared to non-ADHD controls (Loo
and Makeig, 2012). While (limited) discriminant validity of these
EEG measures for ADHD has been suggested, signiﬁcant EEG het-
erogeneity also exists across ADHD-diagnosed individuals (Clarke
et al., 2011). In addition to differences in frequency bands, event-
related potential (ERP) studies explored various aspects of brain
functioning in ADHD and identiﬁed a substantial number of ERP
correlates of ADHD (Johnstone et al., 2013). Robust differences
between ADHD patients and healthy controls have been reported in
several components related to attention (among others including
orienting and vigilance), inhibitory control, and performance mon-
itoring, such as error and reward/punishment processes (Johnstone
et al., 2013). MEG  studies comparing ADHD patients to healthy
controls are scarce and have been geared towards investigating
attention-related processes. Alterations in oscillation patterns of
brain regions involved in such processes have been observed in
patients (ter Huurne et al., 2013; Franzen et al., 2013; Heinrichs-
Graham et al., 2014).
Importantly, the brain phenotypes found affected in people with
ADHD are often moderately to highly heritable. Findings from twin
studies showed that brain structure is under strong genetic con-
trol. Additionally, twin studies showed that genetic effects varied
regionally within the brain, with high heritability estimates (h2)
for frontal lobe volumes ranging from 0.9 to 0.95, for region-based
cortical surface areas ranging from 0.48 to 0.77, and moderate esti-
mates for e.g. the hippocampus (h2-range = 0.4–0.69) (Peper et al.,
2007). Surface area was predominantly more heritable than cortical
thickness (h2-range = 0.34–0.64) (Mckay et al., 2014). Global frac-
tional anisotropy (h2 = 0.55) as well as radial diffusivity (h2 = 0.72)
of white matter showed high heritability (Kochunov et al., 2015;
Mckay et al., 2014). Moreover, basal neural activity during a rest-
ing state condition has also been shown to be under genetic control,
as functional connectivity within the default-mode network as a
whole was  signiﬁcantly heritable (h2 = 0.42) (Glahn et al., 2010).
Additional examples for moderate heritabilities of neural activity
are e.g. brain activation in the cerebellum and cerebral cortex dur-
ing working memory tasks (h2-range = 0.5–0.65) (Blokland et al.,
2014). Strong genetic determination has also been reported for dif-
ferent psychophysiological brain phenotypes measured by EEG, e.g.
(Iacono et al., 2014; Smit et al., 2010), and MEG, where different fre-
quency band heritabilities have been described by van Pelt et al.,
2012.
1.3. Rationale for this review
This review aims to provide a systematic overview of brain
imaging genetics studies in ADHD, as brain imaging phenotypes are
frequently used as endophenotypes in ADHD research. Endophe-
notypes (or intermediate phenotypes) have been considered a
promising strategy in order to gain more insight into the mech-
anisms leading from a genetic/biological basis of the disease to the
full clinical phenotype (Faraone et al., 2014a). Endophenotypes are
(1) those characteristics of a disorder that are linked more closely
to its neurobiological substrates than its clinical symptoms (Doyle
et al., 2005) and (2) share genetic susceptibility factors with the
disorder itself (Gottesman and Gould, 2003). As described above,
neuroimaging phenotypes, e.g. derived from sMRI (Hulshoff Pol
et al., 2006) and DTI measurements (Jahanshad et al., 2013) are
highly heritable. Those brain phenotypes altered in ADHD have
therefore been considered key endophenotypes for the disorder,
and investigating the genetic inﬂuences on these brain measures
has been offered as a way for capturing underlying liability for
ADHD (Dresler et al., 2014; Durston, 2010; Wu  et al., 2014). Com-
pared to existing reviews of brain imaging genetics studies in ADHD
(Durston, 2003, 2010; Durston et al., 2009; Wu et al., 2014; Dresler
et al., 2014), this review is more comprehensive by including both
childhood and adult ADHD studies, a large spectrum of brain imag-
ing modalities, and by investigating a more complete list of ADHD
candidate genes. Beyond the systematic review, we also empha-
size the need for additional approaches, describing complementary
methods, which provide insight from alternative angles into the
biological pathways leading from an ADHD risk gene to disease.
Especially, we argue that the integration of methods at different
analytical levels (e.g. in silico, cell, brain, cognition, and behaviour)
is needed to unravel the function of ADHD candidate genes.
2. Methods
For this review, we  selected genes that were previously found
associated with ADHD. The selection was  based on a recent review
of ADHD candidate genes, which described 70 genes that are (with
at least some evidence) related to ADHD risk (Li et al., 2014), see
Table 1. We  discarded eight genes, for which we did not ﬁnd evi-
dence for association with ADHD based on the analysis of genetic
variation: ARVCF,  ATP2C2, CPLX4,  DNM1,  EMP2, IL20RA,  MMP7,  and
TRIO (Table 1). On November 28th 2016, we searched for all remain-
ing 62 genes, all brain imaging modalities, and ADHD using PubMed
(www.ncbi.nlm.nih.gov/pubmed) with the following search algo-
rithm (example is shown for the SLC6A3/DAT1 gene): (((SLC6A3
OR solute carrier family 6 neurotransmitter transporter, mem-
ber 3 protein human OR DAT1 OR dopamine transporter gene
OR dopamine transporter [All ﬁelds])) AND (gene* OR genetic*
OR imaging genetic OR imaging genetics OR genotype OR poly-
morphism OR SNP OR single nucleotide polymorphism)) AND
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Table 1
Candidate genes containing common variants associated with ADHD, adapted from (Li et al., 2014), which served to select genes for this review.
Gene Protein Chr position References for genes associated
with ADHD
ADRA1B Adrenoceptor alpha1B 5q33.3 Segurado et al. (2011)a, Hawi et al.
(2013b)a
ADRA2A* Adrenoceptor alpha 2A 10q25.2 Roman et al. (2003)a, Shiffrin et al.
(2013)b
ADRA2C Adrenoceptor alpha 2C 4p16.3 De Luca et al. (2004)a, Cho et al.
(2008)
ADRB1 Adrenoceptor beta 1 10q25.3 Pascoli et al. (2005)d
ADRB2 Adrenoceptor beta 2, surface 5q31-q32 Lasky-Su et al., (2008a)a,c,  Brookes
et  al. (2006a)
ASTN2 Astrotactin2 9q33 Lesch et al. (2008)a, Lionel et al.
(2011, 2014)
BCHE Butyrylcholinesterase 3q26.1-q26.2 Lesch et al. (2011)a, Jacob et al.
(2013)
BDNF Brain-derived neurotrophic factor 11p14.1 Friedel et al. (2005)a, Lee and Song
(2015)b
CALY Calcyon neuron-speciﬁc vesicular
protein
10q26.3 Plaisancie et al. (2014)a
CCSER1/FAM190A Coiled-coil serine-rich protein 1 4q22.1 Lantieri et al. (2010)a,c
CDH13 Cadherin 13 16q23.3 Lesch et al. (2008)a, Neale et al.
(2010a)c
CHRNA3 Cholinergic Receptor, Nicotinic,
Alpha 3
15q25.1 Polina et al. (2014)a
CHRNA4 Cholinergic Receptor, Nicotinic,
Alpha 4
20q13.33 Guan et al. (2009)a, Wallis et al.
(2009)
CHRNA7 Cholinergic Receptor, Nicotinic,
Alpha 7
5q13.3 spanning
CHRNA7
Williams et al. (2012)a
CNTF Ciliary neurotrophic factor 11q12 Ribases et al. (2008)a, Tzang et al.
(2014)
COMT* Catechol-O-methyltransferase 22q11.21 Eisenberg et al. (1999)a, Lee and
Song (2015)
CPLX2 Complexin 2 5q35.2 Lionel et al. (2011)a
DBH Dopamine beta-hydroxylase
(dopamine beta-mono oxygenase)
9q34 Daly et al. (1999)a, Gizer et al.
(2009)b
DDC Dopa decarboxylase
(aromaticamino acid
decarboxylase)
7p12.1 Ribases et al. (2009)a, Lasky-Su
et al. (2008b)c
DIRAS2 DIRAS family, GTP-binding
RAS-like 2
9q22.32 Reif et al. (2011)a
DRD1* Dopamine receptor D1 5q34-q35 Misener et al. (2004)a, Ribases et al.
(2012)
DRD2/ANNK1 Dopamine receptor D2/Ankyrin
repeat and kinase domain
containing 1
11q22-q23 Comings et al. (1991)a, Pan et al.
(2015)b
DRD3 Dopamine receptor D3 3q13.3 Guan et al. (2009)a, Wu et al.
(2012)b
DRD4* Dopamine receptor D4 11p15 Lahoste et al. (1996)a, Gizer et al.
(2009)b, Wu et al. (2012)b
11p15 Barr et al. (2001)a, Yang et al.
(2008)d, Gizer et al. (2009)b
DRD5 Dopamine receptor D5 4p16.1 Daly et al. (1999)a, Gizer et al.
(2009)b, Wu et al. (2012)b
FADS2 Fatty acid desaturase 2 11q12.2 Brookes et al. (2006b)a
FTO Fat mass and obesity associated 16q12.2 Choudhry et al. (2013)a
GDNF Glial cell derived neurotrophic
factor
5p13.1-p12 Simchon-Tenenbaum et al.
(2015)d, Shim et al. (2015)
GPRC5B G protein-coupled receptor, class
C, group 5, member B
16p12 Albayrak et al. (2013)a
GRIN2A Glutamate receptor, ionotropic,
N-methyl D-aspartate 2A
16p13.2 Turic et al. (2004)a
GRM5 Glutamate receptor, metabotropic
5
11q14.3 Elia et al. (2010)a,  Hinney et al.
(2011)c, Elia et al. (2012)
GRM7 Glutamate receptor, metabotropic
7
3p26-p25 Mick et al. (2008)a,c, Elia et al.
(2012), Park et al. (2014)
HES1 Hes family bHLH transcription
factor 1
3q28-q29 Brookes et al. (2006a)a, Lasky-Su
et al. (2008b)c
HTR1A 5-Hydroxytryptamine (serotonin)
receptor 1A, G protein-coupled
5q11.2-q13 Shim et al. (2010)a,  Zuo et al.
(2015)d
HTR1B 5-Hydroxytryptamine (serotonin)
receptor 1B, G protein-coupled
6q13 Hawi et al. (2002)a, Gizer et al.
(2009)b
HTR1E 5-Hydroxytryptamine (serotonin)
receptor 1E, G protein-coupled
6q14-q15 Lasky-Su et al. (2008b)a,c
HTR2A 5-Hydroxytryptamine (serotonin)
receptor 2A, G protein-coupled
13q14-q21 Quist et al. (2000)a, Lasky-Su et al.
(2008a)c, Lasky-Su et al. (2008b)c
HTR2C 5-Hydroxytryptamine (serotonin)
receptor 2C, G protein-coupled
Xq23 Li et al. (2006b)a,  Xu et al. (2009)
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with ADHD
HTR3A 5-Hydroxytryptamine (serotonin)
receptor 3A, G protein-coupled
11q23.1-q23.2 Hu et al. (2009)d
HTR3B 5-Hydroxytryptamine (serotonin)
receptor 3B, G protein-coupled
11q23.1 Oades et al. (2008)a
LPHN3* Latrophilin 3 4q13.1 Arcos-Burgos et al. (2010)a, Hwang
et al., (2015)d, Ribases et al.,
(2011)d, Labbe et al., (2012)a
MAOA* Monoamine oxidase A Xp11.4-p11.3 Payton et al. (2001)a, Liu et al.
(2011)d
MAOB Monoamine oxidase B Xp11.4-p11.3 Li et al. (2008)a, Ribases et al.
(2009)d
NOS1* Nitric oxide synthase 1 12q24.22 Reif et al. (2009)a, Franke et al.
(2009)c, Weber et al. (2015)b
PNMT Phenylethanolamine
N-methyltransferase
17q12 Brookes et al. (2006a)a
PRKG1 Protein kinase, cGMP-dependent,
type I
10q11.2 Neale et al. (2010a)a
SLC1A3 Solute Carrier Family 1 (Glial High
Afﬁnity Glutamate Transporter),
Member 3
5p13 Turic et al. (2005)a, Elia et al. (2009)
SLC6A2/NET1* Solute Carrier Family 6
(Neurotransmitter Transporter),
Member 2
16q12.2 Bobb et al. (2005)a, Hohmann et al.
(2015)
SLC6A3/DAT1* Solute Carrier Family 6
(Neurotransmitter Transporter),
Member 3; Dopamine transporter
1
5p15.3 Cook et al. (1995)a,  Gizer et al.
(2009)b
Galili-Weisstub and Segman
(2003)a,  Gizer et al. (2009)b
Brookes et al. (2006c)a, Gizer et al.
(2009)b
SLC6A4/5HTT* Solute Carrier Family 6
(Neurotransmitter Transporter),
Member 4; serotonin transporter
17q11.2 Manor et al. (2001)a, Gizer et al.
(2009)b,  Landaas et al. (2010)b
SLC9A9/NHE9 Solute Carrier Family 9, Subfamily
A, Member 9
3q24 de Silva et al. (2003)a, Stergiakouli
et al. (2012)c, Mick et al., (2010)c
SLC18A2/VMAT2 Solute Carrier Family 18 (Vesicular
Monoamine Transporter),
Member2
10q25 Toren et al. (2005)a
SNAP25* Synaptosomal-associated protein,
25 kDa
20p12-p11.2 Brophy et al. (2002)a, Gizer et al.
(2009)b
SPOCK3 Sparc/osteonectin, cwcv and
kazal-like domains proteoglycan
(testican) 3
4q32.3 Weber et al. (2014)a, Gao et al.
(2015)
STX1A Syntaxin1A 7q11.2 Sanchez-Mora et al. (2013)d
SYP Synaptophysin Xp11.23-p11.22 Brookes et al. (2006a)a, Liu et al.
(2013b)d
SYT1 Synaptotagmin I 12q21.2 Guan et al. (2009)a, Lasky-Su et al.
(2008a)c
TCERG1L Transcription elongation regulator
1-like
10q26.3 Neale et al. (2010a)a,c
TH Tyrosine hydroxylase 11p15.5 Segurado et al. (2011)a
TPH1 Tryptophan hydroxylase 1 11p15.3-p14 Gizer et al. (2009)b
TPH2* Tryptophan hydroxylase 2 12q15 Walitza et al. (2005)a,  Sheehan
et al. (2005)a, Gizer et al. (2009)b
VAMP2 Vesicle-associated membrane
protein 2 (synaptobrevin 2)
17p13.1 Gao et al. (2015)a
Bold text indicates signiﬁcant result at P < 0.05 in Gizer et al. (2009).
a Association ﬁrst reported by.
b Meta-analysis article.
c GWAS ﬁnding.
d Association in large sample or validation using animal model.
* Gene with at least one case-control imaging genetics study; ADHD = Attention-deﬁcit/hyperactivity disorder, chr = chromosome.
(structural magnetic resonance imaging OR functional magnetic
resonance imaging OR sMRI OR fMRI OR electroencephalography
OR diffusion tensor imaging OR DTI OR resting-state functional
magnetic resonance imaging OR rsfMRI OR EEG OR magnetoen-
cephalography OR MEG  OR single photon emission computed
tomography OR SPECT OR positron emission tomography OR PET
OR near-infrared spectroscopy OR NIRS OR volume [Title/Abstract])
AND (ADHD OR Attention-deﬁcit/hyperactivity disorder OR [All
ﬁelds] NOT “review” [Publication Type]). Titles and abstracts of the
retrieved records were evaluated for relevant publications. Studies
were required to investigate genetic variants in/near the selected
ADHD candidate genes, and only studies including patients with
ADHD were included. Review articles, medical hypotheses, non-
English articles, and studies on animal models were not considered.
The preferred reporting items for systematic reviews and meta-
analysis (PRISMA) diagram in Fig. 1 describes the number of articles
identiﬁed and their classiﬁcation.
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Fig. 1. Preferred Reporting Items for Systematic reviews and Meta-Analysis (PRISMA) ﬂowchart of the literature search and study selection for qualitative analysis. Note: see
http://www.prismastatement.org for more information in this reporting system.
3. Results
For 25 out of the 62 ADHD candidate genes, we retrieved
a total number of 171 reports linking genetic variation in/near
the gene to neuroimaging by using the above mentioned search
term in PubMed (Fig. 1). To those, we added two recent papers
from our own group (Sokolova et al., 2015; van Ewijk et al., in
revision) and three additional papers that were missing, from read-
ing the retrieved reports (Dresler et al., 2010; Albrecht et al., 2014;
Fernandez-Jaen et al., 2016). After removal of 54 duplicates, we
screened 117 records and discarded an additional 66 papers, mostly
because they described animal studies, did not include ADHD
patients, or did not fulﬁl our eligibility criteria otherwise. We  ﬁnally
included 51 original research articles on brain imaging genet-
ics studies for 13 ADHD candidate genes (ADRA2A, COMT,  DRD1,
DRD4, HTR1B,  LPHN3,  MAOA,  NOS1, SLC6A2/NET1, SLC6A3/DAT1,
SLC6A4/5HTT, SNAP25, TPH2; Tables 2 and 3). Most of the studies
investigated a single gene (32 in Caucasians, 6 in Asians), thirteen
studies investigated multiple genes (12 in Caucasians, 1 in Asians).
The dopamine transporter gene (SLC6A3/DAT1) and the dopamine
D4 receptor gene (DRD4) were the most frequently studied ADHD
candidate genes (Tables 2 and 3).
3.1. Findings for the dopamine transporter gene (SLC6A3, DAT1)
The gene DAT1 (ofﬁcial name SLC6A3) codes for a solute carrier
protein (DAT) responsible for the reuptake of dopamine from the
synaptic cleft into the presynaptic neuron, representing a primary
mechanism of dopamine regulation in the striatum (Ciliax et al.,
1999). The most widely studied polymorphism in SLC6A3/DAT1 is
a variable number of tandem repeat (VNTR) sequence in the 3’
untranslated region (3’UTR) that is 40 base pairs (bp) in length. Most
common alleles are those with 9 and 10 repeats (9R and 10R). Addi-
tionally, a 30 bp VNTR in intron 8 of the gene (most common alleles
with 5 and 6 repeats [5R and 6R]), is sometimes studied together
with the 3’UTR VNTR as a haplotype. The 10R/10R genotype of the
3’UTR VNTR and the 10-6 haplotype of the two  VNTRs are thought to
be risk factors for childhood ADHD (Asherson et al., 2007; Brookes
et al., 2006). In contrast, the 9R/9R genotype and the 9-6 haplotype
are associated with persistent ADHD (Franke et al., 2010). This sug-
gests a differential association of the gene with ADHD depending on
age, and a role of DAT1 in modulating the ADHD phenotype across
the lifespan. In addition to the VNTRs, several SNPs in DAT1 have
been studied for their effect on ADHD and/or brain phenotypes.
Two studies performed PET to study the role of DAT1 genotype
on DAT availability, one using 11Altropane as the ligand and one
11Cocaine. In an early study investigating a very small sample of 6
patients with ADHD and 9 controls, Drgon and colleagues studied
a haplotype of two  SNPs (rs2652511, rs2937639) in the 5’ regu-
latory region of the SLC6A3/DAT1 gene, and found the CG-allele
associated with ventral striatal in vivo DAT availability indepen-
dent of diagnosis; this ﬁnding was conﬁrmed through investigation
of striatal DAT expression in post-mortem brain samples (2006).
Spencer and coworkers observed that, in adults, the 9R genotype
of the 3’UTR VNTR increased DAT binding in caudate nucleus both
in patients and healthy controls, whereas the intron 8 VNTR and a
haplotype of both variants were not associated with DAT binding
(2013); (Table 3).
Four SPECT studies, using different ligands, investigated the
effect of the 3’UTR VNTR on DAT availability (Table 3). Two early
case-only studies, both in children with ADHD (n = 8 and 11, respec-
tively), showed that basal ganglia DAT density was increased
(Cheon et al., 2005) and that the regional cerebral blood ﬂow
(rCBF) was  larger in medial frontal and left basal ganglia during
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Table  2
Overview of imaging genetics studies identiﬁed per gene.
Gene barticles found barticles
discarded
barticles
included
References of articles included in review.
ADRA2A 4 2 2 Kim et al. (2010), Park et al. (2013).
BCHE  1 1 0
BDNF 4 4 0
CHRNA4 2 2 0
CHRNA7 1 1 0
COMT 13 7 6 Heinzel et al. (2013), Hong et al. (2014),
Shimada et al. (2015), Villemonteix et al.
(2015), Kabukcu Basay et al. (2016), van Rooij
et al. (2015b)
DBH 2 2 0
DRD1 3 1 2 Bobb et al. (2005), Shaw et al. (2007a)
DRD2 27 27 0
DRD3 1 1 0
DRD4 20 9 12 Castellanos et al. (1998), Durston et al. (2005),
Heinzel et al. (2013), Hong et al. (2014), Loo
et  al. (2010), Monuteaux et al. (2008),  Shaw
et al. (2007b), Szobot et al. (2005), Szobot et al.
(2011), Albrecht et al. (2014), Richards et al.
(2016), Schweren et al. (2016)
DRD5 2 2 0
GRM5 1 1 0
HTR1B 1 0 1 van Rooij et al. (2015a)
LPHN3 2 0 2 Arcos-Burgos et al. (2010), Fallgatter et al.
(2013)
MAOA 3 2 1 Ko et al. (2015)
MAOB 3 3 0
NOS1 2 1 2a Hoogman et al. (2011), van Ewijk et al. (in
revision)
SLC6A2/NET1 7 4 3 Bobb et al. (2005), Park et al. (2012),
Sigurdardottir et al. (2015)
SLC6A3/DAT1 48 22 29a Althaus et al. (2010), Bedard et al. (2010), Braet
et  al. (2011), Brown et al. (2011), Brown et al.
(2010), Cheon et al. (2005), Drgon et al. (2006),
Durston et al. (2005), Durston et al. (2008),
Hong et al. (2014), Hoogman et al. (2013),
Krause et al. (2006), Loo et al. (2003), Paloyelis
et al. (2012), Rohde et al. (2003), Shaw et al.
(2007b), Shook et al. (2011), Spencer et al.
(2013), Szobot et al. (2005), Szobot et al.
(2011), Sokolova et al. (2015), Dresler et al.
(2010), Onnink et al. (2016), Albrecht et al.
(2014), Fernandez-Jaen et al. (2016),
Fernandez-Jaen et al. (2015), Richards et al.
(2016), van Rooij et al. (2015b), Schweren et al.
(2016)
SLC6A4/5HTT 10 6 4 van der Meer et al. (2015), Richards et al.,
(2016), van der Meer et al. (2016), van Rooij
et al. (2015a)
SNAP25 7 6 1 Oner et al. (2011)
SYP 1 1 0
TH  5 5 0
TPH2 1 0 1 Baehne et al. (2009)
Total 171 110 66b
a Papers were added manually (two recent papers from our own group (1x NOS1, 1x SLC6A3/DAT1) and three additional papers that were missing from the PubMed search
(3×  SLC6A3/DAT1).
b This number still includes duplicate articles, since some studies investigated more than one candidate gene. No records were retrieved for the following genes: ADRA1B,
ADRA2C,  ADRB1, ADRB2, ASTN2, CALY, CCSER1, CDH13, CHRNA3, CNTF, CPLX2, DDC, DIRAS2, FADS2, FTO, GDNF, GPRC5B, GRIN2A, GRM7, HES1, HTR1A, HTR1E, HTR2A, HTR2C,
HTR3A, HTR3B, PNMT, PRKG1, SLC1A3, SLC18A2, SLC9A9, SPOCK3, STX1A, SYT1, TCERG1L, TPH1, VAMP2.
a continuous performance task (CPT) in response to MPH  treat-
ment in 10R/10R-homozygotes compared to 9R-carriers (Rohde
et al., 2003). A somewhat larger study in adults with ADHD did not
identify a difference in striatal DAT availability between 10R/10R-
homozygotes and 9R-carriers (Krause et al., 2006). Another SPECT
study in boys with ADHD observed a genotypic effect of the 3’UTR
VNTR variant increasing rCBF during a CPT only in the presence
of risk alleles at both SLC6A3/DAT1 (10R/10R) and DRD4 (7R); this
effect was present in the right middle temporal gyrus, an area
associated with working memory and selective attention (Szobot
et al., 2005); (Table 3). An interaction effect between the two  poly-
morphisms was subsequently also shown by the same group in
adolescent patients with ADHD plus substance use disorder (Szobot
et al., 2011); (Table 3). In this case, participants homozygous for the
SLC6A3/DAT1 10R-allele and carrying the DRD4 7R-allele exhibited
decreased DAT occupancy after MPH  treatment in the right and
left caudate nucleus and putamen (Szobot et al., 2011). A recent
meta-analysis, including healthy subjects and patients with differ-
ent psychiatric disorders including ADHD, assessed the association
of the 3’UTR variant with DAT availability (Faraone et al., 2014b).
The PET studies provided signiﬁcant evidence that the 9R-allele was
associated with increased DAT availability in human adults, inde-
pendent of the diagnostic status. The SPECT studies were highly
heterogeneous, but when the analysis was limited to the most
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Table 3
Imaging genetics studies of ADHD candidate genes in ADHD (case-control) samples (for candidate gene list see Table 1).
Gene (s) Variant Imaging
modality
Imaging/cognitive
phenotype or
task
Genotype groups
compared
Samples size
(mean age in
years)
Primary results (main effect of
genotype)
Reference
ADRA2A rs1800544,
rs553668
DTI White matter
integrity, FA
values
C-allele carriers
vs. GG-carriers,
T-allele carriers
vs. CC-carriers
53 ADHD (9.1)b rs1800544 C-allele carriers: ↓
FA in right postcentral gyrus.
rs553668 T-allele carriers: ↓FA
in right middle frontal cortex.
Park et al. (2013)
rs1800544 SPECT with
99mTc-HMPAO
Regional brain
perfusion
C-allele carriers
vs. GG-carriers
21 ADHD
(9.9)a,b
C-allele carriers: ↓ perfusion in
bilateral orbitofrontal regions.
Kim et al. (2010)
COMT rs4680 sMRI (VBM) Striatum,
cerebellum,
temporal lobe
and IFG volume
Met-carriers vs.
Val/Val-carriers
38 ADHD (10.3)
24 HC (10.1)
ADHD Met-carriers: ↓ GM
volume in IFG (whole
brain level) compared to HC.
ADHD Val/Val: ↑ GM volume in
right CN (ROI analysis)
compared to ADHD
Met-carriers and HC.
Villemonteix
et al. (2015)
GM volume Met-carriers vs.
Val/Val-carriers
17 ADHD
(10.3)b
15 HC (12.8)b
ADHD Met-carriers: ↓ GM
volume in left putamen.
Shimada et al.
(2015)
DTI FA and RD values Met-carriers vs.
Val/Val-carriers
71 ADHD (10.9)
24 HC (10.8)
ADHD Val/Val: ↓ FA and ↑ RD in
the right cingulum (cingulated
gyrus) compared to ADHD
Met-carriers and HC Val/Val.
Kabukcu Basay
et al. (2016)
DRD4 exon 3 VNTR sMRI Superior frontal,
middle frontal,
anterior
cingulate, and
cerebellum
cortices volumes
ADHD
7R-carriers vs.
non–7R-carriers
24 ADHD (38.1)
19 ADHD+BPD
(35.8)
20 HC (33.2)
7R- carriers: ↓ volumes of
superior frontal cortex and
cerebellum cortex compared to
non-carriers.
No effects in ADHD+BPD or HC.
Monuteaux et al.
(2008)
TBV, PFC,
cerebellum, CN,
and pallidum
volume
7R-carriers vs.
non–7R-carriers
41 ADHD (9.7)
56 HC (17.6)
No volumetric differences
between 7R and non
7R-carriers.
No group × genotype
interactions.
Castellanos et al.
(1998)
EEG  and 
frequency bands
during a CPT
7R-carriers vs.
non–7R-carriers
340 children
(11.1; 304
ADHD)
191 parents
(44.3; 80
ADHD)
Childhood 7R-carriers: ↑
frontal  and ↓ global 2
power.
Adult 7R-carriers: similar 2
power in ‘eyes closed’
condition, but ↓2 power in
‘eyes open’ and CPT conditions.
Loo et al. (2010)
LPHN3 rs2305339,
rs734644,
rs1397547,
rs1397548,
haplotype
EEG Go/No-Go task
(CPT)
High risk group
(2 copies of risk
haplo-
type = AGCC) vs.
low risk group
114 ADHD high
risk group
(34.85)
102 ADHD low
risk group
(34.92)
High risk group: ↑ anterior
Go-centroid of P300, ↓mean
NGA.
Fallgatter et al.
(2013)
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Table 3 (Continued)
Gene (s) Variant Imaging
modality
Imaging/cognitive
phenotype or
task
Genotype groups
compared
Samples size
(mean age in
years)
Primary results (main effect of
genotype)
Reference
rs6551665,
rs1947274,
rs2345039
haplotype
Proton
magnetic
resonance
spectroscopy
(1H-MRS)
NAA/Cr ratio in
striatum, lateral
and medial
thalamus,
cingulate gyrus,
and cerebellar
vermis
Risk haplotype
vs. protective
haplotype
Risk haplotype:
13 ADHD, 2 HC
Protective
haplotype: 1
ADHD, 9 HC
Different
haplotypes: 8
HC
Risk haplotype carriers: ↓
NAA/Cr in left lateral thalamus,
left medial thalamus, right
striatum, ↑NAA/Cr in
inferior–posterior cerebellar
vermis.
Carriers of two copies of risk
haplotype had lowest levels of
NAA/Cr.
Arcos-Burgos
et al. (2010)
MAOA rs1137070 fMRI Working
memory task
TT-carriers vs.
CC-carriers
21 ADHD
(23.9)a,b
19 HC (25.2)a,b
ADHD TT-carriers: ↑ activation
in left inferior frontal lobe, pars
opercularis.
Ko et al. (2015)
NOS1 Exon 1f-VNTR DTI WM integrity, FA
and MD values
SS-carriers vs.
SL/LL-carriers
178 ADHD
(17.6)
122 HC (16.8)
Female SS-carriers: ↑ MD  in
right parietal WM tracts.
Males: no difference between
genotype groups.
No genotype × diagnostic
group interaction.
van Ewijk et al.
(in revision)
fMRI Reward
anticipation
task/modiﬁed
MID  task
SS-carriers vs.
SL/LL-carriers
63 ADHD (38.3)
41 HC (38.0)
SS-carriers: ↑ activity in VS.
No group × genotype
interactions.
Hoogman et al.
(2011)
SLC6A2/NET1 rs5569,
rs28386840
SPECT with
[99mTc] HMPAO
Cerebral
perfusion in
response to MPH
treatment (8
weeks)
rs5569:
GG-carriers vs.
GA/AA-carriers;
rs28386840:
AA-carriers vs.
AT/TT-carriers
37 ADHD (8.9)b No differences in baseline
clinical assessments or cerebral
perfusion based on genotype.
rs5569 GG-carriers: After 8
weeks of treatment
hyperperfusion in right inferior
temporal gyrus and middle
temporal gyrus.
Park et al. (2012)
rs28386840,
rs2242246,
rs15534,
rs40615
PET with (S,S)-
[18F]FMeNER-
D2
NET BPND in
thalamus,
midbrain with
pons, putamen,
and cerebellum
Minor allele
carriers vs. major
allele
homozygotes
20 ADHD (30.8)
20 HC (30.4)
rs28386840 and rs2242446
ADHD major allele carriers
(A/T): ↑ NET BPND in the
thalamus compared to major
allele carrying controls. No
difference was  detected for the
minor allele between groups.
rs15534 and rs40615 HC major
allele carriers (C / T): ↑ NET
BPND in the cerebellum
compared to major allele
carrying patients.
Sigurdardottir
et al. (2015)
SLC6A3/DAT1 3’ UTR VNTR SPECT
with[99mTc]
TRODAT-1
Striatal DAT
availability
10R/10R-carriers
vs. 9R-carriers
29 ADHD (37.7) No differences in DAT
availability between
10R/10R-carriers and
9R-carriers.
Krause et al.
(2006)
SPECT with
[123I]IPT in
response to
MPH  treatment
Basal ganglia DAT
density
10R/10R-carriers
vs. 9R-carriers
11 ADHD (9.8)b 10R/10R-carriers: ↑ DAT
density in basal ganglia.
Cheon et al.
(2005)
SPECT with
[99mTc]-ECD in
response to
MPH  treatment
rCBF during a CPT 10R/10R-carriers
vs. 9R-carriers
8 ADHD, age
range 8–12a
10R/10R-carriers: ↑ rCBF in
medial frontal and left basal
ganglia areas in response to
MPH.
Rohde et al.
(2003)
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Table 3 (Continued)
Gene (s) Variant Imaging
modality
Imaging/cognitive
phenotype or
task
Genotype groups
compared
Samples size
(mean age in
years)
Primary results (main effect of
genotype)
Reference
3’ UTR, intron 8
VNTR, and
haplotype
PET with [11C]
altropane
DAT binding in
CN
9R-carriers vs.
10R/10R-
carriers;
6R-carriers vs.
5R/5R-carriers
34 ADHD (32.8)
34 HC (27.7)
ADHD and HC 9R-carriers: ↑
DAT binding in CN. No
association between intron 8
polymorphism or
3’-UTR-intron 8 haplotype
with DAT binding.
Spencer et al.
(2013)
rs2652511,
rs2937639
haplotype
PET with [11C]
cocaine
Ventral striatal
DAT expression
CG-haplotype
(rs2652511C-
allele and
rs2937639
G-allele carriers)
vs. rest
6 ADHD
9  HC
CG-haplotype: No effect on
diagnosis. Haplotype was more
frequent in individuals with
high DAT expression.
Drgon et al.
(2006)
3’UTR and
intron 8 VNTR
haplotype
sMRI Bilateral striatal
volumes (nucleus
accumbens, CN,
and putamen)
Three DAT1
alleles (10/10
genotype, and
the haplotypes
10–6 and 9–6)
118 ADHD
(35.9)
111 HC (37)
301 ADHD
(17.2)
186 HC (16.6)
1718 HC (26.1)
Adult ADHD 9-6 haplotype
carriers ↑ 5.9 % larger striatum
volume relative to participants
not carrying this haplotype (in
adult ADHD patients only).
Effect was not replicated in
adolescent case-control and
adult population-based cohort.
Onnink et al.
(2016)
3’ UTR VNTR sMRI Cingulated cortex
thickness
10R/10R-carriers
vs. 9R-carriers
98 ADHD (10.9) 10R/10R-carriers: ↑ thickness
in right cingulated gyrus and
right BA 24.
Fernandez-Jaen
et al. (2016)
3’ UTR VNTR sMRI PFC thickness 10R/10R-carriers
vs. 9R-carriers
63 ADHD (10.9) 10R/10R-carriers: ↓ cortical
thickness in right BA 46 (lateral
PFC). No other prefrontal ROI
differed signiﬁcantly.
Fernandez-Jaen
et al. (2015)
3’ UTR VNTR sMRI CN volume 9R-carriers vs.
10R/10R-carriers
33 ADHD (10.5)
26 HC (10.6)
9R-carriers: ↑ volumes of CN. Shook et al.
(2011)
3’UTR and
intron 8 VNTR
haplotype
fMRI Striatal activity
during reward
anticipation task
9-6 haplotype
carriers vs. non
9-6 haplotype
carriers
87 ADHD (38.3)
77 HC (38)
No differences in striatal
activity compared with non
9-6 haplotype carriers nor 9R-
and 10R/10R-carriers.
Hoogman et al.
(2013)
87 ADHD (38.3)
77 HC (38);
same as above
Bayesian Constraint-based
Causal Discovery (BCCD)
algorithm conﬁrmed that there
is  no direct link between DAT1
genetic variability and brain
activation, but suggested an
indirect link mediated through
inattention symptoms and
diagnostic status of ADHD.
Sokolova et al.
(2015)
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Table 3 (Continued)
Gene (s) Variant Imaging
modality
Imaging/cognitive
phenotype or
task
Genotype groups
compared
Samples size
(mean age in
years)
Primary results (main effect of
genotype)
Reference
VS and CN
activity during
reward-
predicting
cues
SLC6A3 10-6
dosage (2 copies
vs. <2 copies)
29 ADHD
(combined
type; 15.8)a
30 HC (15.6)a
ADHD: Activation in CN ↓ as
number of copies ↑, but in
control group reverse was
found.
Paloyelis et al.
(2012)
3’ UTR VNTR fMRI Working
memory task
9R-carriers vs.
10R/10R-carriers
53 ADHD (35.7)
38 HC (31.2)
9R-carriers: ↓ left medial PFC
activation compared to
10R/10R-carriers.
Group × genotype interaction
showed that 10R/10R-ADHD
patients had ↑ activity in
pre-SMA/dorsal ACC compared
to HC.
Brown et al.
(2011)
Go/No-Go task 10R/10R-carriers
vs. 9R-carriers
20 ADHD (14.1)
38 HC (13.12)
10R/10R carriers: ↑ activity in
frontal, medial, and parietal
regions during response
inhibition compared to
9R-carriers; ↓error response in
the parahippocampal gyrus.
Braet et al. (2011)
10R/10R-carriers
vs. 9R-carriers
33 ADHD (11.1) 10R/10R carriers: ↑ activity in
left striatum, right dorsal
premotor cortex, and
temporoparietal cortical
junction compared to
9R-carriers.
Bedard et al.
(2010)
9R-carriers vs.
10R/10R-carriers
10 ADHD
(14.6)a
10 unaffected
siblings (14.8)a
9 HC (15.3)a
9R-carriers: ↑ activity in CN
and ↓ in cerebellar vermis
compared to 10R/10R-carriers.
Group × genotype interaction:
effect in CN is observed in
ADHD and unaffected siblings,
but not HC.
Durston et al.
(2008)
Multi-source
interference task
10R/10R-carriers
vs. 9R-carriers
42 ADHD (35.4) 9R-carriers: ↓ activity in dorsal
ACC compared to
10R/10R-carriers.
Brown et al.
(2010)
EEG Go/No-Go task 10R/10R-carriers
vs. 9R-carriers
161 ADHD
(35.6)
109 HC (35.8)
ADHD 9R-carriers: ↓ NGA
(indicating impaired cognitive
response control); No genotype
effect in control group
Dresler et al.
(2010)
Feedback-based
learning task;
measuring ERPs
10R/10R-carriers
vs. 9R-carriers
27 ADHD (11.5)
18 PDD (11.3)
20 HC (11.5)
10R/10R-carriers: ↓ Pe to errors
and ↓ SPN in anticipation of
negative feedback, particularly
with learning.
Althaus et al.
(2010)
EEG, single
dose of 10 mg
MPH
(double-blind,
placebo-
controlled)
Sustained
attention and
vigilance task
10R/10R-carriers
vs. 9R-carriers
27 ADHD (10.1) 10R/10R-carriers:
medication-related EEG
changes of ↑ central and
parietal  power, ↓ right
frontal  power, ↓ / ratios.
9R-carriers: showed opposite
pattern.
Loo et al. (2003)
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Table 3 (Continued)
Gene (s) Variant Imaging
modality
Imaging/cognitive
phenotype or
task
Genotype groups
compared
Samples size
(mean age in
years)
Primary results (main effect of
genotype)
Reference
SLC6A4/
5HTT
5-HTTLPR sMRI (VBM) GM volume S-carriers vs.
LL-carriers
291 ADHD
78
subthreshold
ADHD
332 HC;
Average age:
17 years
S-carriers: stress exposure is
associated with ↓ GM volume
in precentral gyrus, middle and
superior frontal gyri, frontal
pole, and cingulated gyrus.
Association of GxE interaction
with ADHD symptom count
was mediated by GM volume
in frontal pole and anterior
cingulated gyrus only.
van der Meer
et al. (2015)
SNAP25 rs1051312,
rs3746544
fNIRS MPH  treatment-
related
hemodynamic
changes during
interference
condition of
Stroop task
rs1051312: TT-
vs.
TC/CC-carriers,
rs3746544: TT-
vs.
TG/GG-carriers; 4
groups for
interaction
analysis
15 ADHD (26.1)
16 ADHD (9.7)
rs1051312 TT-carriers: ↓ right
[HHb] with treatment
rs3746544 TT-carriers:
changes in genotype right
[HbO2] and [HHb] as well as
left [HHb].
Interaction analysis –
participants with rs1051312
CC/TC and rs3746544 GG/TG: ↑
right [HHb] with MPH  use.
Interaction analysis –
participants with rs1051312 TT
and rs3746544 TT or
rs1051312 TT and rs3746544
GG/TG: ↓ right prefrontal
[HHb] with MPH use.
Oner et al. (2011)
TPH2 rs4570625,
rs11178997
EEG Go/No-Go task
(CPT)
rs4570625: GG-
vs. T-carriers,
rs11178997: TT-
vs. TA-carriers
124 ADHD
(34.7)
84 HC (34.8)
rs11178997 TT-carriers and
rs4570625 GG-carriers: ↓ NGA
in both HC and ADHD.
No group × genotype
interactions.
Baehne et al.
(2009)
SLC6A3/DAT1,
DRD4
3’ UTR VNTR,
exon 3 VNTR
SPECT with
[99mTc]TRODAT-
1 in response to
MPH  treatment
Striatal DAT
binding potential
10/10R-carriers
vs. 9R-carriers;
7R-carriers vs.
non–7R-carriers;
10/10R+7R-
carriers vs.
rest
17 ADHD/SUDs,
age range
15–21 yearsa
10/10R-carriers: no effect on
DAT occupancy after MPH
treatment.
7R-carriers: no effect on DAT
occupancy after MPH
treatment.
10/10R+7R-carriers: ↓ DAT
occupancy after MPH
treatment in right and left CN
and putamen.
Szobot et al.
(2011)
SPECT with
[99m Tc] ECD
rCBF during a CPT 10/10R-carriers
vs. 9R-carriers;
7R-carriers vs.
non–7R-carriers;
10/10R+7R-
carriers vs.
rest
34 ADHD
(11.6)a
10/10R-carriers: no effect on
rCBF.
7R-carriers: no effect on rCBF.
10/10R+7R-carriers: ↑ rCBF in
right middle temporal gyrus
area.
Szobot et al.
(2005)
sMRI PFC GM and CN
volume
9R-carriers vs.
10R/10R-carriers,
4R/4R-carriers vs.
rest
26 ADHD (12.1)
26 unaffected
siblings (11.6)
20 HC (10.7);
alla
SLC6A3 ADHD 10/10R-carriers:
↓  CN volumes
DRD4 unaffected siblings
7R-carriers: ↑ prefrontal GM
volume. No effects on CN, or
TBV. No interactions between
ADHD status and genotype.
Durston et al.
(2005)
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Table 3 (Continued)
Gene (s) Variant Imaging
modality
Imaging/cognitive
phenotype or
task
Genotype groups
compared
Samples size
(mean age in
years)
Primary results (main effect of
genotype)
Reference
3’UTR and
intron 8 VNTR
haplotype,
exon 3 VNTR
sMRI Striatum, frontal
cortex, and
hippocampus
volumes
10-6 haplotype
carriers vs.
non-10-6
haplotype
carriers,
7R-carriers vs.
non–7R-carriers
316 ADHD
(17.2)
187 HC (16.5)
SLC6A3 10-6
haplotype-carriers: ↓ left
striatal volume, irrespective of
treatment.
DRD4 7R-carriers: frontal
cortex volume is associated
with stimulant treatment at
younger age.
Schweren et al.
(2016)
SLC6A3/DAT1,
DRD4,
SLC6A4/5HTT
sMRI Total GM,
caudate, and
putamen volume
9R-carriers vs.
rest, 7R-carriers
vs. rest,
S-allele-carriers
vs. rest
368 high ADHD
severity (17.3)
374 low ADHD
severity (16.8)
For total GM,  differential age
effects were found for SLC6A3
9R- and SLC6A4 L/L carriers,
depending on the amount of
positive peer afﬁliation. For
putamen volume, DRD4 7R-
carriers and SLC6A3 10/10
homozygotes showed opposite
age relations. Results were
independent of ADHD severity.
Richards et al.
(2016)
SLC6A3/DAT1,
DRD4, DRD1
3’ UTR VNTR,
exon 3 VNTR,
rs4532
sMRI;
longitudinal
study (mean
follow-up, 6
years)
Cortical thickness 9R-carriers vs.
10R/10R-carriers,
7R-carriers vs.
non–7R-carriers,
C-allele carriers
vs. non-C-allele
carriers
105 ADHD
(10.1; 13.1;
15.9) 103 HC
(10.0; 12.4;
14.4)
SLC6A3 9R-carriers: No effect
on cortical development.
DRD4 7R-carriers: thinner right
orbitofrontal/inferior
prefrontal and posterior
parietal cortex.
ADHD 7R-carriers: distinct
trajectory of cortical
development; normalization of
right parietal cortical region.
DRD1: No effect of genotype on
clinical outcome or cortical
development.
Shaw et al.
(2007b)
SLC6A3/DAT1,
DRD4, COMT
3’ UTR VNTR,
exon 3 VNTR,
rs4680
DTI WM integrity, FA
values
9R-carriers vs.
10R/10R-
carriers;
4R/4R-carriers vs.
rest;
Met-carriers vs.
Val/Val
58 stimulant-
and atomoxe-
tine-naïve
ADHD (8.7)b
SLC6A3 9R-carriers: no effect
on WM integrity
DRD4 4R/4R-carriers: no effect
on WM integrity.
Met-carriers: ↓ Network of
WM  connections linking 18
brain regions
Hong et al. (2014)
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Table 3 (Continued)
Gene (s) Variant Imaging
modality
Imaging/cognitive
phenotype or
task
Genotype groups
compared
Samples size
(mean age in
years)
Primary results (main effect of
genotype)
Reference
SLC6A3/DAT1,
COMT
3’UTR and
intron 8 VNTR
haplotype,
rs37020,
rs460000,
rs4680
fMRI Stop-signal task 10-6 haplotype-
carriers vs.
non-10-6
haplotype-
carriers;
rs37020: CC vs.
rest; rs460000:
GG vs. rest;
Val/Val vs
Met-carriers
185 ADHD
(17.3)
111 unaffected
siblings (17.3)
124 HC (16.5)
No genotype × ADHD
interaction effects.
SLC6A3 10-6
haplotype-homozygotes: ↑
activity related to successful
stop-trials in
pre-supplementary motor
areas, ↓ activity in superior
frontal and temporal pole
areas.
rs37020 AA-carriers: ↓ activity
during failed stop-trials in IFG,
pre-supplementary motor
areas, and post-central gyrus.
rs4680 Val/Val-carriers: ↓
activity during successful
stop-trials in thalamus, frontal
pole, and left IFG; ↑ activity in
hippocampus during failed
stop-trials.
van Rooij et al.
(2015b)
SLC6A3/DAT1,
DRD4
3’UTR and
intron 8 VNTR
haplotype,
exon 3 VNTR
EEG CPT 10-6 haplotype-
carriers vs.
non-10-6
haplotype-
carriers;
7R-carriers vs.
non–7R-carriers
94 ADHD;
31 HC ; age
range 8–16 ;
alla
SLC6A3 10-6
haplotype-carriers: ↑ activity
related to inhibitory response
control (Nogo-P3)
DRD4 7R-carriers: ↓ activity
related to attentional orienting
(Cue-P3) and cognitive or
response preparation (CNV).
No genotype x ADHD
interactions.
Albrecht et al.
(2014)
DRD4, COMT exon 3 VNTR,
rs4680
EEG Go/No-Go task 7R-carriers vs.
non–7R-carriers;
Val/Val vs.
Val/Met vs.
Met/Met-carriers
181 ADHD
(35.3, age
range: 18–60)
114 HC
Single genes and diagnosis had
no effect on neural correlates
of  prefrontal response control
(NGA).
DRD4 VNTR and COMT SNP
epistatically interacted on
NGA.
Heinzel et al.
(2013)
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Table 3 (Continued)
Gene (s) Variant Imaging
modality
Imaging/cognitive
phenotype or
task
Genotype groups
compared
Samples size
(mean age in
years)
Primary results (main effect of
genotype)
Reference
DRD1,
SLC6A2/NET1
rs4532 and
rs265981,
rs998424 and
rs3785157
sMRI TCV, volumes of
total GM and
WM,  CN,
cerebellum,
frontal, temporal,
parietal lobes
2 and 3 genotype
groups per SNP
114 ADHD (9)
79 HC (16)
DRD1 and NET1 SNPs: No
genotype effects on GM or WM
volume and no
group × genotype interactions.
Bobb et al. (2005)
SLC6A4/5HTT,
HTR1B
5-HTTLPR,
rs6296
fMRI Stop-signal task 3 genotype
groups per
variant
184 ADHD
(17.3)
111 unaffected
siblings (17.3)
124 HC (16.5)
SLC6A4 SS-genotype group: ↓
activation in frontal nodes and
↑ activation in posterior nodes.
HTR1B genotype: associated
with differential activation in
anterior cingulate, occipital,
inferior temporal, and
cerebellar regions during
successful stop trials.
No associations between
SLC6A4 and HTR1B variants and
ADHD or ADHD-related neural
activation.
van Rooij et al.
(2015a)
SLC6A4/5HTT,
NR3C1
5-HTTLPR,
rs6189, rs6198
sMRI GM volume S-allele carriers
vs. rest; NR3C1
risk haplotype-
carriers (rs6189G
and rs6198G) vs.
rest
539 ADHD,
unaffected
siblings, and
HC combined
(17.2)
NR3C1 risk haplotype-carriers :
↑  positive relation between
stress exposure and ADHD
severity; which was stronger
for SLC6A4 L-allele
homozygotes. Interactions
were reﬂected in GM volume of
cerebellum, parahippocampal
gyrus, intracalcarine cortex,
and angular gyrus.
van der Meer
et al. (2016)
BP = binding potential, BPND = nondisplaceable binding potential, BPD = bipolar disorder, CN = caudate nucleus, CPT = continuous performance test, dACC = dorsal anterior cingulated cortex, DAT = dopamine transporter,
DTI  = Diffusion tensor imaging, ECD = ethyl-cisteinate-dimer, EEG = electroencephalography, ERP = event related potential, FA = fractional anisotropy, fMRI = functional magnetic resonance imaging, fNIRS = functional near-infrared
spectroscopy, HC = healthy control, IFG = inferior frontal gyrus, NAA/Cr = ratio of N-acetylaspartate to creatine, NAcc = nucleus accumbens, NGA = NoGo-anteriorization, PDD = Pervasive Developmental Disorder, Pe = error-related
positivity, PET = positron emission tomography, PFC = prefrontal cortex, pre-SMA = pre-supplementary motor area, rCBF = regional cerebral blood ﬂow, RD = radial diffusivity, ROI = region of interest, sMRI, structural magnetic reso-
nance  imaging, SPECT = single-photon emission tomography, SPN = stimulus-preceding negativity, SUD = substance use disorder, TBV = total brain volume, TCV = total cerebral volume, UTR = untranslated region, VBM = voxel-based
morphometry, VNTR = variable number tandem repeat, VS = ventral striatum, 4R = 4 repeat allele, 5R = 5 repeat allele, 7R = 7 repeat allele, 9R = 9 repeat allele, 10R = 10 repeat allele, [HHb] = deoxyhemoglobin, [HbO2] = oxygenated
hemoglobin, [99mTc] = technetium-99; 1H MRS = Proton magnetic resonance spectroscopy, [99m]Tc-HMPAO = technetium-99m hexamethylpropylene amine oxime.
a Only males.
b Asian sample.
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commonly used ligand, stratiﬁcation by affection status dramati-
cally reduced heterogeneity and revealed a signiﬁcant association
of the 9R allele with increased DAT availability for healthy subjects.
The authors concluded that in humans, the 3’UTR polymorphism
of SLC6A3/DAT1 regulates dopamine activity in the striatal brain
regions independent of the presence of neuropsychiatric illness.
Eight sMRI studies for SLC6A3/DAT1 were performed thus far
(Table 3). Two studies reported a smaller volume of the striatal
caudate nucleus in homozygotes for the 10R allele when compared
to children with the 9R/10R genotype (Durston et al., 2005; Shook
et al., 2011). While Durston and coworkers found this effect to be
most pronounced in children with ADHD, rather than their unaf-
fected siblings or healthy comparison subjects, the overall genotype
effect was independent of diagnosis. Two recent studies investi-
gated cortical thickness in children and adolescents with ADHD.
Fernández-Jaén and colleagues suggested that thickness of the lat-
eral PFC and the cingulated cortex might be inﬂuenced by the
presence of the 10R-allele (2015; 2016). Interestingly, homozy-
gotes for the 10R allele showed increased thickness in the right
cingulated gyrus (Fernandez-Jaen et al., 2016), but decreased cor-
tical thickness in the lateral PFC (Fernandez-Jaen et al., 2015).
In addition, a large observational study in an adolescent cohort
revealed that irrespective of stimulant treatment, left striatal vol-
ume  was reduced in participants with ADHD carrying one 10-6
haplotype (Schweren et al., 2016). A recent cross-sectional sMRI
study included three cohorts (a childhood/adolescent ADHD case-
control sample, an adult ADHD case-control sample, and an adult
population-based sample) and showed that only in the adult ADHD
case-control cohort, carriers of the DAT1 adult ADHD risk haplo-
type 9-6 had a 5.9% larger striatum volume relative to participants
not carrying this haplotype. The effect varied by diagnostic status,
with the risk haplotype affecting striatal volumes only in patients
with ADHD (Onnink et al., 2016). A longitudinal study did not
reveal any effect of SLC6A3/DAT1 genotype on cortical thickness
(Shaw et al., 2007b), consistent with the predominant expression of
DAT1 in subcortical (striatal) structures (and cerebellum). A recent
gene-environment (GxE) interaction study reported differential
age effects for SLC6A3/DAT1 9R-allele carriers for total grey matter
volume and for SLC6A3/DAT1 10R-allele homozygotes on putamen
volume, depending on positive peer afﬁliation (Richards et al.,
2016) (Table 3). These ﬁndings were independent of ADHD severity.
The presence of such differential age-dependent GxE effects might
explain the diverse and sometimes opposing results of genetic and
environmental effects on brain phenotypes (Richards et al., 2016). A
single DTI study was performed in a sample of children with ADHD
to assess DAT1’s effect on structural connectivity (Table 3). How-
ever, the investigated 3’UTR VNTR genotype did not appear to affect
white matter integrity (Hong et al., 2014).
In total, nine fMRI studies were performed to investigate the
effect of SLC6A3/DAT1 genotype on brain activity related to differ-
ent tasks, most often examining reward processing and different
aspects of executive functioning (Table 3). The studies included
childhood, adolescent, and adult ADHD samples. Three fMRI stud-
ies investigated the role of the SLC6A3/DAT1 VNTR haplotype using
reward-processing paradigms. Reward processing is altered in
ADHD, and meta-analysis has shown that activation of the ven-
tral striatum in anticipation of reward is lower in patients with
ADHD than in controls (Plichta and Scheres, 2014). In a study in
male adolescents, the activation of the caudate nucleus within the
ventral striatum was found reduced in the ADHD group as the
number of 10-6 haplotype copies increased (Paloyelis et al., 2012).
A sizeable study in adult ADHD cases and controls, on the other
hand, found no effect of SLC6A3/DAT1 haplotype on striatal activity
(Hoogman et al., 2013). The latter dataset was re-analyzed using a
Bayesian constraint-based causal discovery algorithm; this analysis
suggested that any links between the genetic haplotype in DAT1 and
reward anticipatory brain activity may  be indirect only, mediated
through inattention symptoms (Sokolova et al., 2015).
In studies of response inhibition, tested through a Go/No-Go task
in children and adolescents, the 10R/10R genotype was found to
be linked to higher (Bedard et al., 2010), but also lower (Durston
et al., 2008) striatal activation. Interestingly, Durston and col-
leagues observed genotypic effects in the caudate nucleus in the
patients and their unaffected siblings, but not in healthy controls
(2008). Beyond the striatum, SLC6A3/DAT1 genotype effects were
also found in additional brain regions, such as during cerebellar
activation in children with ADHD (Durston et al., 2008), and in
frontal, medial, and parietal regions, where activity was increased
during response inhibition in adolescents homozygous for the
10R allele (Braet et al., 2011). Increased activity in the (temporo-
)parietal regions in homozygous carriers of the 10R-allele was  also
observed in a second study, in addition to increased activity in the
right dorsal premotor cortex (Bedard et al., 2010). The effects of the
SLC6A3/DAT1 haplotype and rs37020 genotype on neural activa-
tion during response inhibition have been investigated as well (van
Rooij et al., 2015b) (Table 3). Homozygous carriers of the SLC6A3
10-6 haplotype exhibited increased activity related to successful
stop-trials in pre-supplementary motor areas and reduced activity
in superior frontal and temporal pole areas, whereas homozy-
gous carriers of the rs37020 A-allele showed reduced activity
during failed stop-trials in the IFG, pre-supplementary motor areas,
and post-central gyrus (van Rooij et al., 2015b). Despite these
wide-spread effects on neural activation changes of the response
inhibition network, these changes were independent of ADHD diag-
nostic status (van Rooij et al., 2015b). As expression of DAT1 is
limited outside of striatum and cerebellum, these latter effects are
likely due to direct or indirect connections between the regions of
gene expression and the rest of the brain.
A working memory task in adult participants elicited increased
activity in the dorsal ACC in patients homozygous for the 10R allele,
whereas this genotype caused reduced activity in controls (Brown
et al., 2011). Additionally, the authors showed a marginal associ-
ation of the SLC6A3/DAT1 genotype with task-related suppression
in the left medial PFC (Brown et al., 2011). Also in a multi-source
interference task, the 10R/10R homozygotes had increased activity
in the dorsal ACC compared to carriers of the 9R-allele (Brown et al.,
2010). The dorsal ACC is thought to play a crucial role in numer-
ous cognitive control functions including attention modulation,
competition monitoring, complex motor control, novelty, error
detection, working memory, anticipation of cognitively demand-
ing tasks, and the modulation of reward-based decision making
(Shenhav et al., 2013). Functional abnormalities associated with
the dorsal ACC have been repeatedly reported in ADHD (Cao et al.,
2009; Castellanos et al., 2008; Tamm et al., 2004; Zang et al.,
2007; Tian et al., 2006), and the results above suggest that these
effects might be most pronounced in 10R-allele homozygotes,
which constitute approximately 71.9% of the Caucasian population
(Doucette-Stamm et al., 1995).
No studies in patients have yet investigated effects of DAT1
genotype on functional brain connectivity assessed through resting
state fMRI. A single study in healthy participants using seed-based
analysis revealed that carriers of the 9R-allele showed stronger
connectivity between dorsal caudate nucleus and insula, dor-
sal ACC, and dorsolateral prefrontal regions, as well as between
ventral striatum and centrolateral prefrontal cortex, suggesting
wide-spread effects of the SLC6A3/DAT1 genotype on functional
connectivity of striatal structures with the rest of the brain (Gordon
et al., 2015).
Four EEG studies in ADHD childhood samples investigated the
effects of SLC6A3/DAT1 variation (Table 3). One study examined
the inﬂuence of the common 9R and 10R alleles on prefrontal
brain functioning and cognitive response control in participants
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with adult ADHD and healthy controls (Dresler et al., 2010). By
means of a Go-NoGo task (CPT) they inspected a neurophysiolog-
ical marker of cognitive response control (NoGo-anteriorization,
NGA). The NGA is a endophenotypic marker of prefrontal func-
tioning, reﬂecting neural correlates of both response inhibition and
execution in a Go-NoGo test situation (Fallgatter and Strik, 1999).
It is a topographic event-related potential parameter quantifying
the brain’s electrical ﬁeld frontalization during motor inhibition
(NoGo, when compared with response execution Go). As such, the
NGA reﬂects “NoGo” activation of the medial PFC (anterior cingu-
late cortex, ACC) (Fallgatter et al., 2002). The NGA and the electrical
ﬁeld frontalization during NoGo trials have been found reduced
in patients with ADHD (as well as those with schizophrenia) com-
pared with healthy controls, reﬂecting diminished activation of the
medial PFC in these patient groups (Fallgatter and Muller, 2001;
Fallgatter et al., 2005). In the study of SLC6A3/DAT1 genotype car-
riers of the 9R-allele within the ADHD group showed signiﬁcantly
reduced NGA, whereas no inﬂuence of genotype was  observed in
the control group (Dresler et al., 2010). A second EEG study inves-
tigated the effect of the 10-6 haplotype on response control, by
using a CPT task in a childhood case-control sample (Albrecht et al.,
2014). Independent of ADHD diagnosis, 10-6 haplotype-carriers
exhibited elevated brain activity related to inhibitory response con-
trol (Albrecht et al., 2014). Another study investigated the effect of
the SLC6A3/DAT1 3’UTR genotype on neurophysiological correlates
of performance monitoring by measuring event-related potentials
(ERPs) during a feedback-based learning task. The authors showed
that 10R/10R homozygotes had a smaller error-related positivity
(Pe) response to errors and a smaller stimulus-preceding negativ-
ity (SPN) in the anticipation of negative feedback, especially with
learning (Althaus et al., 2010), suggesting that SLC6A3/DAT1 geno-
type inﬂuences a system that is sensitive to aversive stimuli and
their conscious processing (Althaus et al., 2010). The third EEG
study investigated MPH  medication-related changes on cortical
power spectra during a sustained attention and vigilance task in
a patient-only sample. ADHD patients have been shown to have
increased frontocentral  band activity and increased / ratio
compared to non-ADHD controls during rest (Loo and Makeig,
2012). Generally, the  band activity has been associated with
attentional arousal, and it has been suggested that the / ratio may
reﬂect increased impulsivity and difﬁculty negotiating the speed-
accuracy trade-off (faster speed but poorer performance) in ADHD
(Loo and Makeig, 2012). In their study of DAT1 genetic variation
during MPH  treatment, the authors reported that those children
with ADHD homozygous for the 10R-allele, exhibited medication-
related cortical changes of increased central and parietal  power,
decreased right frontal  power, and lower / ratios; 9R carriers
showed the opposite pattern (Loo et al., 2003).
Summarizing, sMRI studies (as well as PET/SPECT by deﬁnition)
ﬁnd SLC6A3/DAT1 genotype effects mainly in regions, in which the
gene is preferentially is expressed. These local effects can have
widespread consequences on brain activity, as fMRI and EEG stud-
ies reveal. However, it is still unclear how the PET/SPECT ﬁndings,
such as high DAT binding and density in nucleus accumbens and
dorsal striatum (Kuczenski and Segal, 2002; Segal and Kuczenski,
1997) or the differences observed in brain activity are related to
structural volume differences in the speciﬁc brain regions of ADHD
patients. Therefore, studies could beneﬁt from combining different
imaging methodologies. The effects of genotype are often observed
independent of diagnostic status, as would be expected for bona
ﬁde risk factors. Additionally, credibility of most of the existing
studies can be questioned, since many of them are limited by their
small sample sizes (Mier et al., 2010; Munafo et al., 2008). The
actual neuroanatomical and brain activity-based mechanisms by
which SLC6A3/DAT1 genotype increases ADHD risk remain to be
clariﬁed, as the results of studies published thus far are too patchy
(and based on too small samples) to allow a coherent story to be
deﬁned. Moreover, links with cognitive performance and behaviour
have often not been investigated. A further complicating matter for
the interpretation of studies on SLC6A3/DAT1 is the switch in ADHD
risk allele from childhood to adulthood. Longitudinal studies or at
least cross-sectional studies including large samples of both chil-
dren and adult participants (preferably also including persistent
and remitted forms of ADHD) are therefore needed to advance the
ﬁeld.
3.2. Findings for the dopamine receptor D4 gene (DRD4)
The dopamine D4 receptor, encoded by DRD4, is a G protein-
coupled receptor and belongs to the dopamine D2-like receptor
family (Oldenhof et al., 1998). The most widely studied DRD4 poly-
morphism in ADHD has been the 48 bp VNTR in exon 3 of the
gene, with the 2-, 4-, and 7-repeat alleles being the most common
alleles. Allele frequencies vary signiﬁcantly across ethnic groups
(Chang et al., 1996; van Tol et al., 1992), and the ADHD risk allele in
the Caucasian population (7R) seems to be a different one from
that in Asians (Nikolaidis and Gray, 2010; Wang et al., 2004; Li
et al., 2006a). The DRD4 48 bp VNTR seems to show differen-
tial association with ADHD in children, where it may  be one of
the strongest risk factors among the common genetic variants
(Gizer et al., 2009), and adults, where no association with the dis-
order could be observed (Sanchez-Mora et al., 2011), though it
might occur as part of gene-environment interactions (Sanchez-
Mora et al., 2015). DRD4 is abundantly expressed in areas of the
brain affected in ADHD, including frontal lobe regions, such as the
orbitofrontal cortex and anterior cingulate (Lahti et al., 1995; De La
Garza and Madras, 2000; Li et al., 2007b); the risk allele has been
found to affect receptor binding and to produce a blunted response
to dopamine (Asghari et al., 1995), although the functionality of the
DRD4 VNTR has recently been challenged by meta-analysis (Pappa
et al., 2015). The exon 3 VNTR has been the sole target of imaging
genetic studies involving patients with ADHD, in which different
imaging modalities have been used (Table 3).
An early sMRI study in children and adolescents did not report
differences between carriers and non-carriers of the 7R-allele in
selected regional and global brain volumes (Castellanos et al.,
1998). A second study observed smaller prefrontal grey matter
volumes in children homozygous for the 4R-allele, an effect that
appeared particularly pronounced in unaffected siblings of patients
with ADHD (Durston et al., 2005). In contrast, adult patients car-
rying the 7R-allele were found to have smaller volumes of the
superior frontal and cerebellar cortex (Monuteaux et al., 2008). In
a longitudinal study, DRD4 genotype also affected cortical develop-
ment (by measuring cortical thickness), with 7R-carriers showing
thinner prefrontal and parietal cortex; patients with ADHD carrying
this allele had a distinct trajectory of cortical development charac-
terized by normalization of parietal cortical regions (Shaw et al.,
2007b). Additionally, an observational cohort study evaluating the
effects of cumulative stimulant treatment, revealed associations
between treatment and frontal and hippocampal volume depen-
dent on DRD4 genotype and age (Schweren et al., 2016). More
speciﬁcally, carriers of the 7R-allele showed decreased frontal cor-
tex volume at younger age and lower treatment levels, whereas
left hippocampal volume was increased in those with treatment
at younger age (Schweren et al., 2016) (Table 3). By studying GxE
interaction effects, carriers of the 7R-allele were found to have
larger putamen volumes over age when exposed to high positive
peer afﬁliation (Richards et al., 2016). This result was  independent
of ADHD severity. Effects of DRD4 genotype on structural brain
connectivity were investigated in a single study in Asian children
with ADHD, resulting in a report of no effects for 4R-homozygotes
(Hong et al., 2014). A very large recent study in healthy participants
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(n = 765) revealed an absence of signiﬁcant effects of the DRD4 5R-
allele on FA as well (Takeuchi et al., 2015). However, widespread
changes in another measure of structural connectivity, mean dif-
fusivity (MD), were observed, with increased MD in 5R-carriers in
grey and white matter areas of the cerebral cortex, and in subcorti-
cal areas including the globus pallidus, amygdala, midbrain areas,
and the brain stem (Takeuchi et al., 2015).
An EEG study administering a CPT as a measure of response
inhibition and sustained attention, reported that children with the
7R-allele showed increased frontal  and reduced global  power.
Similar effects of DRD4 genotype were also apparent on the  fre-
quency band in the parents (Loo et al., 2010); in both generations,
carriers of the 7R-allele had reduced cortical activation upon per-
forming the CPT task compared to participants not carrying this
allele (Loo et al., 2010). Similarly, Albrecht and colleagues also
applied the CPT to a childhood case-control sample and reported
signiﬁcant effects of the 7R-allele on ERP components. Speciﬁcally,
they observed reduced activity related to attentional orienting and
cognitive or response preparation in 7R-carriers (2014). This effect
was found to be independent of an ADHD diagnosis (Albrecht et al.,
2014). Extrapolating to behaviour, a recent meta-analysis showed
that longer DRD4 variants (including the 7R-allele) were associated
with lower levels of executive functioning (Pappa et al., 2015). In
contrast to the continuous performance measure, an EEG study of
inhibition applying another Go/No-Go task to adults with and with-
out ADHD did not ﬁnd an effect of DRD4 genotype on the NGA neural
correlate of prefrontal response control (Heinzel et al., 2013). How-
ever, in this study, an epistatic interaction between the DRD4 VNTR
and a SNP in the COMT gene (rs4680; Val/Met) was  observed for
the NGA; in homozygous carriers of the DRD4 7R-allele, the NGA
followed a more pronounced U-relationship based on an increas-
ing number of COMT Met-alleles compared with 7R-heterozygotes.
In COMT Val/Met carriers, DRD4 7R-homozygosity was  associated
with decreased NGA compared with 7R-heterozygosity. This inter-
action could be localized to the right premotor and supplementary
motor areas (Heinzel et al., 2013). These ﬁndings were independent
of diagnostic status.
Thus, though existing evidence does not support ﬁrm con-
clusions about the pathways from gene to disease, genotypic
variability in DRD4 may  affect brain structure and/or activity and
mark a particular developmental trajectory in cortical brain struc-
ture related to adult outcome of ADHD.
3.3. Findings for other ADHD candidate genes
Adrenergic neurotransmitter systems inﬂuence attentional pro-
cesses and certain aspects of executive control (Arnsten, 2006), and
the gene encoding the alpha-2A adrenergic receptor (ADRA2A) has
been found to be a candidate gene for ADHD. The alpha-2A adren-
ergic receptor is the most prevalent noradrenergic receptor in the
PFC (Park et al., 2005; Arnsten et al., 1996). Two variants appear to
be risk factors for ADHD, the rs1800544 SNP in the promoter region,
for which the G-allele was considered risk-increasing (Park et al.,
2005), and the rs553668 SNP in the promoter region, for which the
T-allele was considered the risk allele (Park et al., 2005). However,
meta-analyses have not conﬁrmed associations with ADHD risk for
either SNP (Gizer et al., 2009). Alpha-2 adrenoreceptors have also
been implicated in other major neuropsychiatric diseases that are
often comorbid with ADHD, such as major depressive disorder and
schizophrenia (Langer, 2015).
Genotypic effects of ADRA2A on the brain were studied in only
two studies of Asian children with ADHD. A SPECT study showed
that carriers of the non-risk allele for rs1800544 exhibited reduced
perfusion in bilateral orbitofrontal regions (Kim et al., 2010). A
DTI study investigated the effect of both SNPs (rs1800544 and
rs553668) on white matter integrity. Carriers of the rs553668 non-
risk-allele (C-allele) showed reduced fractional anisotropy (FA) in
the right postcentral gyrus, whereas carriers of the rs553668 T-
allele (non-risk group) showed reduced FA in the right middle
frontal cortex (Park et al., 2013).
The Catechol-O-methyl-transferase enzyme (encoded by the
COMT gene, located at 22q11.21) is involved in the degradation
of the catecholamines dopamine and norepinephrine. It is highly
expressed in the frontal lobe regions, where it is responsible for the
regulation of dopamine levels (Hong et al., 1998). Studies inves-
tigating the association between COMT and ADHD have largely
focused on a functional SNP (rs4860) in exon 4 that leads to an
amino acid substitution (valine → methionine). This polymorphism
has been shown to considerably affect COMT enzyme activity,
such that homozygous carriers of the valine-allele show 3–4 times
higher activity than homozygous carriers of the methionine-allele,
resulting in decreased dopamine availability in valine homozygotes
(Chen et al., 2004). An initial small study suggested that the valine-
allele was  associated with increased risk for ADHD (Eisenberg et al.,
1999), although a recent meta-analysis failed to conﬁrm this associ-
ation (Lee and Song, 2015). The functional COMT rs4680 variant also
seems relevant to other psychiatric and cognitive phenotypes. A
recent study evaluating the association of the COMT genotype with
schizophrenia in a systematic review and meta-analysis in 32,816
subjects, revealing a signiﬁcant association (Gonzalez-Castro et al.,
2016). Another recent meta-analysis revealed an association of the
COMT genotype and reward learning, suggesting that variability
in dopamine signalling associated with COMT rs4680 inﬂuences
individual differences in reward processing, which may  potentially
contribute to psychopathology characterized by reward dysfunc-
tion, such as ADHD (Corral-Frias et al., 2016).
Two very small sMRI studies, both using VBM, examined the
genotypic effect of rs4680 on the brain in children with and without
ADHD (Table 3). Villemonteix and colleagues observed that chil-
dren with ADHD and at least one methionine-allele had reduced
grey matter volume in the insula/IFG relative to children without
ADHD (2015). In an additional ROI analysis within the small ADHD
group only (n = 34), the study showed that those children with
ADHD who  were homozygous for the valine-allele had increased
grey matter volume in the caudate nucleus compared to ADHD chil-
dren carrying the methionine-allele, and also compared to children
without ADHD (Villemonteix et al., 2015). A second sMRI study in
a Japanese childhood sample also found a relation of COMT geno-
type with striatal volume pointing in the same direction, as the
authors showed that the smaller grey matter volume observed in
the left putamen in children with ADHD was moderated by the
methionine-allele, whose carriers showed smaller volume than
the valine homozygotes (Shimada et al., 2015). Effects of COMT on
structural connectivity were investigated by two DTI studies. One
study in Asian children with ADHD revealed that carriers of the
methionine-allele showed a weakened network of white matter
connections linking 18 different brain regions (Hong et al., 2014)
(Table 3). This ﬁnding is in line with a report on healthy partic-
ipants, showing that the methionine-allele was associated with
impaired structural maturation of brain white matter connectivity
(Thomason et al., 2010). Based on these ﬁndings, Hong and cowork-
ers formulated the hypothesis that higher dopamine availability
may  inhibit myelination (2014). Recently, Kabukcu Basay and col-
leagues reported that children with ADHD, who  were homozygous
for the Valine-allele, had reduced FA and increased RD values in the
right cingulum bundle (2016). This indicates demyelination effects
in the white matter connections between the cingulated cortex to
the PFC, premotor regions, cortical association areas in the parietal
and occipital lobes, thalamus, and hippocampus (Kabukcu Basay
et al., 2016). The cingulated cortex is known to be involved in com-
plex cognitive processing (Bush et al., 2000) and functions that are
believed to be impaired in ADHD (Bush, 2011; Makris et al., 2008).
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A single fMRI study investigated the association of COMT rs4680
genotype on task performance and whole-brain neural activation
during response inhibition (van Rooij et al., 2015b). Although the
COMT Val158Met variant resulted in differential activation patterns
during successful and failed stop-trials in the combined ADHD-
control sample, no interactions between genetic effects and ADHD
diagnostic status were observed in any of the whole-brain fMRI
results (van Rooij et al., 2015b) (Table 3). This indicates that genetic
variation in the COMT gene exerts large-scale effects on neural
activation changes of the response inhibition network, but these
changes are independent of ADHD.
The single EEG study of COMT in ADHD, using a Go/No-Go
task in adults with and without ADHD, did not reveal an effect of
COMT genotype on brain activity individually. However, an epistatic
interaction of DRD4 × COMT genotype on neurophysiological cor-
relates of prefrontal function was observed (Heinzel et al., 2013).
In homozygous carriers of the DRD4 7R allele, the anteriorization
of the NoGo response (NGA, explained above) followed a more
pronounced U-relationship with increasing numbers of Met  alle-
les compared with 7R heterozygotes. In COMT Val/Met carriers,
DRD4 7R homozygotes showed a signiﬁcantly decreased NGA com-
pared with 7R heterozygotes. The genotype-dependent effects on
the NGA were localized in the right premotor and supplementary
motor area. The epistatic interactions were independent of ADHD
diagnosis (Heinzel et al., 2013). Given the role of fronto-striatal
circuits and dopamine in reward processing (Plichta and Scheres,
2014; von Rhein et al., 2015), an important domain of impair-
ment in ADHD (see above), it is surprising that no studies have yet
investigated the role of COMT in brain activity related to reward
anticipation and receipt.
The dopamine D1 receptor (encoded by the DRD1 gene) is the
most abundant dopamine receptor subtype in the brain; it is highly
expressed in the striatum and cerebral cortex (Bergson et al., 1995).
Common genetic variation in the DRD1 gene (rs5326) has been
associated with schizophrenia risk (Pan et al., 2014) and impaired
cognition in patients with bipolar disorder (Zhao et al., 2015), both
often found comorbid with ADHD. Several studies explored associ-
ations between ADHD and genetic variants of DRD1,  such as SNPs
rs4532 and rs265981 (Bobb et al., 2005). In the initial study, partici-
pants with ADHD were more likely than healthy controls to have the
C-allele or rs4532 and the A-allele of rs265981 (Bobb et al., 2005).
However, results of a meta-analysis of rs4532 did not support its
association with ADHD (Wu  et al., 2012), and also replication for
rs265981 is still pending. Nevertheless, two sMRI studies investi-
gated the effect of genetic variation in DRD1 on cortical thickness
(Shaw et al., 2007b) and on brain volume (Bobb et al., 2005). Nei-
ther study found an effect of DRD1 genotype or group × genotype
interactions (Table 3).
The 5-Hydroxytryptamine receptor 1B (encoded by the HTR1B
gene) is the most widely studied serotonin receptor gene in rela-
tion to ADHD. HTR1B is a G protein-coupled receptor that inhibits
cyclic AMP  formation (Murphy et al., 1998). It is highly expressed
in the dorsal raphe nucleus, which is involved in the sleep/wake
cycle, and to lesser degrees in the striatum and frontal regions, such
as the dorsolateral PFC (Ichikawa et al., 2005). The initial study,
investigating 273 nuclear families with ADHD, reported preferen-
tial transmission of the rs6296 G-allele to ADHD probands (Hawi
et al., 2002). Results of a meta-analysis supported this associa-
tion between childhood ADHD and rs6296 genotype (Gizer et al.,
2009). A single fMRI study investigated the relationship of rs6296
genotype with neural correlates of response inhibition, using a
stop-signal task in a childhood sample (van Rooij et al., 2015a). The
rs6296 genotype was associated with widespread differential acti-
vation during successful and failed stop trials (Table 3). However,
the direction of these effects was inconsistent, with both increased
and decreased activation for the GG genotype being observed in
frontal and posterior nodes, and the differential activation patterns
were independent of ADHD diagnosis (van Rooij et al., 2015a).
The latrophilin 3 gene (LPHN3; ofﬁcial name Adhesion G
Protein-Coupled Receptor L3 [ADGRL3]) codes for a member of the
LPHN subfamily of G-protein-coupled receptors (GPCRs). Subtype
3 is the most brain-speciﬁc LPHN (Sugita et al., 1998; Ichtchenko
et al., 1998) and is expressed in regions implicated in ADHD, i.e.
the caudate nucleus, cerebellum, amygdala, and cerebral cortex
(Arcos-Burgos et al., 2010). LPHN3 was identiﬁed as an ADHD risk
gene downstream of genetic linkage studies in multicase families
from a genetic isolate. In multisite association studies, initially, a
haplotype of three SNPs (rs6551665, rs1947274, and rs2345039)
was shown to be associated with ADHD (Arcos-Burgos et al., 2010).
The association of LPHN3 genotypes with ADHD has been repli-
cated in children (rs6551665) (Hwang et al., 2015) and adults with
ADHD (multiple markers) (Ribases et al., 2011). By use of proton
magnetic resonance spectroscopy (1H-MRS), Arcos-Burgos and col-
leagues showed that individuals carrying the LPHN3 susceptibility
haplotype exhibited a decreased ratio of N-acetylaspartate to cre-
atine (NAA/Cr ratio) in the left lateral and medial thalamus as well
as the right striatum, and an increased ratio in inferior–posterior
cerebellar vermis; this suggested that the maintenance of neu-
ron viability is altered in those carrying the ADHD risk haplotype
(2010). Since the ADHD susceptibility haplotype itself did not cause
any signiﬁcant coding region changes or canonical splice site alter-
ations, it was  suggested that non-coding variations may  be likely
contributors to ADHD (Domene et al., 2011).
Although LPHN3 is among the best-supported candidate genes
for ADHD, thus far, imaging genetics studies of the gene are still
limited in the literature. No studies on structural or connectiv-
ity alterations related to the risk variant of the gene in patients
with ADHD have been published yet, nor have any fMRI studies. An
EEG study using a Go/No-Go task revealed that adult patients with
ADHD carrying a ‘high-risk’ LPHN3 haplotype (comprised out of
rs2305339, rs734644, rs1397547, and rs1397548) showed a more
anterior Go-centroid of the P300, had a reduced NGA, and had
worse behavioural task performance due to more omission errors
(Fallgatter et al., 2013).
Monamine oxidase A, encoded by MAOA,  is an enzyme, which
catalyzes the oxidative deamination of amines, such as dopamine,
norepinephrine, and serotonin. For this gene located on the X-
chromosome, studies have largely focused on a functional 30 bp
VNTR 1.2 kb upstream of the gene, which has been previously asso-
ciated with impulsivity and aggression (Caspi et al., 2002; Manuck
et al., 2000). The polymorphism consists of alleles of 2, 3, 3.5, 4,
and 5 repeat copies, and evidence suggests that the 2 and 3 repeat
(‘low-activity/MAOA-L’) alleles are less efﬁciently transcribed than
the longer (‘high-activity/MAOA-H’) alleles (Deckert et al., 1999).
Although the MAOA gene has received a lot of attention as a can-
didate gene for ADHD given the prior ﬁndings for impulsivity, a
meta-analysis did not indicate a signiﬁcant association between
ADHD and the high activity alleles of the VNTR (Gizer et al., 2009).
A SNP, rs1137070 (located in exon 14), has also been reported to
contribute to impulsivity and the outcome of ADHD (Li et al., 2007a;
Liu et al., 2011). Especially, the C-allele of rs1137070 has been asso-
ciated with high ADHD scores and poor outcomes (Li et al., 2007a).
With evidence for a role of MAOA in aggression being more con-
sistent than for ADHD (e.g. (Brunner et al., 1993; Caspi et al., 2002;
Byrd and Manuck, 2014)), imaging genetics studies have largely
concentrated on population groups other than patients with ADHD,
e.g. (Holz et al., 2016; Meyer-Lindenberg et al., 2006). A recent fMRI
study forms an exception. Using a phonological working memory
task in male Asian adults with and without ADHD, the authors
showed that the effect of MAOA (rs1137070 T- versus C-allele)
interacted with diagnosis in the left inferior frontal lobe, pars oper-
cularis (Table 3); further analysis demonstrated that the increased
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brain activation observed in this region in patients was only signiﬁ-
cantly different to controls among those hemizygous for the T-allele
(Ko et al., 2015).
The NOS1 gene codes for nitric oxide synthase 1, an enzyme
that synthesizes nitric oxide from l-arginine. Nitric oxide is a reac-
tive free radical, which can act as a biological mediator in several
processes, including dopaminergic and serotonergic neurotrans-
mission (Kiss and Vizi, 2001) and neurite outgrowth (Chen et al.,
2006). The NOS1 gene has a complex structure, including 12 alter-
native untranslated ﬁrst exons (exon 1a-1l). In exon 1f, a VNTR that
affects gene expression has been linked to hyperactive and impul-
sive behaviour in humans (Reif et al., 2009; Weber et al., 2015); the
short allele was shown to be the risk factor for ADHD, especially in
females.
No studies have yet reported effects of NOS1 on brain structure.
A recent case-control DTI study of structural connectivity in ado-
lescents revealed that female homozygous carriers of the ADHD
risk allele showed higher MD  values in several major white mat-
ter tracts of the brain compared with long allele carriers. This effect
was present in both female patients and controls (van Ewijk et al., in
revision). The white matter tracts found affected by NOS1 genotype
overlap with those earlier found associated with ADHD (Onnink
et al., 2015; van Ewijk et al., 2012; Wu  et al., 2016). Since higher
MD values can be indicative of demyelination, lower axonal den-
sity, or axonal degeneration, homozygosity of the short allele might
thus be a risk factor for aberrant development of white matter tracts
involved in ADHD etiology.
NOS1 exon 1f is particularly highly expressed in striatum. There-
fore, the single study of gene effects on brain function investigated
the effect of the VNTR on ventral striatal activity during reward
anticipation using fMRI (Hoogman et al., 2011) (Table 3). The study
revealed that homozygous carriers of short alleles of NOS1 demon-
strated higher ventral striatal activity than carriers of the other
NOS1 VNTR genotypes (Hoogman et al., 2011). Again, this effect
was independent of diagnostic status. Similar effects of the geno-
type were also observed for behavioural impulsivity, with those
carrying the ADHD risk factor acting more impulsive than other
participants. As the authors did not perform mediation studies, it
remains to be investigated, whether the observed genotype effects
on brain connectivity and/or activity directly link to behavioural
effects.
The norepinephrine transporter gene (SLC6A2, NET1) codes for
a protein responsible for the reuptake of norepinephrine (as well as
dopamine) from the synaptic cleft back into the presynaptic neuron
(Pacholczyck, 1991). The gene is highly expressed in the frontal
lobes (Stahl, 2003). Candidate gene studies of SLC6A2/NET1 selected
numerous SNPs to test for association, but conﬂicting results have
been reported, with each study yielding evidence of association, but
differing in which speciﬁc SNPs were associated with ADHD (Gizer
et al., 2009).
A SPECT study examined the effects of rs5569 and rs28386840
on cerebral perfusion in response to MPH  treatment in Asian chil-
dren with ADHD (Table 3) (Park et al., 2012). At baseline, no
differences were observed, but after eight weeks of MPH  treatment
increased regional brain perfusion in the right inferior temporal
gyrus and middle temporal gyrus in homozygous carriers of the
rs5569 G-allele was demonstrated (Park et al., 2012). Given that
no previous studies had reported a signiﬁcant association between
this polymorphism and ADHD, no ‘risk’ allele was indicated. A
PET study reported the inﬂuence of four genetic variants within
the transporter gene on in vivo norepinephrine transporter bind-
ing in adults with and without ADHD (Table 3) (Sigurdardottir
et al., 2015); the authors found differences in cerebellar and tha-
lamic norepinephrine transporter binding depending on genotype
between adult patients and controls (Sigurdardottir et al., 2015).
For the two SNPs rs28386840 and rs2242446, patients carrying
the major alleles (A/T) showed increased norepinephrine trans-
porter binding in the thalamus compared to controls carrying the
major alleles. For the SNPs rs15534 and rs40615, controls carrying
the major alleles (C/T) showed increased norepinephrine trans-
porter binding in the cerebellum compared to patients carrying
the major alleles (Sigurdardottir et al., 2015). In the patients with
ADHD, a high correlation between hyperactivity/impulsivity symp-
toms and norepinephrine transporter binding in the cerebellum
was detected, an effect which was strongly moderated by genotype
(Sigurdardottir et al., 2015).
With this knowledge on SNP functionality related to ADHD,
studies using additional imaging modalities are warranted, but
thus far, only a single sMRI study investigated the effect of
genetic variation in SLC6A2/NET1 on brain volume (Table 3).
No effect of SLC6A2/NET1 genotype (for SNPs rs998424 and
rs3785157–different SNPs from those having been investigated
through PET and SPECT) and no group x genotype interactions were
reported (Bobb et al., 2005).
The serotonin transporter gene (5HTT, SERT; ofﬁcial name
SLC6A4) codes for a solute carrier protein responsible for the reup-
take of serotonin from the synaptic cleft back into the presynaptic
neuron, which is the primary mechanism for regulating sero-
tonergic activity in the brain (Lesch et al., 1996). A functional
polymorphism exists in the promoter region of this gene (5HTTLPR)
in the form of a 44-bp insertion/deletion yielding short (S) and long
(L) alleles. The long variant is associated with more rapid serotonin
reuptake, resulting in lower levels of active serotonin (Lesch et al.,
1996). A SNP in the long allele, rs25531, additionally modiﬁes its
activity (Lesch et al., 1996). SLC6A4/5HTT has been implicated in
emotion regulation, (emotional) memory, and learning processes
(Araragi and Lesch, 2013; Barzman et al., 2015; Meneses and Liy-
Salmeron, 2012). The serotonin transporter is expressed in regions
implicated in attention, memory, and motor activities, such as the
amygdala, hippocampus, thalamus, putamen, and ACC (Frankle
et al., 2004; Oquendo et al., 2007). The 5HTTLPR has been exten-
sively studied for its role in depression and anxiety – especially in
the context of environmental adversity, with the S-allele being the
risk allele (Caspi et al., 2003; Oo et al., 2016). For ADHD, the evidence
for association is more limited, although an earlier meta-analysis
provided signiﬁcant evidence of an association between ADHD (in
children) and the ‘long’ variant of 5HTTLPR (Gizer et al., 2009).
However, an international multicentre study reported a slight, non-
signiﬁcant overrepresentation of the S-allele in adult patients with
ADHD (Landaas et al., 2010).
Given the evidence for SLC6A4 as a depression gene, imaging
genetics research has largely concentrated on non-ADHD sam-
ples; in healthy individuals, functional genetic variation in the
SLC6A4/5HTT gene has been linked to emotion regulation through
effects on brain activation in the amygdala and the wider ‘threat
circuit’, while effects on regional brain volumes are inconsistent
(Klein et al., under review; Jonassen and Landro, 2014). Three sMRI
studies have been performed for 5HTTLPR in ADHD thus far, all
investigating GxE interactions. The initial study showed that the
interaction between exposure to environmental stress and car-
riership of the 5HTTLPR S-allele, which was linked to increased
ADHD severity in a longitudinal study of ADHD families (van der
Meer et al., 2014), was  associated with reduced cortical grey mat-
ter volume in the precentral gyrus, middle and superior frontal gyri,
frontal pole, and cingulate gyrus in S-allele carriers compared with
participants homozygous for the L-allele (van der Meer et al., 2015).
Importantly, this paper showed that only some of these regions,
the frontal pole and the ACC, actually mediated the effects of the
gene-environment interaction on ADHD severity. Similarly, van der
Meer and colleagues reported that individuals carrying the NR3C1
risk haplotype, who  were homozygous for the 5HTTLPR L-allele,
showed a negative relation between stress and grey matter vol-
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ume  (2016). However, no mediation effects were found, meaning
that the local effects of these interaction on grey matter volume
did not signiﬁcantly explain their association with ADHD sever-
ity (van der Meer et al., 2016). Such studies testing the mediation
of effects through the observed brain phenotypes (as opposed to
those just being epiphenomena of the genetic variation) are largely
lacking in the imaging genetics literature thus far, but are criti-
cally needed to map  gene to disease pathways. However, sample
sizes will have to be substantial to allow valid conclusions to
be drawn from such studies. Another sMRI study used the same
dataset and revealed that, in agreement with age-related reduc-
tions of total grey matter volume found in longitudinal studies
(Brain Development Cooperative, 2012; Raznahan et al., 2014), par-
ticipants scoring high on positive peer afﬁliation and carrying two
5HTTLPR L-alleles had smaller total grey matter volumes with age
(Richards et al., 2016). Moreover, participants with the same geno-
type, but low positive peer afﬁliation had larger GM volumes with
age (Richards et al., 2016). These ﬁndings were independent of
ADHD severity and were in line with a longitudinal study reporting
regional GM reductions with age in adolescents exposed to high
positive maternal behavior, but increased putamen volumes when
exposed to maternal aggression (Whittle et al., 2014).
In contrast to the sMRI studies, which investigated GxE effects
related to stress and social environments, the only fMRI study
focused on the relationship between 5HTTLPR genetic variation
and neural correlates of response inhibition using a stop-signal
task (van Rooij et al., 2015a) (Table 3). Using a childhood sam-
ple, van Rooij and colleagues revealed that homozygous carriers
of the 5HTTLPR S-allele showed decreased activation in the frontal
nodes and increased activation in the posterior nodes in success-
ful stop trials (2015a). However, no signiﬁcant associations were
found between differential neural activation and ADHD diagnosis
or ADHD severity (van Rooij et al., 2015a).
The synaptosomal-associated protein 25 (encoded by the
SNAP25 gene) is involved in axonal growth and synaptic plasticity,
as well as in the docking and fusion of synaptic vesicles in presy-
naptic neurons necessary for the regulation of neurotransmitter
release (Sollner et al., 1993). Several studies have tested for linkage
and association between SNAP25 and ADHD, and these studies have
consistently genotyped multiple SNPs within the gene rather than
focusing on any single polymorphism. An early meta-analysis of
SNP rs3746544 suggested SNAP25 as ADHD risk gene (Faraone et al.,
2005). A more recent meta-analysis of rs3746544 also provided evi-
dence of a modest but signiﬁcant association between childhood
ADHD and the T-allele, whereas no evidence of association with
rs1051312 was found (Gizer et al., 2009).
Again, only a single imaging genetics study is currently available
for this gene. In this case, the interaction of MPH  treatment-
related hemodynamic changes with genetic variation in SNAP25
(rs3746544 and rs1051312) was studied in small samples of chil-
dren and adults with ADHD on and off single dose MPH  using
fNIRS (Table 3). Through fNIRS, brain haemodynamics in pre-
frontal cortices can be measured, since brain activation causes
increased cerebral blood ﬂow, but not all of this oxygenized blood
is used, therefore oxygenated haemoglobin increases and deoxy-
haemoglobin decreases during e.g. sustained attention (Villringer
and Chance, 1997). Homozygous carriers of the rs3746544 T-allele
exhibited changes in right oxygenated haemoglobin and right as
well as left deoxyhaemoglobin levels. Additionally, homozygous
carriers of the rs1051312 T-allele showed decreased right pre-
frontal deoxyhaemoglobin with treatment. Combination of the
genotypes also showed interaction effects on right prefrontal
deoxyhaemoglobin levels (Oner et al., 2011).
Tryptophan hydroxylase 2 catalyzes the reaction of tryptophan
to 5-hydroxytryptophan, which is subsequently decarboxylated to
form the neurotransmitter serotonin. Two isoforms of tryptophan
hydroxylase have been identiﬁed (encoded by the TPH1 and TPH2
genes). The TPH2 gene codes for a rate-limiting enzyme in the pro-
duction of serotonin in serotonergic neurons in the midbrain raphe
nuclei, while TPH1 seems to be involved in synthesizing serotonin
in peripheral tissues (Walther et al., 2003). For several SNPs of the
TPH2 gene, an association with ADHD was  found (Brookes et al.,
2006; Sheehan et al., 2005; Walitza et al., 2005). For rs4570625, the
G-allele was  shown to be transmitted more often to offspring with
ADHD (Walitza et al., 2005). For rs11178997, the T-allele was iden-
tiﬁed as the risk allele for ADHD (Walitza et al., 2005). However,
the initial ﬁndings could not be replicated in a larger, multicen-
tre study (Brookes et al., 2006). Mouse models in conjunction with
approaches focusing on TPH2 variants in humans described a role of
serotonin in brain development and in disorders related to negative
emotionality, aggression, antisocial behaviour, and bipolar disor-
der (Waider et al., 2011; Gao et al., 2012, 2016). The TPH2 gene has
also been a candidate for the investigation of gene by environment
interaction studies, in depression and suicidal behaviour as well as
in aggression; for review see (Mandelli and Serretti, 2013; Lesch
et al., 2012).
As the evidence for a role of TPH2 in ADHD is limited, only a
single imaging genetics study involving patients with this disorder
has yet been performed for this gene. This EEG study investigated
the genotypic effect of the two  SNPs of the TPH2 gene mentioned
above (rs4570625 and rs11178997) on the NGA during a Go/NoGo
task in adult patients with ADHD and healthy individuals (Table 3).
Risk alleles of each of the SNPs were found associated with a reduc-
tion in the NGA in both participant groups, indicating an effect on
ADHD-relevant prefrontal brain function independent of a speciﬁc
psychiatric diagnosis (Baehne et al., 2009). These promising ﬁrst
ﬁndings may  warrant further analysis of TPH2 variants, especially
in combination with adverse environmental factors.
4. Outlook
In this review we set out to summarize the current literature on
imaging genetics studies of candidate genes involving patients with
ADHD. As no genome-wide association studies have yet reported
loci/genes with signiﬁcant evidence for association with ADHD, we
used a liberal deﬁnition of a candidate (having shown association
with the disorder in at least one earlier study) and used an adapted
version of the list of ADHD candidate genes recently compiled by
Li et al. (2014). Of the 62 candidate genes selected for review, we
found that only 12 had been studied with any brain imaging tech-
nique in an ADHD population. For most of those 12, only a very
limited number of studies was available. The two most frequently
studied ADHD candidate genes were the SLC6A3/DAT1 and DRD4
genes, and even for those two genes most ﬁndings await replication.
Brain imaging phenotypes offer an important level of investi-
gation in mapping the biological pathways from gene to disease.
Brain structure, function, and connectivity can provide endophe-
notypes (or intermediate phenotypes) for a disease (Gottesman
and Gould, 2003). As those brain endophenotypes are thought
to lie in-between a genetic factor and the clinical phenotype, it
has been argued that effect sizes for effects of genes on those
brain phenotypes may  be larger than the ones for effects on
behaviour. However, for structural brain phenotypes (i.e. brain vol-
umes) and for structural connectivity, this has been refuted by
recent large-scale studies; see (Franke et al., 2016; Jahanshad et al.,
in preparation). For brain activity measured by fMRI, comparisons
of cognitive and brain imaging studies for several genetic vari-
ants (Rose and Donohoe, 2013) and evidence from meta-analyses
(Mier et al., 2010; Murphy et al., 2013) suggests that effect sizes
might be larger. However, it is still unclear, how large the effects of
publication bias on those results are (Murphy et al., 2013). Never-
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theless, power estimates indicate that several hundred samples are
needed, while the majority of studies discussed in this review had
less than 50 participants per group (see Table 3). This has implica-
tions for the generalizability/replicability of positive ﬁndings (as
the sample investigated may  not sufﬁciently well represent the
population it was sampled from) as well as harbouring the risk
of false-negative ﬁndings (Button et al., 2013). Importantly, the
term endophenotype has also often been misused in recent years,
as for many of the so-called endophenotypes, the required criteria
have not all been investigated. As such, many of the endopheno-
types may  not be intermediates between gene and behavioural
phenotype, but rather be simple markers of disease (Kendler and
Neale, 2010). Assessing, whether a brain phenotype observed for
a risk genotype really mediates between the risk variant and the
behavioural/clinical phenotype has been done in hardly any of the
papers reviewed here. The paper by van der Meer and colleagues,
in which such an analysis has been performed, shows the impor-
tance of such mediation analyses, as only a subgroup of the brain
substrates of the gene-environment interaction investigated was
also linked to ADHD severity (2015).
Shortly summarizing the results of the review, our understand-
ing of the mechanisms underlying the action of genetic risk factors
for ADHD is still limited. A promising start has been made. We  see,
for example, that SLC6A3/DAT1 genotype regulates dopamine activ-
ity in striatal regions implicated in ADHD neurobiology (Spencer
et al., 2013). Genetic variants also appear to affect brain structure
and function beyond the regions of gene expression (Hong et al.,
2014; van der Meer et al., 2014; Villemonteix et al., 2015), which
is likely due to effects on structural and/or functional connectiv-
ity. Some studies reported differential genotype effects for ADHD
patients and controls, whereas others did not observe genotype by
diagnosis interactions (Table 3). However, such ﬁndings have not
been replicated yet, and genotype effects may  differ in the context
of other ADHD-related risk factors.
As there is room for improvement of study designs, and
research focusing on new ADHD candidate genes identiﬁed through
hypothesis-free, genome-wide association studies will soon be
needed, we address main challenges and opportunities for imag-
ing genetics studies in the following paragraph. Additionally, since
imaging genetics approaches cannot explain the full complexity
of a biological system such as the human brain, we also highlight
additional levels of investigation and methodologies that can com-
plement the insights provided by imaging genetics studies.
4.1. Main challenges and opportunities for imaging genetics
studies
The size of individual studies is potentially the biggest challenge
in imaging genetics today, as also discussed above. Given the small
(to potentially modest) effect sizes to be expected (Franke et al.,
2016; Murphy et al., 2013; Rose and Donohoe, 2013), larger samples
are essential in order to gain the necessary statistical power.
Common confounding factors encountered in the published
brain imaging genetics studies are mainly related to the study sam-
ple itself, and many are aggravated by the limited sample sizes
used.
False-negative ﬁndings may  occur due to the large variability of
the ADHD phenotype. Additionally, comorbidities occur frequently
in ADHD (Kessler et al., 2006; Mcgough et al., 2005; Wilens et al.,
2009), and differences in medication use may  further increase phe-
notypic heterogeneity (Schweren et al., 2013). Together with the
low effect sizes of individual common genetic variants and limited
sample sizes, phenotypic heterogeneity in a sample challenges the
discovery of effects. Meaningful subtyping of this heterogeneous
condition to decrease phenotypic heterogeneity and maximize
power might therefore be helpful. Besides that, potential differ-
ences of effects between age groups, with gender distribution,
intelligence levels, and between ethnicities can still make it chal-
lenging to replicate and generalize ﬁndings.
Although most genetic risk factors investigated here were
derived from studies of ADHD in children, our review shows that
imaging genetics studies have employed childhood, adolescent, and
adult ADHD samples. Knowing about the age-dependence of the
genetic contribution to ADHD (Chang et al., 2013; Pingault et al.,
2015), which e.g. results in differential association of SLC6A3/DAT1
(Franke et al., 2010) and DRD4 (Sanchez-Mora et al., 2011) with
ADHD in children and adults, makes the deﬁnition of appropri-
ate research questions highly important. Only one study thus far
used a longitudinal approach, with a follow-up period of six years
(Shaw et al., 2007b). Longitudinal samples are best suited to inves-
tigate potential age-dependent changes in the effects of genetic
factors on the brain, and therefore more longitudinal studies of
ADHD including imaging and genetic assessments are needed. This
is especially important in light of a recent discussion on whether not
only the onset of ADHD can occur in adulthood, but also whether
childhood-onset and adult-onset ADHD may  be distinct syndromes
or trajectories (Agnew-Blais et al., 2016; Caye et al., 2016; Faraone
and Biederman, 2016; Mofﬁtt et al., 2015). Therefore, longitudi-
nal studies including participants with remitted versus persistent
ADHD, can help us in understanding the genetic and neurobiologi-
cal correlates of this multifactorial disorder.
All of the imaging genetics studies reviewed here employed
hypothesis-driven approaches. This means, that candidate genetic
variants were only investigated in relation to speciﬁed candidate
brain phenotypes and by this it severely limits our ability to cre-
ate new knowledge on genetic effects on the brain. Even main
effects of a variant may  have been missed, as our ability to deﬁne
the right hypotheses is hampered by the still so limited under-
standing of ADHD etiology. Besides that, most studies investigated
single genetic variants (SNPs or VNTRs), although we know that
frequently more than one risk allele exists in a single gene/locus;
see e.g. (Schizophrenia Working Group of the Psychiatric Genomics
Consortium et al., 2014). Also, only few studies looked for epistatic
or gene-environment interaction effects.
In the face of limited sample sizes available for an imaging genet-
ics study, data reduction strategies might help to preserve power.
By moving to gene-based mass-univariate and multivariate statis-
tics, it is possible to test the combined effect of multiple genetics
variants in a single test statistic. Such models thus reduce the num-
ber of statistical tests, e.g. through gene-wide analyses, and – by
explaining more phenotypic variance – may  enable the discovery of
gene effects that would have been otherwise undetectable with sin-
gle variant methods (Hibar et al., 2011; Bralten et al., 2011, 2013).
Alternatively – or rather in addition – analyses of multiple genetic
factors may  be performed in the context of international collabo-
rations, like ENIGMA and CHARGE (Psaty et al., 2009; Thompson
et al., 2014) or using the publicly available data from large national
research efforts (like the UK Biobank; http://www.ukbiobank.ac.
uk/). These are mainly population studies, but since ADHD is cur-
rently viewed as an extreme on a continuum of population traits
(Larsson et al., 2013a; Chen et al., 2008), we can learn a lot from
studies performed in healthy individuals. While for this review, we
speciﬁcally selected studies that had included patients with ADHD,
it is indeed apparent also from those studies that genes affect traits
rather than disorders (Hoogman et al., 2011). We  have referred to
some relevant studies in healthy individuals already in the previ-
ous sections. An additional example is an fMRI study investigating a
genetic variant in SNAP25, which was  found associated with altered
activation of the posterior cingulate cortex during a working mem-
ory task, a ﬁnding that was  replicated in a second, independent
sample (Soderqvist et al., 2010). With working memory being one
of the cognitive domains affected in ADHD (Alderson et al., 2013),
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this ﬁnding can contribute to unravelling the biological pathways
from gene to disease. However, some studies have also suggested
differential genotype effects in subjects with ADHD and healthy
participants (Durston et al., 2008; Monuteaux et al., 2008; Onnink
et al., 2016). In those cases, imaging genetics studies in healthy
participants will not reveal the full spectrum of the genetic effects,
and studies in patients are warranted. The ENIGMA-ADHD Work-
ing Group, with its sample spanning 60 years of the human lifespan
(Hoogman et al., epub head of print), is an important resource for
the investigation of diagnosis-speciﬁc effects.
There are a number of additional areas, in which we foresee
that imaging genetics studies will proﬁt from technical advances
as well as recent insights into disease etiology. Importantly, a
new GWAS meta-analysis is now underway by the ADHD Working
Group of the Psychiatric Genomics Consortium (PGC) and the Dan-
ish iPSYCH consortium, which will provide several bona ﬁde ADHD
risk genes identiﬁed in hypothesis-free analyses (PGC and iPSYCH
ADHD working groups, in preparation). Those will be interesting
targets for investigation through imaging genetics approaches. In
addition, the introduction of next generation sequencing (NGS)
technology in psychiatric research will allow us to go beyond study-
ing SNPs and VNTRs. It is likely that also more rare genetic variants,
identiﬁed through exome and whole-genome sequencing will ﬁnd
their way into imaging genetics studies, e.g. through mutational
load or burden tests (Medland et al., 2014).
Most imaging genetics studies in the ﬁeld of ADHD have used
MRI  as their main brain imaging technique. For subcortical brain
structures, grey matter volume has been the most frequently inves-
tigated characteristic. For the cortex, measurements of surface
area (SA) and cortical thickness (CT) were found to be genetically
and phenotypically rather independent (Winkler et al., 2010). Vol-
ume  has been shown to be more closely related to SA than CT
(Winkler et al., 2010). Therefore, it has been suggested that SA
and CT measurements should be considered separately in imag-
ing genetics studies (Winkler et al., 2010), in addition or instead of
cortical volume. Until now, only very few studies have made use
of this opportunity, however. Because of its low invasiveness, high
spatial resolution, and wide availability of MRI  scanners, this tech-
nique dominates the brain imaging ﬁeld. Imaging genetic studies
investigating genetic variation in the SLC6A2/NET1, SLC6A3/DAT1,
and DRD4 also used PET and SPECT (Table 3). These modalities
enable direct localization and quantiﬁcation of e.g. binding capac-
ities of transporters and receptors, but are quite invasive. An
alternative method for investigating the neurochemistry of the
brain in vivo might be proton magnetic resonance spectroscopy
(1H-MRS), which allows for non-invasive quantiﬁcation of several
neurometabolites, such as N-acetylaspartate, (phospho-) crea-
tine, choline, myo-inositol, glutamate and glutamine, and gamma
aminobutyric acid (GABA) (Naaijen et al., 2015). While no signif-
icant differences in GABA levels were found in ADHD compared
with controls (Schur et al., 2016), a possible increased signal of a
combination of glutamate, glutamine, and GABA in the striatum
of ADHD patients was observed, as well as an increased signal in
the ACC in a paediatric ADHD sample and a reduced signal in an
adult ADHD sample; reviewed by (Naaijen et al., 2015). The neu-
rodevelopmental changes in fronto-striatal glutamatergic circuits
across the lifespan suggested by this might be interesting targets
for future imaging genetics studies. By combining different meth-
ods, it should be possible to create a comprehensive picture of how
polymorphisms in ADHD-related genes affect the brain at chemical,
structural, and functional levels. To date, also no MEG  genetics stud-
ies has been reported. The high temporal resolution of this modality
might be of great additional value in understanding genetic effects
on brain function. Resting-state fMRI studies are also still lacking
from the imaging genetics literature. Especially the combination
and integration of different modalities in the study of individual
participants may  provide more comprehensive insights into gene
effects (Kobiella et al., 2011). With respect to functional brain mark-
ers that might serve as a useful endophenotype, it is crucial to use
a functional contrast that isolates brain activity speciﬁcally associ-
ated with the cognitive process of interest. For example, stop/NoGo
and Go conditions in traditional stop-signal/Go-NoGo tasks not
only differ in the involvement of response inhibition, but also in
other processes such as novelty/probability of occurrence and per-
ceptual processing (Boehler et al., 2010; Sanchez-Carmona et al.,
2016). Results of a recent study highlight the importance of control-
ling for the different strategies adopted by participants to perform
selective stopping tasks before analyzing brain activation patterns
(Sanchez-Carmona et al., 2016). Thus, activity emerging from a
functional contrast (e.g., Go versus NoGo) will probably reﬂect a
mixture of different processes. This is an important issue to be con-
sidered, when interpreting task-based fMRI studies and designing
new studies.
Another opportunity to improve the design of imaging genetics
studies is the use of mediation and moderation analyses. In media-
tion analysis, a causal explanation for the effect of an independent
on a dependent variable is statistically modelled. The assumption of
causality is important in this type of analysis and thus should be jus-
tiﬁed by a plausible biological theory or appropriate experimental
constraints. In moderation analysis, the inﬂuence of a third vari-
able on the association of an independent and dependent variable
is modelled. The simple moderation and mediation models can be
combined to account for more complex data structures and biolog-
ical models (Hayes and Scharkow, 2013; van der Meer et al., 2014).
Such models have e.g. been employed in psychological (Aram et al.,
2010; Graziano et al., 2011) and medical research questions (Nigg
et al., 2008), but could be also promising for analyses of the path-
way from genes to phenotypes in complex disorders, such as ADHD,
which involves different biological and non-biological factors act-
ing synergistically during an individual’s developmental trajectory
(Bale et al., 2010; Krain and Castellanos, 2006). Indeed, van der Meer
and coworkers recently used such analyses to inspect the mod-
eration of the effect of stress on ADHD severity by the 5HTTLPR
genetic variant. The researchers could show that an interaction of
5HTTLPR genotype and stress was  associated with ADHD severity
(van der Meer et al., 2014), and that this gene-environment interac-
tion had several substrates in the brain. Importantly however, only
a subset of those substrates did really mediate the effects of the
gene-environment interaction, whereas others were epiphenom-
ena (van der Meer et al., 2015).
While imaging genetics studies with the goal of mapping path-
ways from gene to disease up to now have always started with
the selection of the candidate gene/variant to study, the advances
brought about by international consortia now start to allow entirely
data-driven approaches to be used for imaging genetics. For exam-
ple, we  have recently developed a comprehensive pipeline for the
analysis of genetic overlap of GWAS results for disease risk (in that
case schizophrenia risk data from the PGC) and the GWAS  results
for brain volume (Franke et al., 2016). The latter was  based on data
from the ENIGMA consortium (Stein et al., 2012; Medland et al.,
2014; Thompson et al., 2014), in which MRI  scans and genome-wide
genotyping data from up to 30,717 individuals were analysed, and
several genetic factors contributing to the volumes of speciﬁc brain
structures were identiﬁed (Hibar et al., 2015). Finding such over-
lap between disease risk variants and those for brain phenotypes
would be indicative of etiologic sharing, and would thus directly
ﬂag the pathways from gene to disease (Franke et al., 2016). For
their previous studies, ENIGMA used mainly regional brain vol-
ume  measures (Hibar et al., 2015; Stein et al., 2012), but one can
also envisage more comprehensive voxel-wise genome-wide scans
(vGWAS) to examine evidence for associations across the genome
at each voxel in the brain image (Stein et al., 2010). While these
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approaches still are limited by the fact that a stringent correction
for type I errors dramatically increases the threshold for statistical
signiﬁcance (as genomes and images are both highly dimensional),
data reduction strategies are being devised that can preserve power
in such settings (Medland et al., 2014). With respect to the different
imaging modalities, structural MRI  and DTI seem to be best suited
for larger collaborations and data sharing, but also fMRI imaging
genetics meta-analyses have been shown to be feasible (Mier et al.,
2010; Murphy et al., 2013). First analyses of overlap between ADHD
GWAS ﬁndings and results of the ENIGMA volume analyses are
currently underway (Klein et al., in preparation).
4.2. Complementary methods for the evaluation of the
mechanisms underlying ADHD risk genes
Imaging genetics analyses of the human brain provide informa-
tion on the effect of ADHD risk genes/variants on brain structure,
activity, and connectivity, but other levels of investigation are
needed to provide a more complete picture (Fig. 2). We  also need
information about the molecular networks, in which an ADHD gene
acts, and the cellular processes that are affected by it. In the follow-
ing section we highlight different methodologies and approaches
that can be used to shed light on these additional levels of complex-
ity contributing to the mechanisms underlying the effects of ADHD
genes on behaviour and disease.
4.2.1. Bioinformatics approaches help to integrate ﬁndings from
different types of molecular studies
Bioinformatics is a broad ﬁeld of research, which can support our
efforts to map  pathways from gene to disease in several different
ways. A ﬁrst goal to be pursued through bioinformatics analyses is
the clariﬁcation of the actual effects of risk variants on gene expres-
sion and regulation. Risk variants for a disease are often found in
non-protein coding sequences, and therefore the molecular con-
sequences are difﬁcult to evaluate (Paul et al., 2014; Civelek and
Lusis, 2014). We  will not go into this type of bioinformatics anal-
yses any deeper, but would want to point the interested reader
to a recent example for a comprehensive bioinformatic follow-up
study demonstrating how to elucidate the mechanisms by which a
genetic risk variant (e.g. rs1344706; ZNF408A gene) confers suscep-
tibility to disease, in this case schizophrenia and bipolar disorder
(Hess et al., 2015).
Bioinformatics can also help to unravel the molecular net-
works and cellular processes that an ADHD risk gene is involved
in. ADHD-associated genetic factors are distributed throughout
the genome; however, they have been found to be enriched
within functional categories. This clustering of ADHD-related genes
within functional networks or pathways has helped to identify
biological processes of importance to ADHD etiology. As also men-
tioned earlier, through those bioinformatics studies we  learned that
functions related to nervous system development, cell migration,
neuron projection morphogenesis/neurite outgrowth, oxogen-
esis, cell–cell communication, glutamatergic synapse/receptor
Fig. 2. This schematic representation of the endophenotype concept shows the pathway from gene to disease at different levels of complexity in psychiatric genetics. The
ﬁgure  has been modiﬁed from a previous publication (Fig. 1, (Franke et al., 2009)). Polygenicity (schematically depicted by gene A–I) is involved in causing disease symptoms.
A  reduced number of genes is involved in disease-related endophenotypes. These can be studied at various biological levels, e.g. biochemical processes and cell function can
be  assessed by biological assays in cell or animal models by measuring e.g. neuron morphology or synaptic functioning. Neuroimaging methods (structural and functional)
can  be applied to assess relevant endophenotypes at the level of brain morphology (‘Morphology brain region A–C’). Endophenotypes, related to the ‘function of brain units’,
can  be e.g. investigated by functional MRI  or through performance measurements on neuropsychological tests. Aberrations at this level can result in altered behavior and
disease-related behavioral traits, that subsequently lead to disease symptoms. Environmental inﬂuences can impact on all levels and need more attention in future studies.
Bioinformatic pathway and network analyses can help to integrate data from various sources and to identify molecular networks or cellular processes in which ADHD-related
genes  are enriched.
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signalling, multicellular organismal development, RhoA signalling,
glycosaminoglycan biosynthesis, ﬁbroblast growth factor receptor
activity, ion (potassium) channel function, transmembrane trans-
port, as well as synaptic transmission, catecholamine metabolic
processes, G-protein signalling and organonitrogen compound
catabolic processes are enriched in the results of hypothesis-free,
genome-wide ADHD-GWAS and CNV studies (Poelmans et al.,
2011; Hawi et al., 2015; Yang et al., 2013; Cristino et al., 2014;
Mooney et al., 2016; Thapar et al., 2015). Those studies mainly used
childhood ADHD data; little is yet known about biological path-
ways leading to persistence of ADHD. A ﬁrst, small-scale GWAS of
rare and common genetic variants in adults with persistent ADHD
showed that the top SNPs implicated biological pathways involved
in the regulation of gene expression, cell adhesion, and inﬂam-
mation (Zayats et al., 2015). The Network and Pathway Analysis
Subgroup of the PGC focussed on common pathways under-
lying additional, ADHD-related psychiatric disorders in adults,
i.e. schizophrenia, major depression, and bipolar disorder (The
Network Pathway Analysis Subgroup of The Psychiatric Genomics
Consortium, 2015). Histone methylation processes (playing impor-
tant roles in the regulation of gene expression) showed the
strongest association, and the researchers also found signiﬁcant
evidence for involvement of immune and neuronal signalling path-
ways and for processes occurring at the postsynaptic density (The
Network Pathway Analysis Subgroup of The Psychiatric Genomics
Consortium, 2015).
Comprehensive studies applied to the ADHD-related autism
spectrum disorders (ASD) point out, how the combination and
integration across several molecular modalities can advance our
knowledge about pathways from gene to disease. For example, sys-
tematic integration of ﬁndings from multiple levels of genomics
data and studies of mouse models highlighted the period of fetal
development and the processes of chromatin structure, neurite
outgrowth, steroidogenesis, synaptic function, and neuron-glial
signalling (Poelmans et al., 2013; Chen et al., 2015). Additional
studies revealed that ASD genes grouped together in terms of func-
tional annotations, protein–protein interactions and coexpression
(Voineagu et al., 2011; Ben-David and Shifman, 2012; O’roak et al.,
2012; Neale et al., 2012), and gene interaction and coevolutionary
patterns (Gilman et al., 2011). By integrating gene expression data
representing normal human fetal development, developmental
timing and cellular speciﬁcity of the molecular pathways disrupted
in ASD could be clariﬁed (Willsey et al., 2013; Parikshak et al.,
2013). Such integrative studies are still lacking for ADHD, but highly
warranted in order to shed more light on the onset and neurode-
velopmental trajectory of the disorder.
4.2.2. Animal models provide proof of causality for genes and
molecular processes found associated with ADHD
The complexity and crucial role of the brain in the human body
largely restrict studies in humans to the described non-invasive
imaging methods for investigating brain structure and function.
However, to fully understand the role of a disease gene in the
ﬁne-tuning of this sophisticated organ, we also need to be able to
manipulate genes and monitor the effects of such manipulation on
molecular and cellular processes. For this, animal models are indis-
pensable. They can be genetically modiﬁed to enable determination
of causality, have a natural complexity of the nervous system, and
allow a tight control of environmental inﬂuences, including diet
and drug delivery (Lange et al., 2012; van der Voet et al., 2016).
During the last decades, studies were performed on several ADHD
animal models, including monkey (Ma  et al., 2005; Seu et al., 2009),
rat (Ruocco et al., 2014; Williams et al., 2009b; Russell et al., 1995),
mouse (Wallis et al., 2012; Zhu et al., 2014; Zimmermann et al.,
2015 Zhu et al., 2014; Zimmermann et al., 2015), zebraﬁsh (Lange
et al., 2012), and fruit ﬂy (van der Voet et al., 2016). The particu-
larity of each model, like the different levels of complexity of the
nervous system, provide complementary information to the broad
picture of ADHD.
Most studies in monkeys were mainly based on drug administra-
tion to stimulate/inhibit certain brain regions or neurotransmitter
receptors and to study its effect on a nearly as sophisticated brain
structure as the human (Ma  et al., 2005; Seu et al., 2009).
The rat and mouse models additionally provided evidence for
involvement of genes in ADHD (Gainetdinov et al., 1999; Simchon
et al., 2010; Wallis et al., 2012; Zhuang et al., 2001; Zimmermann
et al., 2015 Zhuang et al., 2001; Zimmermann et al., 2015). This
was done by measuring face-valid hyperactivity, inattentiveness,
or impulsivity, and also looking for physiological and histological
abnormalities in reverse and forward genetic approaches. Reverse
genetic approaches are employed for disease candidate genes iden-
tiﬁed in human studies; the orthologues of the observed human
genes are manipulated in the animal model to evoke measur-
able phenotypes and to study their involvement on cellular and/or
behavioural levels (Rivero et al., 2013; Wallis et al., 2012). Forward
genetics use the opposite tactic by studying inbred animal strains
for ADHD-associated conducts, and analysing their protein expres-
sion pattern and behaviour (Dimatelis et al., 2015; Womersley et al.,
2015; Li et al., 2007b). In reverse genetics approaches, early stud-
ies proved the involvement of candidate genes from association
studies in ADHD, e.g. by showing ADHD-like behavioural pheno-
types in Dat1 knock-out mice and the coloboma mouse showing a
mutation in Snap25 (Heyser et al., 1995; Giros et al., 1996). Most
knock-out and transgenic mouse models targeted genes involved
in dopamine transmission. These mutant models provide an excel-
lent opportunity to evaluate the contribution of dopamine-related
processes to brain pathophysiology, to analyse the neuronal cir-
cuits and molecular mechanisms involved in the action of ADHD
medication, and to test novel treatments for ADHD; for review see
(Leo and Gainetdinov, 2013). More recent studies of a mouse model
containing a null mutation of the latrophilin 3 gene (Lphn3), which
showed a hyperactive phenotype in an open ﬁeld test, revealed that
this ADHD candidate gene is involved in gene expression regulation
of monoamine signalling genes, such as dopamine and serotonin
receptors and transporters, neurotransmitter metabolism genes,
and neural development genes (Wallis et al., 2012). Additionally,
actin depolymerising factor and n-coﬁllin double mutant mice dis-
played hyperlocomotion, impulsivity, impaired working memory,
and disturbed morphology of striatal excitatory synapses, accom-
panied by strongly increased glutamate release (Zimmermann
et al., 2015). Of note, the hyperlocomotion and impulsivity were
reversed by methylphenidate (Zimmermann et al., 2015).
While reverse genetics approaches are most often applied in
ADHD research to date, forward genetics has led to new models to
study ADHD, like the spontaneous hypertensive rat (SHR), which
was created to study hypertension by inbreeding albino Wistar
rats showing elevated blood pressure (Okamoto and Aoki, 1963).
These rats also showed deﬁcits in attention, and ADHD-associated
conducts, such as increased impulsivity and hyperactivity, and are
therefore widely employed as a model for ADHD (Li et al., 2007b;
Williams et al., 2009a,c,b). Studies of the molecular and cellu-
lar characteristics of this forward genetic model have provided
evidence that proteins involved in energy metabolism, neuro-
transmitter function, neural development, and myelination are
differently expressed in the striatum and PFC (Dimatelis et al., 2015;
Womersley et al., 2015). The observed changes in the striatal energy
metabolism support the neuroenergetics hypothesis of Killeen et al.
(2013), which states that inadequate neuronal energy supply can
lead to ADHD symptoms (2013). Moreover, the GABAergic system
was shown to be involved in ADHD-like behaviour of SHR rats by
investigating the physiological response of GABA on hippocampal
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slices and ﬁnding GABA signiﬁcantly altered during early-life stress
in these animals (Sterley et al., 2013b,a).
Novel animal models for the study of ADHD include zebraﬁsh
(Danio rerio) and the fruit ﬂy (Drosophila melanogaster) (Lange
et al., 2012; van der Voet et al., 2016). These models have the
great advantage of being relatively inexpensive, having a wide
range of genomic tools available, and being highly suitable for fast,
high throughput studies of (candidate) genes. The combination of
those characteristics, with the availability of valid and quantiﬁable
phenotypic readouts for ADHD-relevant traits makes these ani-
mal  models a potent addition to non-invasive studies in humans.
Even though both zebraﬁsh and fruit ﬂy diverged from the human
lineage early in evolution, there is still a high level of conserva-
tion of neuronal genes; for example, in a screen for intellectual
disability genes, more than 70% of candidate genes had an unam-
biguous orthologue in the fruit ﬂy (Oortveld et al., 2013; van der
Voet et al., 2014). Also genes involved in the phenotypic mani-
festation of hyperactivity were crucial during early evolution and
thus can be found in species with a much simpler nervous sys-
tem. Several studies show the strength of such models. In zebraﬁsh,
e.g. the orthologues of the human ADHD candidate genes LPHN3,
PER1, and PER2 have been studied and shown to cause hyperactiv-
ity (Huang et al., 2015; Lange et al., 2012; Wang et al., 2015a). The
lphn3.1 mutant ﬁsh showed, besides the behavioural phenotypes,
misplaced dopamineric neurons in the brain (Lange et al., 2012).
Functional studies on Per2 null mutants in zebraﬁsh showed differ-
ential expression of the circadian clock genes aanat2 and bmal1b
and indicated the involvement of Per2 in the circadian regulation
(Wang et al., 2015a). In addition, per1b mutant ﬁsh display hyperac-
tive and impulsivity-like behaviours and low levels of dopamine, of
which hyperactivity could be rescued by ADHD medication (Huang
et al., 2015). It could be shown that the circadian clock has direct
inﬂuence on the structure and abundance of dopaminergic neurons
and lower expression of transcription factors directly regulating
development, maintenance and differentiation of these neurons
(Huang et al., 2015). In the fruit ﬂy, manipulation of the orthologues
of the dopamine-related genes DAT1 and LPHN3,  caused character-
istic darkness-dependent hyperactivity, an ADHD-like behaviour
(van der Voet et al., 2016). Also in those models, ADHD medication
was able to reverse the behavioural phenotype (van der Voet et al.,
2016). Finally, the vacuolar protein sorting-associated protein 4A
(VPS4A) in the striatal node was signiﬁcantly associated with dys-
functional reward, a cognitive (e.g. poor inhibitory control or timing
estimation), but also affective (e.g. delay aversion or hyposensi-
tivity to reward) deﬁcit observed in ADHD (Jia et al., 2016). The
orthologue was studied in the fruit ﬂy, showing that ﬂies with an
overexpression of Vps4 have a reduced overall activity similar to
a Drd1 knockout ﬂy, while a knockdown of Vps4 leads to hyper-
activity, suggesting the involvement of VPS4A in the regulation of
DRD1-mediated activity (Jia et al., 2016).
At the level of animal models, the integration of knowledge
from models of different evolutional complexity will optimally sup-
port the elucidation of gene to disease pathways, as it is already
apparent from the initial study of LPHN3 orthologues across mouse,
zebraﬁsh, and fruit ﬂy.
4.2.3. Modelling psychiatric disorders at the cellular level by using
human induced pluripotent stem cell (hiPSC)-derived neurons
ADHD is a multifactorial disorder, and in most patients, sev-
eral to multiple genetic factors are likely to contribute to disease.
Animal models are mostly based on highly penetrant single gene
mutations, which limits the translation of ﬁndings from molecu-
lar and cellular levels to the human situation. A human model,
especially one derived from a patient him-/herself, might there-
fore be preferable in certain situations. Until recently, the only way
to study cellular processes and molecular pathways in patient brain
cells was  through post-mortem material. Due to the scarceness of
available post-mortem brain tissues, only a very limited number
of studies was performed to date, concentrated on demonstrating
an inﬂuence of ADHD-related genetic variants on gene expression
(Weber et al., 2015; Hawi et al., 2013a; Brookes et al., 2010, 2007).
Fortunately, cell reprogramming technology has been developed
throughout the past decade, which provides a powerful tool to
simulate neural developmental processes in vitro in a petri dish
(Brennand et al., 2015b; Takahashi et al., 2007; Yu et al., 2007).
Neurons from both healthy individuals and psychiatric patients can
be derived by (1) reprogramming human skin ﬁbroblasts or blood
mononuclear cells into induced pluripotent stem cells (iPSCs) and
then differentiating these into neurons (Zhang et al., 2013), or by
(2) directly reprogramming skin ﬁbroblasts into neural stem cells
or neurons (Pang et al., 2011; Vadodaria et al., 2015; Brennand and
Gage, 2012). The human induced pluripotent stem cell (hiPSC)-
derived neurons from a patient then have a genetic background
identical to the disorder state, and thereby provide the possibility
to characterize the effects of the cocktail of genetic perturbations
leading to disease in this patient (Brennand et al., 2015a; Madison
et al., 2015; O’shea and Mcinnis, 2015; Wang et al., 2015b; Lim
et al., 2015). Such effects may  be speciﬁc to cell types and/or spe-
ciﬁc developmental stages (Duan, 2015; Hockemeyer and Jaenisch,
2016). Moreover, a temporal analysis of disease initiation and pro-
gression can be performed in the cell type(s) most relevant to a
disorder (Brennand et al., 2012). For example, studying hiPSC neu-
rons from patients with disease-associated large CNVs provides
the opportunity to perform comprehensive molecular analyses
of the effects of these large CNVs in several cell lineages (Urban
and Purmann, 2015). Until now, several studies were published
using hiPSC-derived neurons from patients with ASD, schizophre-
nia, or bipolar disorder (Marchetto et al., 2010; Ananiev et al.,
2011; Urbach et al., 2010; Sheridan et al., 2011; Chiang et al.,
2011; Brennand et al., 2011; Wen  et al., 2014). For example, hiPSC-
derived neurons from patients with schizophrenia were shown
to have synapse deﬁcits and transcriptional dysregulation (Wen
et al., 2014). Additionally, by comparing hiPSC-derived neurons
from patients with bipolar disorder and controls, alterations in
key components of the microRNA processing pathway were iden-
tiﬁed, potentially altering neuronal cell fate determination (O’shea
and Mcinnis, 2015). To overcome confounding effects of variable
genetic backgrounds, when comparing cells from patients to those
from healthy controls, genome-editing technology can be applied
(Duan, 2015), such as Zinc-ﬁnger nucleases (ZFN) (Reinhardt et al.,
2013), transcription activator-like effector nucleases (TALEN) (Wen
et al., 2014), and recently developed clustered regularly interspaced
short palindromic repeats (CRISPR) (Ran et al., 2013; Wang et al.,
2015b; Liu et al., 2016). Such genome-editing enables the gen-
eration of isogenic hiPSC-derived neurons that differ only at the
genetic site of interest (Ding et al., 2013; Bedell et al., 2012; Choi
et al., 2013). In this way, speciﬁc mutations can be either introduced
in control cells or corrected in patient cells to investigate causality
(Duan, 2015; Hendriks et al., 2016).
Beyond mechanistic insights, hiPSC neurons might also serve as
a platform for high throughput screening to identify novel thera-
peutics for psychiatric disorders (Schadt et al., 2014). For example,
the ability to test drugs to rescue synaptic deﬁciency in Rett syn-
drome neurons has been demonstrated (Brennand et al., 2012).
Generally, it is suggested that these cell models are suited for
longitudinal observations, studying on-off-medication effects, and
investigating the mechanisms of comorbid disorders in individual
patients (O’shea and Mcinnis, 2015).
A current limitation of hiPSC-based models is the high hetero-
geneity of the derived differentiated neuronal populations (Gore
et al., 2011; Hu et al., 2010; Lister et al., 2011; Osafune et al.,
2008). Although almost pure glutamatergic neurons can be dif-
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ferentiated from hiPSCs, the differentiation efﬁciency for other
types of neurons, such as dopaminergic, GABAergic, serotonergic,
or cholinergic neurons, is relatively low, which can cause vari-
ability in the outcome of in vitro experiments (Swistowski et al.,
2010; Vadodaria et al., 2015; Zhang et al., 2013; Liu et al., 2013a;
Hu et al., 2016). Therefore, ideally a comparison of several hiPSC-
derived neuronal lines from multiple patients should be performed
(Brennand and Gage, 2012). It seems advantageous to model the
psychiatric disorders in a pure, speciﬁed type of neuron; however, it
is also reasonable to carry out investigations at the network level in
different types of neurons interacting, better mimicking the multi-
dimensional integration in the brain through 3D culture systems or
brain ‘organoids’, which are currently being developed (Kim et al.,
2015; Lancaster et al., 2013).
Based on the above, it is clear that the reprogramming tech-
nology will revolutionize our use of model systems. Although still
very much under development, and not yet applied to ADHD risk
genes, ﬁrst results for other psychiatric disorders already suggest
that valuable ﬁndings about molecular and cellular pathways from
gene to disease can be derived from iPSC-derived neurons.
5. Conclusion
Results from studies described in this review show that imag-
ing genetics approaches are highly suitable to provide more insight
into the pathways from gene to behaviour via the brain in ADHD.
However, this ﬁeld is clearly still in its early stages. Inconsistency
of ﬁndings, due to the use of relatively small sample sizes, clinical
and biological heterogeneity of ADHD, methodological differences
in study design, and analysis methodology, make it difﬁcult, yet, to
draw ﬁrm conclusions about effects of genes on brain morphology,
function, and connectivity. Individual genes need to be investigated
more extensively and in larger samples, and additional genes need
to be studied – preferably focussing on those implicated in ADHD
through genome-wide, hypothesis-free approaches. We  emphasize
that a combination and integration of imaging genetics studies with
complementary approaches at different levels of biological com-
plexity – including bioinformatics as well as cell and animal models
– will be necessary to fully map  the biological pathways from gene
to disease.
Conﬂict of interest
None of the authors report conﬂicts of interest. Barbara Franke
discloses having received educational speaking fees from Merz and
Shire.
Acknowledgements
Funding: This works was supported by the Netherlands Orga-
nization for Scientiﬁc Research (NWO), i.e. the NWO  Brain &
Cognition Excellence Program (grant 433-09-229) and the Vici
Innovation Program (grant 016-130-669 to BF). Additional support
was received from the European Community’s Seventh Frame-
work Programme (FP7/2007–2013) under grant agreements n◦
602805 (Aggressotype), n◦ 602450 (IMAGEMEND), and n◦ 278948
(TACTICS) as well as from the European Community’s Horizon
2020 Programme (H2020/2014–2020) under grant agreements n◦
643051 (MiND) and n◦ 667302 (CoCA). The work was also sup-
ported by grants for the ENIGMA Consortium (grant number U54
EB020403) from the BD2K Initiative of a cross-NIH partnership, and
by the ECNP Network ADHD across the Lifespan.
References
Agnew-Blais, J.C., Polanczyk, G.V., Danese, A., Wertz, J., Mofﬁtt, T.E., Arseneault, L.,
2016. Evaluation of the persistence, remission, and emergence of
attention-deﬁcit/hyperactivity disorder in young adulthood. JAMA Psychiatry
73, 713–720.
Ahmad, R.F., Malik, A.S., Kamel, N., Reza, F., Abdullah, J.M., 2016. Simultaneous
EEG-fMRI for working memory of the human brain. Australas. Phys. Eng. Sci.
Med. 39, 363–378.
Akutagava-Martins, G.C., Salatino-Oliveira, A., Genro, J.P., Contini, V., Polanczyk, G.,
Zeni, C., Chazan, R., Kieling, C., Anselmi, L., Menezes, A.M., Grevet, E.H., Bau,
C.H., Rohde, L.A., Hutz, M.H., 2014. Glutamatergic copy number variants and
their role in attention-deﬁcit/hyperactivity disorder. Am. J. Med. Genet. B
Neuropsychiatr. Genet. 165B, 502–509.
Albayrak, O., Putter, C., Volckmar, A.L., Cichon, S., Hoffmann, P., Nothen, M.M.,
Jockel, K.H., Schreiber, S., Wichmann, H.E., Faraone, S.V., Neale, B.M.,
Herpertz-Dahlmann, B., Lehmkuhl, G., Sinzig, J., Renner, T.J., Romanos, M.,
Warnke, A., Lesch, K.P., Reif, A., Schimmelmann, B.G., Scherag, A., Hebebrand, J.,
Hinney, A., Psychiatric, G.C.A.S., 2013. Common obesity risk alleles in
childhood attention-deﬁcit/hyperactivity disorder. Am.  J. Med. Genet. B
Neuropsychiatr. Genet. 162B, 295–305.
Albrecht, B., Brandeis, D., Uebel-Von Sandersleben, H., Valko, L., Heinrich, H., Xu, X.,
Drechsler, R., Heise, A., Kuntsi, J., Muller, U.C., Asherson, P., Steinhausen, H.C.,
Rothenberger, A., Banaschewski, T., 2014. Genetics of preparation and
response control in ADHD: the role of DRD4 and DAT1. J. Child Psychol.
Psychiatry 55, 914–923.
Alderson, R.M., Kasper, L.J., Hudec, K.L., Patros, C.H., 2013.
Attention-deﬁcit/hyperactivity disorder (ADHD) and working memory in
adults: a meta-analytic review. Neuropsychology 27, 287–302.
Althaus, M.,  Groen, Y., Wijers, A.A., Minderaa, R.B., Kema, I.P., Dijck, J.D., Hoekstra,
P.J.,  2010. Variants of the SLC6A3 (DAT1) polymorphism affect performance
monitoring-related cortical evoked potentials that are associated with ADHD.
Biol. Psychol. 85, 19–32.
American Psychiatric Association, 2013. Diagnostic and Statistical Manual of
Mental Disorders: DSM 5. Books4US.
Ananiev, G., Williams, E.C., LI, H., Chang, Q., 2011. Isogenic pairs of wild type and
mutant induced pluripotent stem cell (iPSC) lines from Rett syndrome patients
as  in vitro disease model. PLoS One 6, e25255.
Aram, D., Bazelet, I., Goldman, H., 2010. Early literacy and parental writing
mediation in young children with and without ADHD. Eur. J. Spec. Needs Educ.
25, 397–412.
Araragi, N., Lesch, K.P., 2013. Serotonin (5-HT) in the regulation of
depression-related emotionality: insight from 5-HT transporter and
tryptophan hydroxylase-2 knockout mouse models. Curr. Drug Targets 14,
549–570.
Arcos-Burgos, M., Jain, M.,  Acosta, M.T., Shively, S., Stanescu, H., Wallis, D., Domene,
S.,  Velez, J.I., Karkera, J.D., Balog, J., Berg, K., Kleta, R., Gahl, W.A., Roessler, E.,
Long, R., Lie, J., Pineda, D., Londono, A.C., Palacio, J.D., Arbelaez, A., Lopera, F.,
Elia, J., Hakonarson, H., Johansson, S., Knappskog, P.M., Haavik, J., Ribases, M.,
Cormand, B., Bayes, M.,  Casas, M.,  Ramos-Quiroga, J.A., Hervas, A., Maher, B.S.,
Faraone, S.V., Seitz, C., Freitag, C.M., Palmason, H., Meyer, J., Romanos, M.,
Walitza, S., Hemminger, U., Warnke, A., Romanos, J., Renner, T., Jacob, C., Lesch,
K.P., Swanson, J., Vortmeyer, A., Bailey-Wilson, J.E., Castellanos, F.X., Muenke,
M.,  2010. A common variant of the latrophilin 3 gene, LPHN3, confers
susceptibility to ADHD and predicts effectiveness of stimulant medication.
Mol. Psychiatry 15, 1053–1066.
Arnsten, A.F., Steere, J.C., Hunt, R.D., 1996. The contribution of alpha
2-noradrenergic mechanisms of prefrontal cortical cognitive function.
Potential signiﬁcance for attention-deﬁcit hyperactivity disorder. Arch. Gen.
Psychiatry 53, 448–455.
Arnsten, A.F., 2006. Fundamentals of attention-deﬁcit/hyperactivity disorder:
circuits and pathways. J. Clin. Psychiatry 67 (Suppl. 8), 7–12.
Asghari, V., Sanyal, S., Buchwaldt, S., Paterson, A., Jovanovic, V., Van Tol, H.H., 1995.
Modulation of intracellular cyclic AMP  levels by different human dopamine D4
receptor variants. J. Neurochem. 65, 1157–1165.
Asherson, P., Brookes, K., Franke, B., Chen, W.,  Gill, M.,  Ebstein, R.P., Buitelaar, J.,
Banaschewski, T., Sonuga-Barke, E., Eisenberg, J., Manor, I., Miranda, A., Oades,
R.D., Roeyers, H., Rothenberger, A., Sergeant, J., Steinhausen, H.C., Faraone, S.V.,
2007. Conﬁrmation that a speciﬁc haplotype of the dopamine transporter gene
is  associated with combined-type ADHD. Am.  J. Psychiatry 164, 674–677.
Baehne, C.G., Ehlis, A.C., Plichta, M.M.,  Conzelmann, A., Pauli, P., Jacob, C.,
Gutknecht, L., Lesch, K.P., Fallgatter, A.J., 2009. Tph2 gene variants modulate
response control processes in adult ADHD patients and healthy individuals.
Mol. Psychiatry 14, 1032–1039.
Bale, T.L., Baram, T.Z., Brown, A.S., Goldstein, J.M., Insel, T.R., Mccarthy, M.M.,
Nemeroff, C.B., Reyes, T.M., Simerly, R.B., Susser, E.S., Nestler, E.J., 2010. Early
life  programming and neurodevelopmental disorders. Biol. Psychiatry 68,
314–319.
Banaschewski, T., Becker, K., Scherag, S., Franke, B., Coghill, D., 2010. Molecular
genetics of attention-deﬁcit/hyperactivity disorder: an overview. Eur. Child
Adolesc. Psychiatry 19, 237–257.
Banerjee, T.D., Middleton, F., Faraone, S.V., 2007. Environmental risk factors for
attention-deﬁcit hyperactivity disorder. Acta Paediatr. 96, 1269–1274.
Barr, C.L., Feng, Y., Wigg, K.G., Schachar, R., Tannock, R., Roberts, W.,  Malone, M.,
Kennedy, J.L., 2001. 5’-untranslated region of the dopamine D4 receptor gene
and attention-deﬁcit hyperactivity disorder. Am. J. Med. Genet. 105, 84–90.
144 M. Klein et al. / Neuroscience and Biobehavioral Reviews 80 (2017) 115–155
Barzman, D., Geise, C., Lin, P.I., 2015. Review of the genetic basis of emotion
dysregulation in children and adolescents. World J. Psychiatry 5, 112–117.
Bedard, A.C., Schulz, K.P., Cook Jr., E.H., Fan, J., Clerkin, S.M., Ivanov, I., Halperin,
J.M., Newcorn, J.H., 2010. Dopamine transporter gene variation modulates
activation of striatum in youth with ADHD. Neuroimage 53, 935–942.
Bedell, V.M., Wang, Y., Campbell, J.M., Poshusta, T.L., Starker, C.G., Krug 2nd, R.G.,
Tan, W.,  Penheiter, S.G., Ma,  A.C., Leung, A.Y., Fahrenkrug, S.C., Carlson, D.F.,
Voytas, D.F., Clark, K.J., Essner, J.J., Ekker, S.C., 2012. In vivo genome editing
using a high-efﬁciency TALEN system. Nature 491, 114–118.
Ben-David, E., Shifman, S., 2012. Networks of neuronal genes affected by common
and rare variants in autism spectrum disorders. PLoS Genet. 8, e1002556.
Bergson, C., Mrzljak, L., Smiley, J.F., Pappy, M.,  Levenson, R., Goldman-Rakic, P.S.,
1995. Regional, cellular, and subcellular variations in the distribution of D1 and
D5 dopamine receptors in primate brain. J. Neurosci. 15, 7821–7836.
Biederman, J., Faraone, S.V., 2005. Attention-deﬁcit hyperactivity disorder. Lancet
366, 237–248.
Blokland, G.A., Mcmahon, K.L., Thompson, P.M., Hickie, I.B., Martin, N.G., de
Zubicaray, G.I., Wright, M.J., 2014. Genetic effects on the cerebellar role in
working memory: same brain, different genes? Neuroimage 86, 392–403.
Bobb, A.J., Addington, A.M., Sidransky, E., Gornick, M.C., Lerch, J.P., Greenstein, D.K.,
Clasen, L.S., Sharp, W.S., Inoff-Germain, G., Wavrant-De Vrieze, F.,
Arcos-Burgos, M.,  Straub, R.E., Hardy, J.A., Castellanos, F.X., Rapoport, J.L., 2005.
Support for association between ADHD and two candidate genes: NET1 and
DRD1. Am.  J. Med. Genet. B Neuropsychiatr. Genet. 134B, 67–72.
Boehler, C.N., Appelbaum, L.G., Krebs, R.M., Hopf, J.M., Woldorff, M.G., 2010.
Pinning down response inhibition in the brain–conjunction analyses of the
stop-signal task. Neuroimage 52, 1621–1632.
Braet, W.,  Johnson, K.A., Tobin, C.T., Acheson, R., Mcdonnell, C., Hawi, Z., Barry, E.,
Mulligan, A., Gill, M., Bellgrove, M.A., Robertson, I.H., Garavan, H., 2011. fMRI
activation during response inhibition and error processing: the role of the
DAT1 gene in typically developing adolescents and those diagnosed with
ADHD. Neuropsychologia 49, 1641–1650.
Brain Development Cooperative, G., 2012. Total and regional brain volumes in a
population-based normative sample from 4 to 18 years: the NIH MRI  Study of
Normal Brain Development. Cereb. Cortex 22, 1–12.
Bralten, J., Arias-Vasquez, A., Makkinje, R., Veltman, J.A., Brunner, H.G., Fernandez,
G., Rijpkema, M.,  Franke, B., 2011. Association of the Alzheimer’s gene SORL1
with hippocampal volume in young, healthy adults. Am.  J. Psychiatry 168,
1083–1089.
Bralten, J., Franke, B., Waldman, I., Rommelse, N., Hartman, C., Asherson, P.,
Banaschewski, T., Ebstein, R.P., Gill, M.,  Miranda, A., Oades, R.D., Roeyers, H.,
Rothenberger, A., Sergeant, J.A., Oosterlaan, J., Sonuga-Barke, E., Steinhausen,
H.C., Faraone, S.V., Buitelaar, J.K., Arias-Vasquez, A., 2013. Candidate genetic
pathways for attention-deﬁcit/hyperactivity disorder (ADHD) show
association to hyperactive/impulsive symptoms in children with ADHD. J. Am.
Acad. Child Adolesc. Psychiatry 52, 1204–1212, e1201.
Bralten, J., Greven, C.U., Franke, B., Mennes, M.,  Zwiers, M.P., Rommelse, N.N.,
Hartman, C., van der Meer, D., O’dwyer, L., Oosterlaan, J., Hoekstra, P.J.,
Heslenfeld, D., Arias-Vasquez, A., Buitelaar, J.K., 2015. Voxel-based
morphometry analysis reveals frontal brain differences in participants with
ADHD and their unaffected siblings. J. Psychiatry Neurosci. 41, 140377.
Brennand, K.J., Gage, F.H., 2012. Modeling psychiatric disorders through
reprogramming. Dis. Model Mech. 5, 26–32.
Brennand, K.J., Simone, A., Jou, J., Gelboin-Burkhart, C., Tran, N., Sangar, S., Li, Y.,
Mu,  Y., Chen, G., Yu, D., Mccarthy, S., Sebat, J., Gage, F.H., 2011. Modelling
schizophrenia using human induced pluripotent stem cells. Nature 473,
221–225.
Brennand, K.J., Simone, A., Tran, N., Gage, F.H., 2012. Modeling psychiatric
disorders at the cellular and network levels. Mol. Psychiatry 17, 1239–1253.
Brennand, K., Savas, J.N., Kim, Y., Tran, N., Simone, A., Hashimoto-Torii, K.,
Beaumont, K.G., Kim, H.J., Topol, A., Ladran, I., Abdelrahim, M.,
Matikainen-Ankney, B., Chao, S.H., Mrksich, M.,  Rakic, P., Fang, G., Zhang, B.,
Yates Jr., J.R., Gage, F.H., 2015a. Phenotypic differences in hiPSC NPCs derived
from patients with schizophrenia. Mol. Psychiatry 20, 361–368.
Brennand, K.J., Marchetto, M.C., Benvenisty, N., Brustle, O., Ebert, A., Izpisua
Belmonte, J.C., Kaykas, A., Lancaster, M.A., Livesey, F.J., Mcconnell, M.J., Mckay,
R.D., Morrow, E.M., Muotri, A.R., Panchision, D.M., Rubin, L.L., Sawa, A., Soldner,
F.,  Song, H., Studer, L., Temple, S., Vaccarino, F.M., Wu,  J., Vanderhaeghen, P.,
Gage, F.H., Jaenisch, R., 2015b. Creating patient-speciﬁc neural cells for the
in vitro study of brain disorders. Stem Cell Rep. 5 (6), 933–945.
Brookes, K., Xu, X., Chen, W.,  Zhou, K., Neale, B., Lowe, N., Anney, R., Franke, B., Gill,
M.,  Ebstein, R., Buitelaar, J., Sham, P., Campbell, D., Knight, J., Andreou, P.,
Altink, M.,  Arnold, R., Boer, F., Buschgens, C., Butler, L., Christiansen, H.,
Feldman, L., Fleischman, K., Fliers, E., Howe-Forbes, R., Goldfarb, A., Heise, A.,
Gabriels, I., Korn-Lubetzki, I., Johansson, L., Marco, R., Medad, S., Minderaa, R.,
Mulas, F., Muller, U., Mulligan, A., Rabin, K., Rommelse, N., Sethna, V., Sorohan,
J.,  Uebel, H., Psychogiou, L., Weeks, A., Barrett, R., Craig, I., Banaschewski, T.,
Sonuga-Barke, E., Eisenberg, J., Kuntsi, J., Manor, I., Mcgufﬁn, P., Miranda, A.,
Oades, R.D., Plomin, R., Roeyers, H., Rothenberger, A., Sergeant, J., Steinhausen,
H.C., Taylor, E., Thompson, M.,  Faraone, S.V., Asherson, P., 2006a. The analysis
of  51 genes in DSM-IV combined type attention deﬁcit hyperactivity disorder:
association signals in DRD4, DAT1 and 16 other genes. Mol. Psychiatry 11,
934–953.
Brookes, K.J., Chen, W.,  Xu, X., Taylor, E., Asherson, P., 2006b. Association of fatty
acid  desaturase genes with attention-deﬁcit/hyperactivity disorder. Biol.
Psychiatry 60, 1053–1061.
Brookes, K.J., Mill, J., Guindalini, C., Curran, S., Xu, X., Knight, J., Chen, C.K., Huang,
Y.S., Sethna, V., Taylor, E., Chen, W.,  Breen, G., Asherson, P., 2006c. A common
haplotype of the dopamine transporter gene associated with
attention-deﬁcit/hyperactivity disorder and interacting with maternal use of
alcohol during pregnancy. Arch. Gen. Psychiatry 63, 74–81.
Brookes, K.J., Neale, B.M., Sugden, K., Khan, N., Asherson, P., D’souza, U.M., 2007.
Relationship between VNTR polymorphisms of the human dopamine
transporter gene and expression in post-mortem midbrain tissue. Am.  J. Med.
Genet. B Neuropsychiatr. Genet. 144B, 1070–1078.
Brookes, K.J., Hawi, Z., Park, J., Scott, S., Gill, M.,  Kent, L., 2010. Polymorphisms of
the steroid sulfatase (STS) gene are associated with attention deﬁcit
hyperactivity disorder and inﬂuence brain tissue mRNA expression. Am.  J.
Med. Genet. B Neuropsychiatr. Genet. 153B, 1417–1424.
Brophy, K., Hawi, Z., Kirley, A., Fitzgerald, M.,  Gill, M.,  2002.
Synaptosomal-associated protein 25 (SNAP-25) and attention deﬁcit
hyperactivity disorder (ADHD): evidence of linkage and association in the Irish
population. Mol. Psychiatry 7, 913–917.
Brown, A.B., Biederman, J., Valera, E.M., Doyle, A.E., Bush, G., Spencer, T.,
Monuteaux, M.C., Mick, E., Whitﬁeld-Gabrieli, S., Makris, N., Laviolette, P.S.,
Oscar-Berman, M.,  Faraone, S.V., Seidman, L.J., 2010. Effect of dopamine
transporter gene (SLC6A3) variation on dorsal anterior cingulate function in
attention-deﬁcit/hyperactivity disorder. Am. J. Med. Genet. B Neuropsychiatr.
Genet. 153B, 365–375.
Brown, A.B., Biederman, J., Valera, E., Makris, N., Doyle, A., Whitﬁeld-Gabrieli, S.,
Mick, E., Spencer, T., Faraone, S., Seidman, L., 2011. Relationship of DAT1 and
adult ADHD to task-positive and task-negative working memory networks.
Psychiatry Res. 193, 7–16.
Brunner, H.G., Nelen, M., Breakeﬁeld, X.O., Ropers, H.H., Van Oost, B.A., 1993.
Abnormal behavior associated with a point mutation in the structural gene for
monoamine oxidase A. Science 262, 578–580.
Buitelaar, J., Kan, C., Asherson, P., 2011. ADHD in Adults; Characterization,
Diagnosis and Treatment. Cambridge University Press.
Burt, S.A., 2009. Rethinking environmental contributions to child and adolescent
psychopathology: a meta-analysis of shared environmental inﬂuences.
Psychol. Bull. 135, 608–637.
Bush, G., Luu, P., Posner, M.I., 2000. Cognitive and emotional inﬂuences in anterior
cingulate cortex. Trends Cogn. Sci. 4, 215–222.
Bush, G., 2011. Cingulate, frontal, and parietal cortical dysfunction in
attention-deﬁcit/hyperactivity disorder. Biol. Psychiatry 69, 1160–1167.
Button, K.S., Ioannidis, J.P., Mokrysz, C., Nosek, B.A., Flint, J., Robinson, E.S., Munafo,
M.R., 2013. Power failure: why small sample size undermines the reliability of
neuroscience. Nat. Rev. Neurosci. 14, 365–376.
Byrd, A.L., Manuck, S.B., 2014. MAOA, childhood maltreatment, and antisocial
behavior: meta-analysis of a gene-environment interaction. Biol. Psychiatry
75,  9–17.
Cao, X., Cao, Q., Long, X., Sun, L., Sui, M.,  Zhu, C., Zuo, X., Zang, Y., Wang, Y., 2009.
Abnormal resting-state functional connectivity patterns of the putamen in
medication-naive children with attention deﬁcit hyperactivity disorder. Brain
Res. 1303, 195–206.
Caspi, A., Mcclay, J., Mofﬁtt, T.E., Mill, J., Martin, J., Craig, I.W., Taylor, A., Poulton, R.,
2002. Role of genotype in the cycle of violence in maltreated children. Science
297, ce:surname>T.E.MofﬁttJ.MillJ.MartinI.W.CraigA.TaylorR.PoultonRole of
genotype in the cycle of violence in maltreated
childrenScience2972002851–854.
Caspi, A., Sugden, K., Mofﬁtt, T.E., Taylor, A., Craig, I.W., Harrington, H., Mcclay, J.,
Mill, J., Martin, J., Braithwaite, A., Poulton, R., 2003. Inﬂuence of life stress on
depression: moderation by a polymorphism in the 5-HTT gene. Science 301,
386–389.
Castellanos, F.X., Lau, E., Tayebi, N., Lee, P., Long, R.E., Giedd, J.N., Sharp, W.,  Marsh,
W.L., Walter, J.M., Hamburger, S.D., Ginns, E.I., Rapoport, J.L., Sidransky, E.,
1998. Lack of an association between a dopamine-4 receptor polymorphism
and attention-deﬁcit/hyperactivity disorder: genetic and brain morphometric
analyses. Mol. Psychiatry 3, 431–434.
Castellanos, F.X., Lee, P.P., Sharp, W.,  Jeffries, N.O., Greenstein, D.K., Clasen, L.S.,
Blumenthal, J.D., James, R.S., Ebens, C.L., Walter, J.M., Zijdenbos, A., Evans, A.C.,
Giedd, J.N., Rapoport, J.L., 2002. Developmental trajectories of brain volume
abnormalities in children and adolescents with attention-deﬁcit/hyperactivity
disorder. JAMA 288, 1740–1748.
Castellanos, F.X., Margulies, D.S., Kelly, C., Uddin, L.Q., Ghaffari, M., Kirsch, A., Shaw,
D.,  Shehzad, Z., di Martino, A., Biswal, B., Sonuga-Barke, E.J., Rotrosen, J., Adler,
L.A., Milham, M.P., 2008. Cingulate-precuneus interactions: a new locus of
dysfunction in adult attention-deﬁcit/hyperactivity disorder. Biol. Psychiatry
63, 332–337.
Caye, A., Rocha, T.B., Anselmi, L., Murray, J., Menezes, A.M., Barros, F.C., Goncalves,
H.,  Wehrmeister, F., Jensen, C.M., Steinhausen, H.C., Swanson, J.M., Kieling, C.,
Rohde, L.A., 2016. Attention-deﬁcit/hyperactivity disorder trajectories from
childhood to young adulthood: evidence from a birth cohort supporting a
late-onset syndrome. JAMA Psychiatry 73, 705–712.
Chang, F.M., Kidd, J.R., Livak, K.J., Pakstis, A.J., Kidd, K.K., 1996. The world-wide
distribution of allele frequencies at the human dopamine D4 receptor locus.
Hum. Genet. 98, 91–101.
Chang, Z., Lichtenstein, P., Asherson, P.J., Larsson, H., 2013. Developmental twin
study of attention problems: high heritabilities throughout development.
JAMA Psychiatry 70, 311–318.
Chen, J., Lipska, B.K., Halim, N., Ma,  Q.D., Matsumoto, M.,  Melhem, S., Kolachana,
B.S., Hyde, T.M., Herman, M.M.,  Apud, J., Egan, M.F., Kleinman, J.E., Weinberger,
M. Klein et al. / Neuroscience and Biobehavioral Reviews 80 (2017) 115–155 145
D.R., 2004. Functional analysis of genetic variation in
catechol-O-methyltransferase (COMT): effects on mRNA, protein, and enzyme
activity in postmortem human brain. Am. J. Hum. Genet. 75, 807–821.
Chen, J., Zacharek, A., Li, Y., Li, A., Wang, L., Katakowski, M.,  Roberts, C., Lu, M.,
Chopp, M.,  2006. N-cadherin mediates nitric oxide-induced neurogenesis in
young and retired breeder neurospheres. Neuroscience 140, 377–388.
Chen, W.,  Zhou, K., Sham, P., Franke, B., Kuntsi, J., Campbell, D., Fleischman, K.,
Knight, J., Andreou, P., Arnold, R., Altink, M.,  Boer, F., Boholst, M.J., Buschgens,
C.,  Butler, L., Christiansen, H., Fliers, E., Howe-Forbes, R., Gabriels, I., Heise, A.,
Korn-Lubetzki, I., Marco, R., Medad, S., Minderaa, R., Muller, U.C., Mulligan, A.,
Psychogiou, L., Rommelse, N., Sethna, V., Uebel, H., Mcgufﬁn, P., Plomin, R.,
Banaschewski, T., Buitelaar, J., Ebstein, R., Eisenberg, J., Gill, M.,  Manor, I.,
Miranda, A., Mulas, F., Oades, R.D., Roeyers, H., Rothenberger, A., Sergeant, J.,
Sonuga-Barke, E., Steinhausen, H.C., Taylor, E., Thompson, M.,  Faraone, S.V.,
Asherson, P., 2008. DSM-IV combined type ADHD shows familial association
with sibling trait scores: a sampling strategy for QTL linkage. Am.  J. Med.
Genet. B Neuropsychiatr. Genet. 147B, 1450–1460.
Chen, J., Penagarikano, O., Belgard, T.G., Swarup, V., Geschwind, D.H., 2015. The
emerging picture of autism spectrum disorder: genetics and pathology. Annu.
Rev. Pathol. 10, 111–144.
Cheon, K.A., Ryu, Y.H., Kim, J.W., Cho, D.Y., 2005. The homozygosity for 10-repeat
allele at dopamine transporter gene and dopamine transporter density in
Korean children with attention deﬁcit hyperactivity disorder: relating to
treatment response to methylphenidate. Eur. Neuropsychopharmacol. 15,
95–101.
Chiang, C.H., Su, Y., Wen, Z., Yoritomo, N., Ross, C.A., Margolis, R.L., Song, H., Ming,
G.L.,  2011. Integration-free induced pluripotent stem cells derived from
schizophrenia patients with a DISC1 mutation. Mol. Psychiatry 16, 358–360.
Cho, S.C., Kim, J.W., Kim, B.N., Hwang, J.W., Shin, M.S., Park, M.,  Kim, S.A., Cho, D.Y.,
Yoo, H.J., Chung, U.S., Son, J.W., Park, T.W., 2008. Association between the
alpha-2C-adrenergic receptor gene and attention deﬁcit hyperactivity disorder
in  a Korean sample. Neurosci. Lett. 446, 108–111.
Choi, S.M., Kim, Y., Shim, J.S., Park, J.T., Wang, R.H., Leach, S.D., Liu, J.O., Deng, C., Ye,
Z.,  Jang, Y.Y., 2013. Efﬁcient drug screening and gene correction for treating
liver disease using patient-speciﬁc stem cells. Hepatology 57, 2458–2468.
Choudhry, Z., Sengupta, S.M., Grizenko, N., Thakur, G.A., Fortier, M.E., Schmitz, N.,
Joober, R., 2013. Association between obesity-related gene FTO and ADHD.
Obesity (Silver Spring) 21, E738–744.
Ciliax, B.J., Drash, G.W., Staley, J.K., Haber, S., Mobley, C.J., Miller, G.W., Mufson, E.J.,
Mash, D.C., Levey, A.I., 1999. Immunocytochemical localization of the
dopamine transporter in human brain. J. Comp. Neurol. 409, 38–56.
Civelek, M., Lusis, A.J., 2014. Systems genetics approaches to understand complex
traits. Nat. Rev. Genet. 15, 34–48.
Clarke, A.R., Barry, R.J., Dupuy, F.E., Heckel, L.D., Mccarthy, R., Selikowitz, M.,
Johnstone, S.J., 2011. Behavioural differences between EEG-deﬁned subgroups
of  children with attention-deﬁcit/hyperactivity disorder. Clin. Neurophysiol.
122, 1333–1341.
Comings, D.E., Comings, B.G., Muhleman, D., Dietz, G., Shahbahrami, B., Tast, D.,
Knell, E., Kocsis, P., Baumgarten, R., Kovacs, B.W., et al., 1991. The dopamine D2
receptor locus as a modifying gene in neuropsychiatric disorders. JAMA 266,
1793–1800.
Cook Jr., E.H., Stein, M.A., Krasowski, M.D., Cox, N.J., Olkon, D.M., Kieffer, J.E.,
Leventhal, B.L., 1995. Association of attention-deﬁcit disorder and the
dopamine transporter gene. Am.  J. Hum. Genet. 56, 993–998.
Corral-Frias, N.S., Pizzagalli, D.A., Carre, J., Michalski, L.J., Nikolova, Y.S., Perlis, R.H.,
Fagerness, J., Lee, M.R., Drabant Conley, E., Lancaster, T.M., Haddad, S., Wolf, A.,
Smoller, J.W., Hariri, A.R., Bogdan, R., 2016. COMT val met  genotype is
associated with reward learning: a replication study and meta-analysis. Genes
Brain Behav. 15 (5), 503–513.
Cortese, S., Kelly, C., Chabernaud, C., Proal, E., Di Martino, A., Milham, M.P.,
Castellanos, F.X., 2012. Toward systems neuroscience of ADHD: a
meta-analysis of 55 fMRI studies. Am. J. Psychiatry 169, 1038–1055.
Cristino, A.S., Williams, S.M., Hawi, Z., An, J.Y., Bellgrove, M.A., Schwartz, C.E., Costa
Lda, F., Claudianos, C., 2014. Neurodevelopmental and neuropsychiatric
disorders represent an interconnected molecular system. Mol. Psychiatry 19,
294–301.
Cross-Disorder Group of The Psychiatric Genomics Consortium, 2013.
Identiﬁcation of risk loci with shared effects on ﬁve major psychiatric
disorders: a genome-wide analysis. Lancet 381, 1371–1379.
Cruceanu, C., Ambalavanan, A., Spiegelman, D., Gauthier, J., Lafreniere, R.G., Dion,
P.A., Alda, M.,  Turecki, G., Rouleau, G.A., 2013. Family-based exome-sequencing
approach identiﬁes rare susceptibility variants for lithium-responsive bipolar
disorder. Genome 56, 634–640.
Cukier, H.N., Dueker, N.D., Slifer, S.H., Lee, J.M., Whitehead, P.L., Lalanne, E., Leyva,
N.,  Konidari, I., Gentry, R.C., Hulme, W.F., Booven, D.V., Mayo, V., Hofmann,
N.K., Schmidt, M.A., Martin, E.R., Haines, J.L., Cuccaro, M.L., Gilbert, J.R.,
Pericak-Vance, M.A., 2014. Exome sequencing of extended families with
autism reveals genes shared across neurodevelopmental and neuropsychiatric
disorders. Mol. Autism 5, 1.
Daly, G., Hawi, Z., Fitzgerald, M.,  Gill, M.,  1999. Mapping susceptibility loci in
attention deﬁcit hyperactivity disorder: preferential transmission of parental
alleles at DAT1, DBH and DRD5 to affected children. Mol. Psychiatry 4, 192–196.
de La Garza 2nd, R., Madras, B.K., 2000. [(3)H]PNU-101958, a D(4) dopamine
receptor probe, accumulates in prefrontal cortex and hippocampus of
non-human primate brain. Synapse 37, 232–244.
De Luca, V., Muglia, P., Vincent, J.B., Lanktree, M.,  Jain, U., Kennedy, J.L., 2004.
Adrenergic alpha 2C receptor genomic organization: association study in adult
ADHD. Am.  J. Med. Genet. B Neuropsychiatr. Genet. 127B, 65–67.
Deckert, J., Catalano, M.,  Syagailo, Y.V., Bosi, M.,  Okladnova, O., Di Bella, D., Nothen,
M.M.,  Maffei, P., Franke, P., Fritze, J., Maier, W.,  Propping, P., Beckmann, H.,
Bellodi, L., Lesch, K.P., 1999. Excess of high activity monoamine oxidase A gene
promoter alleles in female patients with panic disorder. Hum. Mol. Genet. 8,
621–624.
del Campo, N., Muller, U., Sahakian, B.J., 2012. Neural and behavioral
endophenotypes in ADHD. Curr. Top. Behav. Neurosci. 11, 65–91.
Demontis, D., Lescai, F., Borglum, A., Glerup, S., Ostergaard, S.D., Mors, O., Li, Q.,
Liang, J., Jiang, H., Li, Y., Wang, J., Lesch, K.P., Reif, A., Buitelaar, J.K., Franke, B.,
2016. Whole-exome sequencing reveals increased burden of rare functional
and  disruptive variants in candidate risk genes in individuals with persistent
attention-deﬁcit/hyperactivity disorder. J. Am. Acad. Child Adolesc. Psychiatry
55,  521–523.
Dimatelis, J.J., Hsieh, J.H., Sterley, T.L., Marais, L., Womersley, J.S., Vlok, M.,  Russell,
V.A., 2015. Impaired energy metabolism and disturbed dopamine and
glutamate signalling in the striatum and prefrontal cortex of the
spontaneously hypertensive rat model of attention-deﬁcit hyperactivity
disorder. J. Mol. Neurosci. 56, 696–707.
Ding, Q., Lee, Y.K., Schaefer, E.A., Peters, D.T., Veres, A., Kim, K., Kuperwasser, N.,
Motola, D.L., Meissner, T.B., Hendriks, W.T., Trevisan, M.,  Gupta, R.M., Moisan,
A.,  Banks, E., Friesen, M.,  Schinzel, R.T., Xia, F., Tang, A., Xia, Y., Figueroa, E.,
Wann, A., Ahfeldt, T., Daheron, L., Zhang, F., Rubin, L.L., Peng, L.F., Chung, R.T.,
Musunuru, K., Cowan, C.A., 2013. A TALEN genome-editing system for
generating human stem cell-based disease models. Cell Stem Cell 12, 238–251.
Domene, S., Stanescu, H., Wallis, D., Tinloy, B., Pineda, D.E., Kleta, R., Arcos-Burgos,
M.,  Roessler, E., Muenke, M.,  2011. Screening of human LPHN3 for variants
with a potential impact on ADHD susceptibility. Am.  J. Med. Genet. B
Neuropsychiatr. Genet. 156B, 11–18.
Doucette-Stamm, L.A., Blakely, D.J., Tian, J., Mockus, S., Mao, J.I., 1995. Population
genetic study of the human dopamine transporter gene (DAT1). Genet.
Epidemiol. 12, 303–308.
Doyle, A.E., Faraone, S.V., Seidman, L.J., Willcutt, E.G., Nigg, J.T., Waldman, I.D.,
Pennington, B.F., Peart, J., Biederman, J., 2005. Are endophenotypes based on
measures of executive functions useful for molecular genetic studies of ADHD?
J.  Child Psychol. Psychiatry 46, 774–803.
Dramsdahl, M.,  Westerhausen, R., Haavik, J., Hugdahl, K., Plessen, K.J., 2012. Adults
with attention-deﬁcit/hyperactivity disorder – a diffusion-tensor imaging
study of the corpus callosum. Psychiatry Res. 201, 168–173.
Dresler, T., Ehlis, A.C., Heinzel, S., Renner, T.J., Reif, A., Baehne, C.G., Heine, M.,
Boreatti-Hummer, A., Jacob, C.P., Lesch, K.P., Fallgatter, A.J., 2010. Dopamine
transporter (SLC6A3) genotype impacts neurophysiological correlates of
cognitive response control in an adult sample of patients with ADHD.
Neuropsychopharmacology 35, 2193–2202.
Dresler, T., Barth, B., Ethofer, T., Lesch, K.-P., Ehlis, A.-C., Fallgatter, A.J., 2014.
Imaging genetics in adult attention-deﬁcit/hyperactivity disorder (ADHD): a
way towards pathophysiological understanding? Borderline Personality
Disord. Emot. Dysregul. 1, 6.
Drgon, T., Lin, Z., Wang, G.J., Fowler, J., Pablo, J., Mash, D.C., Volkow, N., Uhl, G.R.,
2006. Common human 5’ dopamine transporter (SLC6A3) haplotypes yield
varying expression levels in vivo. Cell. Mol. Neurobiol. 26, 875–889.
Duan, J., 2015. Path from schizophrenia genomics to biology: gene regulation and
perturbation in neurons derived from induced pluripotent stem cells and
genome editing. Neurosci. Bull. 31, 113–127.
Durston, S., Fossella, J.A., Casey, B.J., Hulshoff Pol, H.E., Galvan, A., Schnack, H.G.,
Steenhuis, M.P., Minderaa, R.B., Buitelaar, J.K., Kahn, R.S., Van Engeland, H.,
2005. Differential effects of DRD4 and DAT1 genotype on fronto-striatal gray
matter volumes in a sample of subjects with attention deﬁcit hyperactivity
disorder, their unaffected siblings, and controls. Mol. Psychiatry 10, 678–685.
Durston, S., Fossella, J.A., Mulder, M.J., Casey, B.J., Ziermans, T.B., Vessaz, M.N., Van
Engeland, H., 2008. Dopamine transporter genotype conveys familial risk of
attention-deﬁcit/hyperactivity disorder through striatal activation. J. Am.  Acad.
Child Adolesc. Psychiatry 47, 61–67.
Durston, S., de Zeeuw, P., Staal, W.G., 2009. Imaging genetics in ADHD: a focus on
cognitive control. Neurosci. Biobehav. Rev. 33, 674–689.
Durston, S., 2003. A review of the biological bases of ADHD: what have we learned
from imaging studies? Ment. Retard. Dev. Disabil Res. Rev. 9, 184–195.
Durston, S., 2010. Imaging genetics in ADHD. Neuroimage 53, 832–838.
Ehlis, A.C., Bahne, C.G., Jacob, C.P., Herrmann, M.J., Fallgatter, A.J., 2008. Reduced
lateral prefrontal activation in adult patients with
attention-deﬁcit/hyperactivity disorder (ADHD) during a working memory
task: a functional near-infrared spectroscopy (fNIRS) study. J. Psychiatr. Res.
42,  1060–1067.
Ehlis, A.C., Schneider, S., Dresler, T., Fallgatter, A.J., 2014. Application of functional
near-infrared spectroscopy in psychiatry. Neuroimage 85 (Pt 1), 478–488.
Eisenberg, J., Mei-Tal, G., Steinberg, A., Tartakovsky, E., Zohar, A., Gritsenko, I.,
Nemanov, L., Ebstein, R.P., 1999. Haplotype relative risk study of
catechol-O-methyltransferase (COMT) and attention deﬁcit hyperactivity
disorder (ADHD): association of the high-enzyme activity Val allele with ADHD
impulsive-hyperactive phenotype. Am.  J. Med. Genet. 88, 497–502.
Elia, J., Capasso, M.,  Zaheer, Z., Lantieri, F., Ambrosini, P., Berrettini, W.,  Devoto, M.,
Hakonarson, H., 2009. Candidate gene analysis in an on-going genome-wide
association study of attention-deﬁcit hyperactivity disorder: suggestive
association signals in ADRA1A. Psychiatr. Genet. 19, 134–141.
146 M. Klein et al. / Neuroscience and Biobehavioral Reviews 80 (2017) 115–155
Elia, J., Gai, X., Xie, H.M., Perin, J.C., Geiger, E., Glessner, J.T., D’arcy, M.,
Deberardinis, R., Frackelton, E., Kim, C., Lantieri, F., Muganga, B.M., Wang, L.,
Takeda, T., Rappaport, E.F., Grant, S.F., Berrettini, W.,  Devoto, M., Shaikh, T.H.,
Hakonarson, H., White, P.S., 2010. Rare structural variants found in
attention-deﬁcit hyperactivity disorder are preferentially associated with
neurodevelopmental genes. Mol. Psychiatry 15, 637–646.
Elia, J., Glessner, J.T., Wang, K., Takahashi, N., Shtir, C.J., Hadley, D., Sleiman, P.M.,
Zhang, H., Kim, C.E., Robison, R., Lyon, G.J., Flory, J.H., Bradﬁeld, J.P., Imielinski,
M.,  Hou, C., Frackelton, E.C., Chiavacci, R.M., Sakurai, T., Rabin, C., Middleton,
F.A., Thomas, K.A., Garris, M.,  Mentch, F., Freitag, C.M., Steinhausen, H.C.,
Todorov, A.A., Reif, A., Rothenberger, A., Franke, B., Mick, E.O., Roeyers, H.,
Buitelaar, J., Lesch, K.P., Banaschewski, T., Ebstein, R.P., Mulas, F., Oades, R.D.,
Sergeant, J., Sonuga-Barke, E., Renner, T.J., Romanos, M.,  Romanos, J., Warnke,
A., Walitza, S., Meyer, J., Palmason, H., Seitz, C., Loo, S.K., Smalley, S.L.,
Biederman, J., Kent, L., Asherson, P., Anney, R.J., Gaynor, J.W., Shaw, P., Devoto,
M.,  White, P.S., Grant, S.F., Buxbaum, J.D., Rapoport, J.L., Williams, N.M., Nelson,
S.F., Faraone, S.V., Hakonarson, H., 2012. Genome-wide copy number variation
study associates metabotropic glutamate receptor gene networks with
attention deﬁcit hyperactivity disorder. Nat. Genet. 44, 78–84.
Ellison-Wright, I., Ellison-Wright, Z., Bullmore, E., 2008. Structural brain change in
Attention Deﬁcit Hyperactivity Disorder identiﬁed by meta-analysis. BMC
Psychiatry 8, 51.
de Silva, M.G., Elliott, K., Dahl, H.H., Fitzpatrick, E., Wilcox, S., Delatycki, M.,
Williamson, R., Efron, D., Lynch, M.,  Forrest, S., 2003. Disruption of a novel
member of a sodium/hydrogen exchanger family and DOCK3 is associated
with an attention deﬁcit hyperactivity disorder-like phenotype. J. Med. Genet.
40, 733–740.
Fallgatter, A.J., Muller, T.J., 2001. Electrophysiological signs of reduced prefrontal
response control in schizophrenic patients. Psychiatry Res. 107, 19–28.
Fallgatter, A.J., Strik, W.K., 1999. The NoGo-anteriorization as a neurophysiological
standard-index for cognitive response control. Int. J. Psychophysiol. 32,
233–238.
Fallgatter, A.J., Bartsch, A.J., Herrmann, M.J., 2002. Electrophysiological
measurements of anterior cingulate function. J. Neural Transm. (Vienna) 109,
977–988.
Fallgatter, A.J., Ehlis, A.C., Rosler, M.,  Strik, W.K., Blocher, D., Herrmann, M.J., 2005.
Diminished prefrontal brain function in adults with psychopathology in
childhood related to attention deﬁcit hyperactivity disorder. Psychiatry Res.
138, 157–169.
Fallgatter, A.J., Ehlis, A.C., Dresler, T., Reif, A., Jacob, C.P., Arcos-Burgos, M.,  Muenke,
M.,  Lesch, K.P., 2013. Inﬂuence of a latrophilin 3 (LPHN3) risk haplotype on
event-related potential measures of cognitive response control in
attention-deﬁcit hyperactivity disorder (ADHD). Eur. Neuropsychopharmacol.
23,  458–468.
Faraone, S.V., Biederman, J., 2016. CAn attention-deﬁcit/hyperactivity disorder
onset occur in adulthood? JAMA Psychiatry 73, 655–656.
Faraone, S.V., Mick, E., 2010. Molecular genetics of attention deﬁcit hyperactivity
disorder. Psychiatr. Clin. North Am.  33, 159–180.
Faraone, S.V., Perlis, R.H., Doyle, A.E., Smoller, J.W., Goralnick, J.J., Holmgren, M.A.,
Sklar, P., 2005. Molecular genetics of attention-deﬁcit/hyperactivity disorder.
Biol. Psychiatry 57, 1313–1323.
Faraone, S.V., Biederman, J., Mick, E., 2006. The age-dependent decline of attention
deﬁcit hyperactivity disorder: a meta-analysis of follow-up studies. Psychol.
Med. 36, 159–165.
Faraone, S.V., Bonvicini, C., Scassellati, C., 2014a. Biomarkers in the diagnosis of
ADHD–promising directions. Curr. Psychiatry Rep. 16, 497.
Faraone, S.V., Spencer, T.J., Madras, B.K., Zhang-James, Y., Biederman, J., 2014b.
Functional effects of dopamine transporter gene genotypes on in vivo
dopamine transporter functioning: a meta-analysis. Mol. Psychiatry 19,
880–889.
Faraone, S.V., Asherson, P., Banaschewski, T., Biederman, J., Buitelaar, J.K.,
Ramos-Quiroga, J.A., Rohde, L.A., Sonuga-Barke, E.J.S., Tannock, R., Franke, B.,
2015. Attention-deﬁcit/hyperactivity disorder. Nat. Rev. Dis. Prim. 1, 15020.
Fernandez-Jaen, A., Lopez-Martin, S., Albert, J., Fernandez-Mayoralas, D.M.,
Fernandez-Perrone, A.L., De la Pena, M.J., Calleja-Perez, B., Rodriguez, M.R.,
Lopez-Arribas, S., Munoz-Jareno, N., 2015. Cortical thickness differences in the
prefrontal cortex in children and adolescents with ADHD in relation to
dopamine transporter (DAT1) genotype. Psychiatry Res. 233, 409–417.
Fernandez-Jaen, A., Albert, J., Fernandez-Mayoralas, D.M., Lopez-Martin, S.,
Fernandez-Perrone, A.L., Jimenez de la Pena, M.,  Calleja-Perez, B., Recio
Rodriguez, M.,  Lopez Arribas, S., 2016. Cingulate cortical thickness and
dopamine transporter (DAT1) genotype in children and adolescents with
ADHD. J. Atten. Disord., epub ahead of print.
Frances, A., 2000. Diagnostic and Statistical Manual of Mental Disorders,
DSM-IV-TR. American Psychiatric Association, Washington, DC.
Franke, B., Neale, B.M., Faraone, S.V., 2009. Genome-wide association studies in
ADHD. Hum. Genet. 126, 13–50.
Franke, B., Vasquez, A.A., Johansson, S., Hoogman, M.,  Romanos, J.,
Boreatti-Hummer, A., Heine, M.,  Jacob, C.P., Lesch, K.P., Casas, M.,  Ribases, M.,
Bosch, R., Sanchez-Mora, C., Gomez-Barros, N., Fernandez-Castillo, N., Bayes,
M.,  Halmoy, A., Halleland, H., Landaas, E.T., Fasmer, O.B., Knappskog, P.M.,
Heister, A.J., Kiemeney, L.A., Kooij, J.J., Boonstra, A.M., Kan, C.C., Asherson, P.,
Faraone, S.V., Buitelaar, J.K., Haavik, J., Cormand, B., Ramos-Quiroga, J.A., Reif,
A., 2010. Multicenter analysis of the SLC6A3/DAT1 VNTR haplotype in
persistent ADHD suggests differential involvement of the gene in childhood
and  persistent ADHD. Neuropsychopharmacology 35, 656–664.
Franke, B., Faraone, S.V., Asherson, P., Buitelaar, J., Bau, C.H., Ramos-Quiroga, J.A.,
Mick, E., Grevet, E.H., Johansson, S., Haavik, J., Lesch, K.P., Cormand, B., Reif, A.,
International Multicentre Persistent, A.C., 2012. The genetics of attention
deﬁcit/hyperactivity disorder in adults, a review. Mol. Psychiatry 17, 960–987.
Franke, B., Stein, J.L., Ripke, S., Anttila, V., Hibar, D.P., Van Hulzen, K.J.,
Arias-Vasquez, A., Smoller, J.W., Nichols, T.E., Neale, M.C., Mcintosh, A.M., Lee,
P.,  Mcmahon, F.J., Meyer-Lindenberg, A., Mattheisen, M.,  Andreassen, O.A.,
Gruber, O., Sachdev, P.S., Roiz-Santianez, R., Saykin, A.J., Ehrlich, S., Mather,
K.A., Turner, J.A., Schwarz, E., Thalamuthu, A., Yao, Y., Ho, Y.Y., Martin, N.G.,
Wright, M.J., Schizophrenia Working Group OF The Psychiatric Genomics, C.,
Psychosis Endophenotypes International, C., Wellcome Trust Case Control, C.,
Enigma, C., O’donovan, M.C., Thompson, P.M., Neale, B.M., Medland, S.E.,
Sullivan, P.F., 2016. Genetic inﬂuences on schizophrenia and subcortical brain
volumes: large-scale proof of concept. Nat. Neurosci. 19, 420–431.
Frankle, W.G., Huang, Y., Hwang, D.R., Talbot, P.S., Slifstein, M.,  Van Heertum, R.,
Abi-Dargham, A., Laruelle, M.,  2004. Comparative evaluation of serotonin
transporter radioligands 11C-DASB and 11C-McN 5652 in healthy humans. J.
Nucl. Med. 45, 682–694.
Franzen, J.D., Heinrichs-Graham, E., White, M.L., Wetzel, M.W.,  Knott, N.L., Wilson,
T.W., 2013. Atypical coupling between posterior regions of the default mode
network in attention-deﬁcit/hyperactivity disorder: a
pharmaco-magnetoencephalography study. J. Psychiatry Neurosci. 38,
333–340.
Friedel, S., Horro, F.F., Wermter, A.K., Geller, F., Dempﬂe, A., Reichwald, K., Smidt, J.,
Bronner, G., Konrad, K., Herpertz-Dahlmann, B., Warnke, A., Hemminger, U.,
Linder, M.,  Kieﬂ, H., Goldschmidt, H.P., Siegfried, W.,  Remschmidt, H., Hinney,
A.,  Hebebrand, J., 2005. Mutation screen of the brain derived neurotrophic
factor gene (BDNF): identiﬁcation of several genetic variants and association
studies in patients with obesity, eating disorders, and
attention-deﬁcit/hyperactivity disorder. Am. J. Med. Genet. B Neuropsychiatr.
Genet. 132B, 96–99.
Frodl, T., Skokauskas, N., 2012. Meta-analysis of structural MRI studies in children
and adults with attention deﬁcit hyperactivity disorder indicates treatment
effects. Acta Psychiatr. Scand. 125, 114–126.
Fusar-Poli, P., Rubia, K., Rossi, G., Sartori, G., Balottin, U., 2012. Striatal dopamine
transporter alterations in ADHD: pathophysiology or adaptation to
psychostimulants? A meta-analysis. Am. J. Psychiatry 169, 264–272.
Gainetdinov, R.R., Jones, S.R., Caron, M.G., 1999. Functional hyperdopaminergia in
dopamine transporter knock-out mice. Biol. Psychiatry 46, 303–311.
Galili-Weisstub, E., Segman, R.H., 2003. Attention deﬁcit and hyperactivity
disorder: review of genetic association studies. Isr. J. Psychiatry Relat. Sci. 40,
57–66.
Gallo, E.F., Posner, J., 2016. Moving towards causality in attention-deﬁcit
hyperactivity disorder: overview of neural and genetic mechanisms. Lancet
Psychiatry 3, 555–567.
Gao, J., Pan, Z., Jiao, Z., Li, F., Zhao, G., Wei, Q., Pan, F., Evangelou, E., 2012. TPH2 gene
polymorphisms and major depression–a meta-analysis. PLoS One 7, e36721.
Gao, Q., Liu, L., Chen, Y., Li, H., Yang, L., Wang, Y., Qian, Q., 2015.
Synaptosome-related (SNARE) genes and their interactions contribute to the
susceptibility and working memory of attention-deﬁcit/hyperactivity disorder
in males. Prog. Neuropsychopharmacol. Biol. Psychiatry 57, 132–139.
Gao, J., Jia, M., Qiao, D., Qiu, H., Sokolove, J., Zhang, J., Pan, Z., 2016. TPH2 gene
polymorphisms and bipolar disorder: a meta-analysis. Am. J. Med. Genet. B
Neuropsychiatr. Genet. 171, 145–152.
Gervain, J., Mehler, J., Werker, J.F., Nelson, C.A., Csibra, G., Lloyd-Fox, S., Shukla, M.,
Aslin, R.N., 2011. Near-infrared spectroscopy: a report from the McDonnell
infant methodology consortium. Dev. Cogn. Neurosci. 1, 22–46.
Gillberg, C., Gillberg, I.C., Rasmussen, P., Kadesjo, B., Soderstrom, H., Rastam, M.,
Johnson, M.,  Rothenberger, A., Niklasson, L., 2004. Co-existing disorders in
ADHD – implications for diagnosis and intervention. Eur. Child Adolesc.
Psychiatry 13 (Suppl. 1), I80–92.
Gilman, S.R., Iossifov, I., Levy, D., Ronemus, M.,  Wigler, M.,  Vitkup, D., 2011. Rare de
novo variants associated with autism implicate a large functional network of
genes involved in formation and function of synapses. Neuron 70, 898–907.
Giros, B., Jaber, M., Jones, S.R., Wightman, R.M., Caron, M.G., 1996.
Hyperlocomotion and indifference to cocaine and amphetamine in mice
lacking the dopamine transporter. Nature 379, 606–612.
Gizer, I.R., Ficks, C., Waldman, I.D., 2009. Candidate gene studies of ADHD: a
meta-analytic review. Hum. Genet. 126, 51–90.
Glahn, D.C., Winkler, A.M., Kochunov, P., Almasy, L., Duggirala, R., Carless, M.A.,
Curran, J.C., Olvera, R.L., Laird, A.R., Smith, S.M., Beckmann, C.F., Fox, P.T.,
Blangero, J., 2010. Genetic control over the resting brain. Proc. Natl. Acad. Sci.
U.  S. A. 107, 1223–1228.
Gonzalez-Castro, T.B., Hernandez-Diaz, Y., Juarez-Rojop, I.E., Lopez-Narvaez, M.L.,
Tovilla-Zarate, C.A., Fresan, A., 2016. The role of a
catechol-O-methyltransferase (COMT) Val158Met genetic polymorphism in
schizophrenia: a systematic review and updated meta-analysis on 32,816
subjects. Neuromolecular Med. 18 (2), 216–231.
Gordon, E.M., Devaney, J.M., Bean, S., Vaidya, C.J., 2015. Resting-state
striato-frontal functional connectivity is sensitive to DAT1 genotype and
predicts executive function. Cereb. Cortex 25, 336–345.
Gore, A., Li, Z., Fung, H.L., Young, J.E., Agarwal, S., Antosiewicz-Bourget, J., Canto, I.,
Giorgetti, A., Israel, M.A., Kiskinis, E., Lee, J.H., Loh, Y.H., Manos, P.D.,
Montserrat, N., Panopoulos, A.D., Ruiz, S., Wilbert, M.L., Yu, J., Kirkness, E.F.,
Izpisua Belmonte, J.C., Rossi, D.J., Thomson, J.A., Eggan, K., Daley, G.Q.,
M. Klein et al. / Neuroscience and Biobehavioral Reviews 80 (2017) 115–155 147
Goldstein, L.S., Zhang, K., 2011. Somatic coding mutations in human induced
pluripotent stem cells. Nature 471, 63–67.
Gottesman, I.I., Gould, T.D., 2003. The endophenotype concept in psychiatry:
etymology and strategic intentions. Am. J. Psychiatry 160, 636–645.
Graziano, P.A., Mcnamara, J.P., Geffken, G.R., Reid, A., 2011. Severity of children’s
ADHD symptoms and parenting stress: a multiple mediation model of
self-regulation. J. Abnorm. Child Psychol. 39, 1073–1083.
Greven, C.U., Bralten, J., Mennes, M.,  O’dwyer, L., Van Hulzen, K.J., Rommelse, N.,
Schweren, L.J., Hoekstra, P.J., Hartman, C.A., Heslenfeld, D., Oosterlaan, J.,
Faraone, S.V., Franke, B., Zwiers, M.P., Arias-Vasquez, A., Buitelaar, J.K., 2015.
Developmentally stable whole-brain volume reductions and developmentally
sensitive caudate and putamen volume alterations in those with
attention-deﬁcit/hyperactivity disorder and their unaffected siblings. JAMA
Psychiatry 72, 490–499.
Guan, L., Wang, B., Chen, Y., Yang, L., Li, J., Qian, Q., Wang, Z., Faraone, S.V., Wang, Y.,
2009. A high-density single-nucleotide polymorphism screen of 23 candidate
genes in attention deﬁcit hyperactivity disorder: suggesting multiple
susceptibility genes among Chinese Han population. Mol. Psychiatry 14,
546–554.
Haavik, J., Halmoy, A., Lundervold, A.J., Fasmer, O.B., 2010. Clinical assessment and
diagnosis of adults with attention-deﬁcit/hyperactivity disorder. Expert Rev.
Neurother. 10, 1569–1580.
Han, J.Y., Kwon, H.J., Ha, M.,  Paik, K.C., Lim, M.H., Gyu Lee, S., Yoo, S.J., Kim, E.J.,
2015. The effects of prenatal exposure to alcohol and environmental tobacco
smoke on risk for ADHD: a large population-based study. Psychiatry Res. 225,
164–168.
Hart, H., Radua, J., Mataix-Cols, D., Rubia, K., 2012. Meta-analysis of fMRI studies of
timing in attention-deﬁcit hyperactivity disorder (ADHD). Neurosci. Biobehav.
Rev. 36, 2248–2256.
Hart, H., Radua, J., Nakao, T., Mataix-Cols, D., Rubia, K., 2013. Meta-analysis of
functional magnetic resonance imaging studies of inhibition and attention in
attention-deﬁcit/hyperactivity disorder: exploring task-speciﬁc, stimulant
medication, and age effects. JAMA Psychiatry 70, 185–198.
Hawi, Z., Dring, M.,  Kirley, A., Foley, D., Kent, L., Craddock, N., Asherson, P., Curran,
S.,  Gould, A., Richards, S., Lawson, D., Pay, H., Turic, D., Langley, K., Owen, M.,
O’donovan, M.,  Thapar, A., Fitzgerald, M.,  Gill, M.,  2002. Serotonergic system
and attention deﬁcit hyperactivity disorder (ADHD): a potential susceptibility
locus at the 5-HT(1B) receptor gene in 273 nuclear families from a
multi-centre sample. Mol. Psychiatry 7, 718–725.
Hawi, Z., Matthews, N., Wagner, J., Wallace, R.H., Butler, T.J., Vance, A., Kent, L., Gill,
M.,  Bellgrove, M.A., 2013a. DNA variation in the SNAP25 gene confers risk to
ADHD and is associated with reduced expression in prefrontal cortex. PLoS
One  8, e60274.
Hawi, Z., Matthews, N., Barry, E., Kirley, A., Wagner, J., Wallace, R.H., Heussler, H.S.,
Vance, A., Gill, M., Bellgrove, M.A., 2013b. A high density linkage disequilibrium
mapping in 14 noradrenergic genes: evidence of association between SLC6A2,
ADRA1B and ADHD. Psychopharmacology (Berl.) 225, 895–902.
Hawi, Z., Cummins, T.D., Tong, J., Johnson, B., Lau, R., Samarrai, W.,  Bellgrove, M.A.,
2015. The molecular genetic architecture of attention deﬁcit hyperactivity
disorder. Mol. Psychiatry 20 (3), 289–297.
Hayes, A.F., Scharkow, M.,  2013. The relative trustworthiness of inferential tests of
the  indirect effect in statistical mediation analysis: does method really matter?
Psychol. Sci. 24, 1918–1927.
Heinrichs-Graham, E., Franzen, J.D., Knott, N.L., White, M.L., Wetzel, M.W.,  Wilson,
T.W., 2014. Pharmaco-MEG evidence for attention related hyper-connectivity
between auditory and prefrontal cortices in ADHD. Psychiatry Res. 221,
240–245.
Heinzel, S., Dresler, T., Baehne, C.G., Heine, M.,  Boreatti-Hummer, A., Jacob, C.P.,
Renner, T.J., Reif, A., Lesch, K.P., Fallgatter, A.J., Ehlis, A.C., 2013. COMT × DRD4
epistasis impacts prefrontal cortex function underlying response control.
Cereb. Cortex 23, 1453–1462.
Hendriks, W.T., Warren, C.R., Cowan, C.A., 2016. Genome editing in human
pluripotent stem cells: approaches, pitfalls, and solutions. Cell Stem Cell 18,
53–65.
Hess, J.L., Quinn, T.P., Akbarian, S., Glatt, S.J., 2015. Bioinformatic analyses and
conceptual synthesis of evidence linking ZNF804A to risk for schizophrenia
and bipolar disorder. Am.  J. Med. Genet. B Neuropsychiatr. Genet. 168B, 14–35.
Heyser, C.J., Wilson, M.C., Gold, L.H., 1995. Coloboma hyperactive mutant exhibits
delayed neurobehavioral developmental milestones. Brain Res. Dev. Brain Res.
89, 264–269.
Hibar, D.P., Stein, J.L., Kohannim, O., Jahanshad, N., Saykin, A.J., Shen, L., Kim, S.,
Pankratz, N., Foroud, T., Huentelman, M.J., Potkin, S.G., Jack, C.R. Jr., Weiner,
M.W., Toga, A.W., Thompson, P.M., ALZHEIMER’S Disease Neuroimaging, I.,
2011. Voxelwise gene-wide association study (vGeneWAS): multivariate
gene-based association testing in 731 elderly subjects. Neuroimage 56,
1875–1891.
Hibar, D.P., Stein, J.L., Renteria, M.E., Arias-Vasquez, A., Desrivieres, S., Jahanshad,
N.,  Toro, R., Wittfeld, K., Abramovic, L., Andersson, M.,  Aribisala, B.S.,
Armstrong, N.J., Bernard, M.,  Bohlken, M.M.,  Boks, M.P., Bralten, J., Brown, A.A.,
Mallar Chakravarty, M.,  Chen, Q., Ching, C.R., Cuellar-Partida, G., Den Braber, A.,
Giddaluru, S., Goldman, A.L., Grimm, O., Guadalupe, T., Hass, J., Woldehawariat,
G.,  Holmes, A.J., Hoogman, M.,  Janowitz, D., Jia, T., Kim, S., Klein, M., Kraemer,
B.,  Lee, P.H., Olde Loohuis, L.M., Luciano, M.,  Macare, C., Mather, K.A.,
Mattheisen, M., Milaneschi, Y., Nho, K., Papmeyer, M.,  Ramasamy, A., Risacher,
S.L., Roiz-Santianez, R., Rose, E.J., Salami, A., Samann, P.G., Schmaal, L., Schork,
A.J., Shin, J., Strike, L.T., Teumer, A., Van Donkelaar, M.M.,  Van Eijk, K.R.,
Walters, R.K., Westlye, L.T., Whelan, C.D., Winkler, A.M., Zwiers, M.P., Alhusaini,
S.,  Athanasiu, L., Ehrlich, S., Hakobjan, M.M.,  Hartberg, C.B., Haukvik, U.K.,
Heister, A.J., Hoehn, D., Kasperaviciute, D., Liewald, D.C., Lopez, L.M., Makkinje,
R.R., Matarin, M.,  Naber, M.A., Reese Mckay, D., Needham, M.,  Nugent, A.C.,
Putz, B., Royle, N.A., Shen, L., Sprooten, E., Trabzuni, D., Van Der Marel, S.S., Van
Hulzen, K.J., Walton, E., Wolf, C., Almasy, L., Ames, D., Arepalli, S., Assareh, A.A.,
Bastin, M.E., Brodaty, H., Bulayeva, K.B., Carless, M.A., Cichon, S., Corvin, A.,
Curran, J.E., Czisch, M.,  et al., 2015. Common genetic variants inﬂuence human
subcortical brain structures. Nature.
Hillman, E.M., 2014. Coupling mechanism and signiﬁcance of the BOLD signal: a
status report. Annu. Rev. Neurosci. 37, 161–181.
Hinney, A., Scherag, A., Jarick, I., Albayrak, O., Putter, C., Pechlivanis, S.,
Dauvermann, M.R., Beck, S., Weber, H., Scherag, S., Nguyen, T.T., Volckmar, A.L.,
Knoll, N., Faraone, S.V., Neale, B.M., Franke, B., Cichon, S., Hoffmann, P., Nothen,
M.M.,  Schreiber, S., Jockel, K.H., Wichmann, H.E., Freitag, C., Lempp, T., Meyer,
J.,  Gilsbach, S., Herpertz-Dahlmann, B., Sinzig, J., Lehmkuhl, G., Renner, T.J.,
Warnke, A., Romanos, M.,  Lesch, K.P., Reif, A., Schimmelmann, B.G., Hebebrand,
J., Psychiatric, G.C.A.S., 2011. Genome-wide association study in German
patients with attention deﬁcit/hyperactivity disorder. Am.  J. Med. Genet. B
Neuropsychiatr. Genet. 156B, 888–897.
Hockemeyer, D., Jaenisch, R., 2016. Induced pluripotent stem cells meet genome
editing. Cell Stem Cell 18, 573–586.
Hohmann, S., Hohm, E., Treutlein, J., Blomeyer, D., Jennen-Steinmetz, C., Schmidt,
M.H., Esser, G., Banaschewski, T., Brandeis, D., Laucht, M.,  2015. Association of
norepinephrine transporter (NET, SLC6A2) genotype with ADHD-related
phenotypes: ﬁndings of a longitudinal study from birth to adolescence.
Psychiatry Res. 226, 425–433.
Holz, N., Boecker, R., Buchmann, A.F., Blomeyer, D., Baumeister, S., Hohmann, S.,
Jennen-Steinmetz, C., Wolf, I., Rietschel, M.,  Witt, S.H., Plichta, M.M.,
Meyer-Lindenberg, A., Schmidt, M.H., Esser, G., Banaschewski, T., Brandeis, D.,
Laucht, M.,  2016. Evidence for a sex-dependent MAOAx childhood stress
interaction in the neural circuitry of aggression. Cereb. Cortex 26, 904–914.
Hong, J., Shu-Leong, H., Tao, X., Lap-Ping, Y., 1998. Distribution of
catechol-O-methyltransferase expression in human central nervous system.
Neuroreport 9, 2861–2864.
Hong, S.B., Zalesky, A., Park, S., Yang, Y.H., Park, M.H., Kim, B., Song, I.C., Sohn, C.H.,
Shin, M.S., Kim, B.N., Cho, S.C., Kim, J.W., 2014. COMT genotype affects brain
white matter pathways in attention-deﬁcit/hyperactivity disorder. Hum. Brain
Mapp. 36 (1), 367–377.
Hoogman, M., Aarts, E., Zwiers, M.,  Slaats-Willemse, D., Naber, M.,  Onnink, M.,
Cools, R., Kan, C., Buitelaar, J., Franke, B., 2011. Nitric oxide synthase genotype
modulation of impulsivity and ventral striatal activity in adult ADHD patients
and healthy comparison subjects. Am. J. Psychiatry 168, 1099–1106.
Hoogman, M., Onnink, M., Cools, R., Aarts, E., Kan, C., Arias Vasquez, A., Buitelaar, J.,
Franke, B., 2013. The dopamine transporter haplotype and reward-related
striatal responses in adult ADHD. Eur. Neuropsychopharmacol. 23, 469–478.
Hoogman, M., Bralten, J., Hibar, D. P., Mennes, M.,  Zwiers, M. P., Schweren, L. S. J.,
van Hulzen, K. J. E., Medland, S. E., Shumskaya, E., Jahanshad, N., Zeeuw, P. d.,
Szekely, E., Sudre, G., Wolfers, T., Onnink, A. M. H., Dammers, J. T., Mostert, J. C.,
Vives-Gilabert, Y., Kohls, G., Oberwelland, E., Seitz, J., Schulte-Rüther, M.,
Ambrosino, S., Doyle, A. E., Høvik, M.  F., Dramsdahl, M.,  Tamm, L., van Erp, T. G.
M.,  Dale, A., Schork, A., Conzelmann, A., Zierhut, K., Baur, R., McCarthy, H.,
Yoncheva, Y. N., Cubillo, A., Chantiluke, K., Mehta, M. A., Paloyelis, Y.,
Hohmann, S., Baumeister, S., Bramati, I., Mattos, P., Tovar-Moll, F., Douglas, P.,
Banaschewski, T., Brandeis, D., Kuntsi, J., Asherson, P., Rubia, K., Kelly, C.,
Martino, A. D., Milham, M.  P., Castellanos, F. X., Frodl, T., Zentis, M.,  Lesch, K.-P.,
Reif, A., Pauli, P., Jernigan, T. L., Haavik, J., Plessen, K. J., Lundervold, A. J.,
Hugdahl, K., Seidman, L. J., Biederman, J., Rommelse, N., Heslenfeld, D. J.,
Hartman, C. A., Hoekstra, P. J., Oosterlaan, J., Polier, G. v., Konrad, K., Vilarroya,
O.,  Ramos-Quiroga, J. A., Soliva, J. C., Durston, S., Buitelaar, J. K., Faraone, S. V.,
Shaw, P., Thompson, P. M.  and Franke, B. Subcortical brain volume differences
in  participants with attention deﬁcit hyperactivity disorder in children and
adults: a cross-sectional mega-analysis. Lancet Psychiatry, epub ahead of print.
Hu,  Y.F., Caron, M.G., Sieber-Blum, M.,  2009. Norepinephrine transport-mediated
gene expression in noradrenergic neurogenesis. BMC Genom. 10, 151.
Hu, B.Y., Weick, J.P., Yu, J., Ma,  L.X., Zhang, X.Q., Thomson, J.A., Zhang, S.C., 2010.
Neural differentiation of human induced pluripotent stem cells follows
developmental principles but with variable potency. Proc. Natl. Acad. Sci. U. S.
A.  107, 4335–4340.
Hu, Y., Qu, Z.Y., Cao, S.Y., Li, Q., Ma,  L., Krencik, R., Xu, M.,  Liu, Y., 2016. Directed
differentiation of basal forebrain cholinergic neurons from human pluripotent
stem cells. J. Neurosci. Methods 266, 42–49.
Huang, J., Zhong, Z., Wang, M.,  Chen, X., Tan, Y., Zhang, S., He, W.,  He, X., Huang, G.,
Lu,  H., Wu,  P., Che, Y., Yan, Y.L., Postlethwait, J.H., Chen, W.,  Wang, H., 2015.
Circadian modulation of dopamine levels and dopaminergic neuron
development contributes to attention deﬁciency and hyperactive behavior. J.
Neurosci. 35, 2572–2587.
Hulshoff Pol, H.E., Schnack, H.G., Mandl, R.C.W., Brans, R.G.H., Van Haren, N.E.M.,
Baaré, W.F.C., Van Oel, C.J., Collins, D.L., Evans, A.C., Kahn, R.S., 2006. Gray and
white matter density changes in monozygotic and same-sex dizygotic twins
discordant for schizophrenia using voxel-based morphometry. Neuroimage 31,
482–488.
Hwang, I.W., Lim, M.H., Kwon, H.J., Jin, H.J., 2015. Association of LPHN3 rs6551665
A/G polymorphism with attention deﬁcit and hyperactivity disorder in Korean
children. Gene 566, 68–73.
148 M. Klein et al. / Neuroscience and Biobehavioral Reviews 80 (2017) 115–155
Iacono, W.G., Malone, S.M., Vaidyanathan, U., Vrieze, S.I., 2014. Genome-wide
scans of genetic variants for psychophysiological endophenotypes: a
methodological overview. Psychophysiology 51, 1207–1224.
Ichikawa, M.,  Okamura-Oho, Y., Okunishi, R., Kanamori, M.,  Suzuki, H., Ritani, A.,
Nitta, H., Eguchi, N., Urade, Y., Hayashizaki, Y., 2005. Expression analysis of
genes responsible for serotonin signaling in the brain. Neurobiol. Dis. 19,
378–385.
Ichtchenko, K., Khvotchev, M., Kiyatkin, N., Simpson, L., Sugita, S., Sudhof, T.C.,
1998. alpha-latrotoxin action probed with recombinant toxin: receptors
recruit alpha-latrotoxin but do not transduce an exocytotic signal. EMBO J. 17,
6188–6199.
Ilgin, N., Senol, S., Gucuyener, K., Gokcora, N., Sener, S., 2001. Is increased D2
receptor availability associated with response to stimulant medication in
ADHD. Dev. Med. Child Neurol. 43, 755–760.
Inoue, Y., Sakihara, K., Gunji, A., Ozawa, H., Kimiya, S., Shinoda, H., Kaga, M.,
Inagaki, M.,  2012. Reduced prefrontal hemodynamic response in children with
ADHD during the Go/NoGo task: a NIRS study. Neuroreport 23, 55–60.
Jacob, C.P., Weber, H., Retz, W.,  Kittel-Schneider, S., Heupel, J., Renner, T., Lesch,
K.P., Reif, A., 2013. Acetylcholine-metabolizing butyrylcholinesterase (BCHE)
copy number and single nucleotide polymorphisms and their role in
attention-deﬁcit/hyperactivity syndrome. J. Psychiatr. Res. 47, 1902–1908.
Jahanshad, N., Kochunov, P.V., Sprooten, E., Mandl, R.C., Nichols, T.E., Almasy, L.,
Blangero, J., Brouwer, R.M., Curran, J.E., De Zubicaray, G.I., Duggirala, R., Fox,
P.T., Hong, L.E., Landman, B.A., Martin, N.G., Mcmahon, K.L., Medland, S.E.,
Mitchell, B.D., Olvera, R.L., Peterson, C.P., Starr, J.M., Sussmann, J.E., Toga, A.W.,
Wardlaw, J.M., Wright, M.J., Hulshoff Pol, H.E., Bastin, M.E., Mcintosh, A.M.,
Deary, I.J., Thompson, P.M., Glahn, D.C., 2013. Multi-site genetic analysis of
diffusion images and voxelwise heritability analysis: a pilot project of the
ENIGMA-DTI working group. Neuroimage 81, 455–469.
Jahanshad, N., Ganjgahi, H., Bralten, J., Den Braber, A., Faskowitz, J., Knodt, A.R.,
Lemaitre, H., Nir, T.M., Patel, B., Ritchie, S., Sprooten, E., Hoogman, M., Van
Hulzen, K., Zavaliangos-Petropulu, A., Zwiers, M.,  Almasy, L., Bastin, M.E.,
Bernstein, M.A., Blangero, J., Curran, J.C., Deary, I.J., De Zubicaray, G.I.,
Duggirala, R., Fisher, S.E., Franke, B., Fox, P., Goldman, D., Haberg, A.K., Hariri,
A.,  Hong, L.E., Huentelman, M.,  Martin, N.G., Martinot, J.L., Mcintosh, A.,
Mcmahon, K.L., Medland, S.E., Mitchell, B.D., Munoz Maniega, S., Olvera, R.L.,
Oosterlaan, J., Peterson, C., Royle, N., Saykin, A.J., Schumann, G., Starr, J., Stein,
E.A., Sussmann, J., Valdes Hernandez, M.C., Van’t Ent, D., Wardlaw, J.M.,
Weiner, M.W.,  Williamson, D.E., Winkler, A.M., Wright, M.J., Yang, Y.,
Thompson, P.M., Glahn, D.C., Nichols, T.E., Kochunov, P. (in preparation). Do
Candidate SNPs Affect the Brain’s White Matter Microstructure? Large Scale
Evaluation of 6165 Diffusion MRI  Scans.
Jia, T., Macare, C., Desrivieres, S., Gonzalez, D.A., Tao, C., Ji, X., Ruggeri, B., Nees, F.,
Banaschewski, T., Barker, G.J., Bokde, A.L., Bromberg, U., Buchel, C., Conrod, P.J.,
Dove, R., Frouin, V., Gallinat, J., Garavan, H., Gowland, P.A., Heinz, A., Ittermann,
B.,  Lathrop, M.,  Lemaitre, H., Martinot, J.L., Paus, T., Pausova, Z., Poline, J.B.,
Rietschel, M.,  Robbins, T., Smolka, M.N., Muller, C.P., Feng, J., Rothenﬂuh, A.,
Flor, H., Schumann, G., Consortium, I., 2016. Neural basis of reward anticipation
and its genetic determinants. Proc. Natl. Acad. Sci. U. S. A. 113, 3879–3884.
Johnstone, S.J., Barry, R.J., Clarke, A.R., 2013. Ten years on: a follow-up review of
ERP research in attention-deﬁcit/hyperactivity disorder. Clin. Neurophysiol.
124, 644–657.
Jonassen, R., Landro, N.I., 2014. Serotonin transporter polymorphisms (5-HTTLPR)
in emotion processing: implications from current neurobiology. Prog.
Neurobiol. 117, 41–53.
Jucaite, A., Fernell, E., Halldin, C., Forssberg, H., Farde, L., 2005. Reduced midbrain
dopamine transporter binding in male adolescents with
attention-deﬁcit/hyperactivity disorder: association between striatal
dopamine markers and motor hyperactivity. Biol. Psychiatry 57, 229–238.
Kabukcu Basay, B., Buber, A., Basay, O., Alacam, H., Ozturk, O., Suren, S., Izci Ay, O.,
Acikel, C., Agladioglu, K., Erdal, M.E., Ercan, E.S., Herken, H., 2016. White matter
alterations related to attention-deﬁcit hyperactivity disorder and COMT
val(158)met polymorphism: children with valine homozygote attention-deﬁcit
hyperactivity disorder have altered white matter connectivity in the right
cingulum (cingulate gyrus). Neuropsychiatr. Dis. Treat. 12, 969–981.
Kendler, K.S., Neale, M.C., 2010. Endophenotype: a conceptual analysis. Mol.
Psychiatry 15, 789–797.
Kerner, B., Rao, A.R., Christensen, B., Dandekar, S., Yourshaw, M., Nelson, S.F., 2013.
Rare genomic variants link bipolar disorder with anxiety disorders to
CREB-Regulated intracellular signaling pathways. Front. Psychiatry 4, 154.
Kessler, R.C., Adler, L., Barkley, R., Biederman, J., Conners, C.K., Demler, O., Faraone,
S.V., Greenhill, L.L., Howes, M.J., Secnik, K., Spencer, T., Ustun, T.B., Walters, E.E.,
Zaslavsky, A.M., 2006. The prevalence and correlates of adult ADHD in the
United States: results from the National Comorbidity Survey Replication. Am.  J.
Psychiatry 163, 716–723.
Killeen, P.R., Russell, V.A., Sergeant, J.A., 2013. A behavioral neuroenergetics theory
of  ADHD. Neurosci. Biobehav. Rev. 37, 625–657.
Kim, B.N., Kim, J.W., Kang, H., Cho, S.C., Shin, M.S., Yoo, H.J., Hong, S.B., Lee, D.S.,
2010. Regional differences in cerebral perfusion associated with the
alpha-2A-adrenergic receptor genotypes in attention deﬁcit hyperactivity
disorder. J. Psychiatry Neurosci. 35, 330–336.
Kim, Y.H., Choi, S.H., D’avanzo, C., Hebisch, M.,  Sliwinski, C., Bylykbashi, E.,
Washicosky, K.J., Klee, J.B., Brustle, O., Tanzi, R.E., Kim, D.Y., 2015. A 3D human
neural cell culture system for modeling Alzheimer’s disease. Nat. Protoc. 10,
985–1006.
Kiss, J.P., Vizi, E.S., 2001. Nitric oxide: a novel link between synaptic and
nonsynaptic transmission. Trends Neurosci. 24, 211–215.
Klein, M.,  Stein, J.L., ENIGMA2 Consortium, PGC ADHD working group, iPSYCH
Consortium, Borglum, A., Faraone, S.V., Thompson, P. M., Medland, S.E., Arias
Vasquez, A., Franke, B. Investigating the overlap between common genetic
factors for ADHD and subcortical brain volumes, (in preparation).
Klein, M.,  Van Donkelaar, M.M.,  Verhoef, E., Franke, B., Imaging Genetics in
Neurodevelopmental Psychopathology, (under review).
Ko, C.H., Hsieh, T.J., Wang, P.W., Lin, W.C., Chen, C.S., Yen, J.Y., 2015. The altered
brain activation of phonological working memory, dual tasking, and
distraction among participants with adult ADHD and the effect of the MAOA
polymorphism. J. Atten. Disord., epub ahead of print.
Kobiella, A., Reimold, M.,  Ulshöfer, D., Ikonomidou, V., Vollmert, C., Vollstädt-Klein,
S.,  Rietschel, M.,  Reischl, G., Heinz, A., Smolka, M.,  2011. How the serotonin
transporter 5-HTTLPR polymorphism inﬂuences amygdala function: the roles
of  in vivo serotonin transporter expression and amygdala structure. Transl
Psychiatry 1, e37.
Kochunov, P., Fu, M.,  Nugent, K., Wright, S.N., Du, X., Muellerklein, F., Morrissey, M.,
Eskandar, G., Shukla, D.K., Jahanshad, N., Thompson, P.M., Patel, B., Postolache,
T.T.,  Strauss, K.A., Shuldiner, A.R., Mitchell, B.D., Hong, L.E., 2015. Heritability of
complex white matter diffusion traits assessed in a population isolate. Hum.
Brain Mapp. 37 (2), 525–535.
Kotte, A., Faraone, S.V., Biederman, J., 2013. Association of genetic risk severity
with ADHD clinical characteristics. Am.  J. Med. Genet. B Neuropsychiatr. Genet.
162B, 718–733.
Krain, A.L., Castellanos, F.X., 2006. Brain development and ADHD. Clin. Psychol.
Rev.  26, 433–444.
Krause, J., Dresel, S.H., Krause, K.H., La Fougere, C., Zill, P., Ackenheil, M., 2006.
Striatal dopamine transporter availability and DAT-1 gene in adults with
ADHD: no higher DAT availability in patients with homozygosity for the
10-repeat allele. World J. Biol. Psychiatry 7, 152–157.
Kuczenski, R., Segal, D.S., 2002. Exposure of adolescent rats to oral
methylphenidate: preferential effects on extracellular norepinephrine and
absence of sensitization and cross-sensitization to methamphetamine. J.
Neurosci. 22, 7264–7271.
Labbe, A., Liu, A., Atherton, J., Gizenko, N., Fortier, M.E., Sengupta, S.M., Ridha, J.,
2012. Reﬁning psychiatric phenotypes for response to treatment: contribution
of  LPHN3 in ADHD. Am. J. Med. Genet. B Neuropsychiatr. Genet. 159B, 776–785.
Lahoste, G.J., Swanson, J.M., Wigal, S.B., Glabe, C., Wigal, T., King, N., Kennedy, J.L.,
1996. Dopamine D4 receptor gene polymorphism is associated with attention
deﬁcit hyperactivity disorder. Mol. Psychiatry 1, 121–124.
Lahti, R.A., Roberts, R.C., Tamminga, C.A., 1995. D2-family receptor distribution in
human postmortem tissue: an autoradiographic study. Neuroreport 6,
2505–2512.
Lancaster, M.A., Renner, M.,  Martin, C.A., Wenzel, D., Bicknell, L.S., Hurles, M.E.,
Homfray, T., Penninger, J.M., Jackson, A.P., Knoblich, J.A., 2013. Cerebral
organoids model human brain development and microcephaly. Nature 501,
373–379.
Landaas, E.T., Johansson, S., Jacobsen, K.K., Ribases, M.,  Bosch, R., Sanchez-Mora, C.,
Jacob, C.P., Boreatti-Hummer, A., Kreiker, S., Lesch, K.P., Kiemeney, L.A., Kooij,
J.J.,  Kan, C., Buitelaar, J.K., Faraone, S.V., Halmoy, A., Ramos-Quiroga, J.A.,
Cormand, B., Reif, A., Franke, B., Mick, E., Knappskog, P.M., Haavik, J., 2010. An
international multicenter association study of the serotonin transporter gene
in  persistent ADHD. Genes Brain Behav. 9, 449–458.
Lange, M.,  Norton, W.,  Coolen, M.,  Chaminade, M.,  Merker, S., Proft, F., Schmitt, A.,
Vernier, P., Lesch, K.P., Bally-Cuif, L., 2012. The ADHD-susceptibility gene
lphn3.1 modulates dopaminergic neuron formation and locomotor activity
during zebraﬁsh development. Mol. Psychiatry 17, 946–954.
Langer, S.Z., 2015. alpha2-Adrenoceptors in the treatment of major
neuropsychiatric disorders. Trends Pharmacol. Sci. 36, 196–202.
Lantieri, F., Glessner, J.T., Hakonarson, H., Elia, J., Devoto, M.,  2010. Analysis of
GWAS top hits in ADHD suggests association to two polymorphisms located in
genes expressed in the cerebellum. Am. J. Med. Genet. B Neuropsychiatr.
Genet. 153B, 1127–1133.
Larsson, H., Asherson, P., Chang, Z., Ljung, T., Friedrichs, B., Larsson, J.O.,
Lichtenstein, P., 2013a. Genetic and environmental inﬂuences on adult
attention deﬁcit hyperactivity disorder symptoms: a large Swedish
population-based study of twins. Psychol. Med. 43, 197–207.
Larsson, H., Chang, Z., D’onofrio, B.M., Lichtenstein, P., 2013b. The heritability of
clinically diagnosed attention deﬁcit hyperactivity disorder across the lifespan.
Psychol. Med., 1–7.
Lasky-Su, J., Anney, R.J., Neale, B.M., Franke, B., Zhou, K., Maller, J.B., Vasquez, A.A.,
Chen, W.,  Asherson, P., Buitelaar, J., Banaschewski, T., Ebstein, R., Gill, M.,
Miranda, A., Mulas, F., Oades, R.D., Roeyers, H., Rothenberger, A., Sergeant, J.,
Sonuga-Barke, E., Steinhausen, H.C., Taylor, E., Daly, M.,  Laird, N., Lange, C.,
Faraone, S.V., 2008a. Genome-wide association scan of the time to onset of
attention deﬁcit hyperactivity disorder. Am.  J. Med. Genet. B Neuropsychiatr.
Genet. 147B, 1355–1358.
Lasky-Su, J., Neale, B.M., Franke, B., Anney, R.J., Zhou, K., Maller, J.B., Vasquez, A.A.,
Chen, W.,  Asherson, P., Buitelaar, J., Banaschewski, T., Ebstein, R., Gill, M.,
Miranda, A., Mulas, F., Oades, R.D., Roeyers, H., Rothenberger, A., Sergeant, J.,
Sonuga-Barke, E., Steinhausen, H.C., Taylor, E., Daly, M.,  Laird, N., Lange, C.,
Faraone, S.V., 2008b. Genome-wide association scan of quantitative traits for
attention deﬁcit hyperactivity disorder identiﬁes novel associations and
conﬁrms candidate gene associations. Am. J. Med. Genet. B Neuro. Psychiatr.
Genet. 147B, 1345–1354.
M. Klein et al. / Neuroscience and Biobehavioral Reviews 80 (2017) 115–155 149
Le Bihan, D., Mangin, J.F., Poupon, C., Clark, C.A., Pappata, S., Molko, N., Chabriat, H.,
2001. Diffusion tensor imaging: concepts and applications. J. Magn. Reson.
Imaging 13, 534–546.
Le Bihan, D., 2003. Looking into the functional architecture of the brain with
diffusion MRI. Nat. Rev. Neurosci. 4, 469–480.
Lee, Y.H., Song, G.G., 2015. BDNF 196 G/A and COMT Val158Met polymorphisms
and susceptibility to ADHD: a meta-analysis. J. Atten. Disord., epub ahead of
print.
Leo, D., Gainetdinov, R.R., 2013. Transgenic mouse models for ADHD. Cell Tissue
Res. 354, 259–271.
Lesch, K.P., Bengel, D., Heils, A., Sabol, S.Z., Greenberg, B.D., Petri, S., Benjamin, J.,
Muller, C.R., Hamer, D.H., Murphy, D.L., 1996. Association of anxiety-related
traits with a polymorphism in the serotonin transporter gene regulatory
region. Science 274, 1527–1531.
Lesch, K.P., Timmesfeld, N., Renner, T.J., Halperin, R., Roser, C., Nguyen, T.T., Craig,
D.W., Romanos, J., Heine, M.,  Meyer, J., Freitag, C., Warnke, A., Romanos, M.,
Schafer, H., Walitza, S., Reif, A., Stephan, D.A., Jacob, C., 2008. Molecular
genetics of adult ADHD: converging evidence from genome-wide association
and extended pedigree linkage studies. J. Neural Transm. 115, 1573–1585.
Lesch, K.P., Selch, S., Renner, T.J., Jacob, C., Nguyen, T.T., Hahn, T., Romanos, M.,
Walitza, S., Shoichet, S., Dempﬂe, A., Heine, M.,  Boreatti-Hummer, A., Romanos,
J.,  Gross-Lesch, S., Zerlaut, H., Wultsch, T., Heinzel, S., Fassnacht, M., Fallgatter,
A., Allolio, B., Schafer, H., Warnke, A., Reif, A., Ropers, H.H., Ullmann, R., 2011.
Genome-wide copy number variation analysis in
attention-deﬁcit/hyperactivity disorder: association with neuropeptide Y gene
dosage in an extended pedigree. Mol. Psychiatry 16, 491–503.
Lesch, K.P., Araragi, N., Waider, J., Van Den Hove, D., Gutknecht, L., 2012. Targeting
brain serotonin synthesis: insights into neurodevelopmental disorders with
long-term outcomes related to negative emotionality, aggression and
antisocial behaviour. Philos. Trans. R Soc. Lond. B Biol. Sci. 367, 2426–2443.
Li, D., Sham, P.C., Owen, M.J., He, L., 2006a. Meta-analysis shows signiﬁcant
association between dopamine system genes and attention deﬁcit
hyperactivity disorder (ADHD). Hum. Mol. Genet. 15, 2276–2284.
Li, J., Wang, Y., Zhou, R., Zhang, H., Yang, L., Wang, B., Faraone, S.V., 2006b.
Association between polymorphisms in serotonin 2C receptor gene and
attention-deﬁcit/hyperactivity disorder in Han Chinese subjects. Neurosci.
Lett. 407, 107–111.
Li, J., Kang, C., Zhang, H., Wang, Y., Zhou, R., Wang, B., Guan, L., Yang, L., Faraone,
S.V., 2007a. Monoamine oxidase A gene polymorphism predicts adolescent
outcome of attention-deﬁcit/hyperactivity disorder. Am.  J. Med. Genet. B
Neuropsychiatr. Genet. 144B, 430–433.
Li, Q., Lu, G., Antonio, G.E., Mak, Y.T., Rudd, J.A., Fan, M.,  Yew, D.T., 2007b. The
usefulness of the spontaneously hypertensive rat to model
attention-deﬁcit/hyperactivity disorder (ADHD) may  be explained by the
differential expression of dopamine-related genes in the brain. Neurochem.
Int. 50, 848–857.
Li, J., Wang, Y., Hu, S., Zhou, R., Yu, X., Wang, B., Guan, L., Yang, L., Zhang, F., Faraone,
S.V., 2008. The monoamine oxidase B gene exhibits signiﬁcant association to
ADHD. Am.  J. Med. Genet. B Neuropsychiatr. Genet. Am.  J. 147, 370–374.
Li, Z., Chang, S.H., Zhang, L.Y., Gao, L., Wang, J., 2014. Molecular genetic studies of
ADHD and its candidate genes: a review. Psychiatry Res. 219 (1), 10–24.
Lim, C.S., Yang, J.E., Lee, Y.K., Lee, K., Lee, J.A., Kaang, B.K., 2015. Understanding the
molecular basis of autism in a dish using hiPSCs-derived neurons from ASD
patients. Mol. Brain 8.
Lionel, A.C., Crosbie, J., Barbosa, N., Goodale, T., Thiruvahindrapuram, B., Rickaby, J.,
Gazzellone, M.,  Carson, A.R., Howe, J.L., Wang, Z., Wei, J., Stewart, A.F., Roberts,
R.,  Mcpherson, R., Fiebig, A., Franke, A., Schreiber, S., Zwaigenbaum, L.,
Fernandez, B.A., Roberts, W.,  Arnold, P.D., Szatmari, P., Marshall, C.R., Schachar,
R.,  Scherer, S.W., 2011. Rare copy number variation discovery and
cross-disorder comparisons identify risk genes for ADHD. Sci Transl Med  3,
95ra75.
Lionel, A.C., Tammimies, K., Vaags, A.K., Rosenfeld, J.A., Ahn, J.W., Merico, D., Noor,
A., Runke, C.K., Pillalamarri, V.K., Carter, M.T., Gazzellone, M.J.,
Thiruvahindrapuram, B., Fagerberg, C., Laulund, L.W., Pellecchia, G.,
Lamoureux, S., Deshpande, C., Clayton-Smith, J., White, A.C., Leather, S.,
Trounce, J., Melanie Bedford, H., Hatchwell, E., Eis, P.S., Yuen, R.K., Walker, S.,
Uddin, M.,  Geraghty, M.T., Nikkel, S.M., Tomiak, E.M., Fernandez, B.A., Soreni,
N.,  Crosbie, J., Arnold, P.D., Schachar, R.J., Roberts, W.,  Paterson, A.D., So, J.,
Szatmari, P., Chrysler, C., Woodbury-Smith, M.,  Brian Lowry, R., Zwaigenbaum,
L., Mandyam, D., Wei, J., Macdonald, J.R., Howe, J.L., Nalpathamkalam, T., Wang,
Z.,  Tolson, D., Cobb, D.S., Wilks, T.M., Sorensen, M.J., Bader, P.I., An, Y., Wu,  B.L.,
Musumeci, S.A., Romano, C., Postorivo, D., Nardone, A.M., Monica, M.D.,
Scarano, G., Zoccante, L., Novara, F., Zuffardi, O., Ciccone, R., Antona, V., Carella,
M.,  Zelante, L., Cavalli, P., Poggiani, C., Cavallari, U., Argiropoulos, B., Chernos, J.,
Brasch-Andersen, C., Speevak, M.,  Fichera, M.,  Ogilvie, C.M., Shen, Y., Hodge,
J.C., Talkowski, M.E., Stavropoulos, D.J., Marshall, C.R., Scherer, S.W., 2014.
Disruption of the ASTN2/TRIM32 locus at 9q33. 1 is a risk factor in males for
autism spectrum disorders, ADHD and other neurodevelopmental phenotypes.
Hum. Mol. Genet. 23, 2752–2768.
Lister, R., Pelizzola, M., Kida, Y.S., Hawkins, R.D., Nery, J.R., Hon, G.,
Antosiewicz-Bourget, J., O’malley, R., Castanon, R., Klugman, S., Downes, M.,  Yu,
R.,  Stewart, R., Ren, B., Thomson, J.A., Evans, R.M., Ecker, J.R., 2011. Hotspots of
aberrant epigenomic reprogramming in human induced pluripotent stem cells.
Nature 471, 68–73.
Liu, L., Guan, L.L., Chen, Y., Ji, N., Li, H.M., Li, Z.H., Qian, Q.J., Yang, L., Glatt, S.J.,
Faraone, S.V., Wang, Y.F., 2011. Association analyses of MAOA in Chinese Han
subjects with attention-deﬁcit/hyperactivity disorder: family-based
association test, case-control study, and quantitative traits of impulsivity. Am.
J.  Med. Genet. B Neuropsychiatr. Genet. 156B, 737–748.
Liu, Y., Liu, H., Sauvey, C., Yao, L., Zarnowska, E.D., Zhang, S.C., 2013a. Directed
differentiation of forebrain GABA interneurons from human pluripotent stem
cells. Nat. Protoc. 8, 1670–1679.
Liu, L., Chen, Y., Li, H., Qian, Q., Yang, L., Glatt, S.J., Faraone, S.V., Wang, Y., 2013b.
Association between SYP with attention-deﬁcit/hyperactivity disorder in
Chinese Han subjects: differences among subtypes and genders. Psychiatry Res
210, 308–314.
Liu, J., Gao, C., Chen, W.,  Ma,  W.,  Li, X., Shi, Y., Zhang, H., Zhang, L., Long, Y., Xu, H.,
Guo,  X., Deng, S., Yan, X., Yu, D., Pan, G., Chen, Y., Lai, L., Liao, W.,  Li, Z., 2016.
CRISPR/Cas9 facilitates investigation of neural circuit disease using human
iPSCs: mechanism of epilepsy caused by an SCN1A loss-of-function mutation.
Transl. Psychiatry, 6.
Loo, S.K., Makeig, S., 2012. Clinical utility of EEG in attention-deﬁcit/hyperactivity
disorder: a research update. Neurotherapeutics 9, 569–587.
Loo, S.K., Specter, E., Smolen, A., Hopfer, C., Teale, P.D., Reite, M.L., 2003. Functional
effects of the DAT1 polymorphism on EEG measures in ADHD. J. Am.  Acad.
Child Adolesc. Psychiatry 42, 986–993.
Loo, S.K., Hale, S.T., Hanada, G., Macion, J., Shrestha, A., Mcgough, J.J., Mccracken,
J.T., Nelson, S., Smalley, S.L., 2010. Familial clustering and DRD4 effects on
electroencephalogram measures in multiplex families with attention
deﬁcit/hyperactivity disorder. J. Am. Acad. Child Adolesc. Psychiatry 49,
368–377.
Ludolph, A.G., Kassubek, J., Schmeck, K., Glaser, C., Wunderlich, A., Buck, A.K.,
Reske, S.N., Fegert, J.M., Mottaghy, F.M., 2008. Dopaminergic dysfunction in
attention deﬁcit hyperactivity disorder (ADHD), differences between
pharmacologically treated and never treated young adults: a
3,4-dihdroxy-6-[18F]ﬂuorophenyl-l-alanine PET study. Neuroimage 41,
718–727.
Lycett, K., Sciberras, E., Mensah, F.K., Hiscock, H., 2015. Behavioral sleep problems
and internalizing and externalizing comorbidities in children with
attention-deﬁcit/hyperactivity disorder. Eur. Child Adolesc. Psychiatry 24,
31–40.
Ma,  C.L., Arnsten, A.F., Li, B.M., 2005. Locomotor hyperactivity induced by blockade
of  prefrontal cortical alpha2-adrenoceptors in monkeys. Biol. Psychiatry 57,
192–195.
Madison, J.M., Zhou, F., Nigam, A., Hussain, A., Barker, D.D., Nehme, R., Van Der Ven,
K.,  Hsu, J., Wolf, P., Fleishman, M.,  O’dushlaine, C., Rose, S., Chambert, K., Lau,
F.H.,  Ahfeldt, T., Rueckert, E.H., Sheridan, S.D., Fass, D.M., Nemesh, J., Mullen,
T.E., Daheron, L., Mccarroll, S., Sklar, P., Perlis, R.H., Haggarty, S.J., 2015.
Characterization of bipolar disorder patient-speciﬁc induced pluripotent stem
cells from a family reveals neurodevelopmental and mRNA expression
abnormalities. Mol. Psychiatry 20, 703–717.
Makris, N., Buka, S.L., Biederman, J., Papadimitriou, G.M., Hodge, S.M., Valera, E.M.,
Brown, A.B., Bush, G., Monuteaux, M.C., Caviness, V.S., Kennedy, D.N., Seidman,
L.J.,  2008. Attention and executive systems abnormalities in adults with
childhood ADHD: a DT-MRI study of connections. Cereb. Cortex 18, 1210–1220.
Mandelli, L., Serretti, A., 2013. Gene environment interaction studies in depression
and suicidal behavior: an update. Neurosci. Biobehav. Rev. 37, 2375–2397.
Manor, I., Eisenberg, J., Tyano, S., Sever, Y., Cohen, H., Ebstein, R.P., Kotler, M., 2001.
Family-based association study of the serotonin transporter promoter region
polymorphism (5-HTTLPR) in attention deﬁcit hyperactivity disorder. Am.  J.
Med. Genet. 105, 91–95.
Manuck, S.B., Flory, J.D., Ferrell, R.E., Mann, J.J., Muldoon, M.F., 2000. A regulatory
polymorphism of the monoamine oxidase-A gene may be associated with
variability in aggression, impulsivity, and central nervous system serotonergic
responsivity. Psychiatry Res. 95 (1), 9–23.
Marchetto, M.C., Carromeu, C., Acab, A., Yu, D., Yeo, G.W., Mu,  Y., Chen, G.,  Gage,
F.H., Muotri, A.R., 2010. A model for neural development and treatment of Rett
syndrome using human induced pluripotent stem cells. Cell 143, 527–539.
Mcgough, J.J., Smalley, S.L., Mccracken, J.T., Yang, M.,  D.E.L’homme, M.,  Lynn, D.E.,
Loo, S., 2005. Psychiatric comorbidity in adult attention deﬁcit hyperactivity
disorder: ﬁndings from multiplex families. Am.  J. Psychiatry 162, 1621–1627.
Mckay, D.R., Knowles, E.E., Winkler, A.A., Sprooten, E., Kochunov, P., Olvera, R.L.,
Curran, J.E., Kent Jr., J.W., Carless, M.A., Goring, H.H., Dyer, T.D., Duggirala, R.,
Almasy, L., Fox, P.T., Blangero, J., Glahn, D.C., 2014. Inﬂuence of age, sex and
genetic factors on the human brain. Brain Imaging Behav. 8, 143–152.
Medland, S.E., Jahanshad, N., Neale, B.M., Thompson, P.M., 2014. Whole-genome
analyses of whole-brain data: working within an expanded search space. Nat.
Neurosci. 17, 791–800.
Meneses, A., Liy-Salmeron, G., 2012. Serotonin and emotion, learning and memory.
Rev. Neurosci. 23, 543–553.
Meyer-Lindenberg, A., Buckholtz, J.W., Kolachana, B., Pezawas, A.R., Hariri, L., Blasi,
G.,  Wabnitz, A., Honea, R., Verchinski, B., Callicott, J.H., Egan, M.,  Mattay, V.,
Weinberger, D.R., 2006. Neural mechanisms of genetic risk for impulsivity and
violence in humans. Proc. Natl. Acad. Sci. U. S. A. 103, 6269–6274.
Mick, E., Neale, B., Middleton, F.A., Mcgough, J.J., Faraone, S.V., 2008. Genome-wide
association study of response to methylphenidate in 187 children with
attention-deﬁcit/hyperactivity disorder. Am. J. Med. Genet. B Neuropsychiatr.
Genet. 147B, 1412–1418.
Mick, E., Todorov, A., Smalley, S., Hu, X., Loo, S., Todd, R.D., Biederman, J., Byrne, D.,
Dechairo, B., Guiney, A., Mccracken, J., Mcgough, J., Nelson, S.F., Reiersen, A.M.,
Wilens, T.E., Wozniak, J., Neale, B.M., Faraone, S.V., 2010. Family-based
150 M. Klein et al. / Neuroscience and Biobehavioral Reviews 80 (2017) 115–155
genome-wide association scan of attention-deﬁcit/hyperactivity disorder. J.
Am.  Acad. Child Adolesc. Psychiatry 49, 898–905, e893.
Mier, D., Kirsch, P., Meyer-Lindenberg, A., 2010. Neural substrates of pleiotropic
action of genetic variation in COMT: a meta-analysis. Mol. Psychiatry 15,
918–927.
Miller, T.W., Nigg, J.T., Faraone, S.V., 2007. Axis I and II comorbidity in adults with
ADHD. J. Abnorm. Psychol. 116, 519–528.
Misener, V.L., Luca, P., Azeke, O., Crosbie, J., Waldman, I., Tannock, R., Roberts, W.,
Malone, M.,  Schachar, R., Ickowicz, A., Kennedy, J.L., Barr, C.L., 2004. Linkage of
the dopamine receptor D1 gene to attention-deﬁcit/hyperactivity disorder.
Mol. Psychiatry 9, 500–509.
Mofﬁtt, T.E., Houts, R., Asherson, P., Belsky, D.W., Corcoran, D.L., Hammerle, M.,
Harrington, H., Hogan, S., Meier, M.H., Polanczyk, G.V., Poulton, R., Ramrakha,
S.,  Sugden, K., Williams, B., Rohde, L.A., Caspi, A., 2015. Is adult ADHD a
childhood-onset neurodevelopmental disorder? Evidence from a four-decade
longitudinal cohort study. Am.  J. Psychiatry 172, 967–977.
Monuteaux, M.C., Seidman, L.J., Faraone, S.V., Makris, N., Spencer, T., Valera, E.,
Brown, A., Bush, G., Doyle, A.E., Hughes, S., Helliesen, M.,  Mick, E., Biederman, J.,
2008. A preliminary study of dopamine D4 receptor genotype and structural
brain alterations in adults with ADHD. Am. J. Med. Genet. B Neuropsychiatr.
Genet. 147B, 1436–1441.
Mooney, M.A., Mcweeney, S.K., Faraone, S.V., Hinney, A., Hebebrand, J., Consortium,
I.,  German, A.G.G., Nigg, J.T., Wilmot, B., 2016. Pathway analysis in attention
deﬁcit hyperactivity disorder: an ensemble approach. Am. J. Med. Genet. B
Neuropsychiatr. Genet. 171 (6), 815–826.
Mostert, J.C., Shumskaya, E., Mennes, M.,  Onnink, A.M., Hoogman, M.,  Kan, C.C.,
Arias Vasquez, A., Buitelaar, J., Franke, B., Norris, D.G., 2016. Characterising
resting-state functional connectivity in a large sample of adults with ADHD.
Prog. Neuropsychopharmacol. Biol. Psychiatry. 67, 82–91.
Munafo, M.R., Brown, S.M., Hariri, A.R., 2008. Serotonin transporter (5-HTTLPR)
genotype and amygdala activation: a meta-analysis. Biol. Psychiatry 63,
852–857.
Murphy, D.L., Andrews, A.M., Wichems, C.H., Li, Q., Tohda, M.,  Greenberg, B., 1998.
Brain serotonin neurotransmission: an overview and update with an emphasis
on  serotonin subsystem heterogeneity, multiple receptors, interactions with
other neurotransmitter systems, and consequent implications for
understanding the actions of serotonergic drugs. J. Clin. Psychiatry 59 (Suppl.
15), 4–12.
Murphy, S.E., Norbury, R., Godlewska, B.R., Cowen, P.J., Mannie, Z.M., Harmer, C.J.,
Munafo, M.R., 2013. The effect of the serotonin transporter polymorphism
(5-HTTLPR) on amygdala function: a meta-analysis. Mol. Psychiatry 18,
512–520.
Naaijen, J., Lythgoe, D.J., Amiri, H., Buitelaar, J.K., Glennon, J.C., 2015. Fronto-striatal
glutamatergic compounds in compulsive and impulsive syndromes: a review
of magnetic resonance spectroscopy studies. Neurosci. Biobehav. Rev. 52,
74–88.
Nakao, T., Radua, J., Rubia, K., Mataix-Cols, D., 2011. Gray matter volume
abnormalities in ADHD: voxel-based meta-analysis exploring the effects of age
and stimulant medication. Am.  J. Psychiatry 168, 1154–1163.
Neale, B.M., Lasky-Su, J., Anney, R., Franke, B., Zhou, K., Maller, J.B., Vasquez, A.A.,
Asherson, P., Chen, W.,  Banaschewski, T., Buitelaar, J., Ebstein, R., Gill, M.,
Miranda, A., Oades, R.D., Roeyers, H., Rothenberger, A., Sergeant, J.,
Steinhausen, H.C., Sonuga-Barke, E., Mulas, F., Taylor, E., Laird, N., Lange, C.,
Daly, M., Faraone, S.V., 2008. Genome-wide association scan of attention deﬁcit
hyperactivity disorder. Am.  J. Med. Genet. B Neuropsychiatr. Genet. 147B,
1337–1344.
Neale, B.M., Medland, S., Ripke, S., Anney, R.J., Asherson, P., Buitelaar, J., Franke, B.,
Gill,  M.,  Kent, L., Holmans, P., Middleton, F., Thapar, A., Lesch, K.P., Faraone, S.V.,
Daly, M.,  Nguyen, T.T., Schafer, H., Steinhausen, H.C., Reif, A., Renner, T.J.,
Romanos, M.,  Romanos, J., Warnke, A., Walitza, S., Freitag, C., Meyer, J.,
Palmason, H., Rothenberger, A., Hawi, Z., Sergeant, J., Roeyers, H., Mick, E.,
Biederman, J., Group, I.I.C., 2010a. Case-control genome-wide association study
of  attention-deﬁcit/hyperactivity disorder. J. Am. Acad. Child Adolesc.
Psychiatry 49, 906–920.
Neale, B.M., Medland, S.E., Ripke, S., Asherson, P., Franke, B., Lesch, K.P., Faraone,
S.V., Nguyen, T.T., Schafer, H., Holmans, P., Daly, M.,  Steinhausen, H.C., Freitag,
C.,  Reif, A., Renner, T.J., Romanos, M.,  Romanos, J., Walitza, S., Warnke, A.,
Meyer, J., Palmason, H., Buitelaar, J., Vasquez, A.A., Lambregts-Rommelse, N.,
Gill,  M.,  Anney, R.J., Langely, K., O’donovan, M.,  Williams, N., Owen, M.,  Thapar,
A.,  Kent, L., Sergeant, J., Roeyers, H., Mick, E., Biederman, J., Doyle, A., Smalley,
S., Loo, S., Hakonarson, H., Elia, J., Todorov, A., Miranda, A., Mulas, F., Ebstein,
R.P., Rothenberger, A., Banaschewski, T., Oades, R.D., Sonuga-Barke, E.,
Mcgough, J., Nisenbaum, L., Middleton, F., Hu, X., Nelson, S., Psychiatric,
G.C.A.S., 2010b. Meta-analysis of genome-wide association studies of
attention-deﬁcit/hyperactivity disorder. J. Am. Acad. Child Adolesc. Psychiatry
49,  884–897.
Neale, B.M., Kou, Y., Liu, L., MA’ayan, A., Samocha, K.E., Sabo, A., Lin, C.F., Stevens, C.,
Wang, L.S., Makarov, V., Polak, P., Yoon, S., Maguire, J., Crawford, E.L., Campbell,
N.G., Geller, E.T., Valladares, O., Schafer, C., Liu, H., Zhao, T., Cai, G., Lihm, J.,
Dannenfelser, R., Jabado, O., Peralta, Z., Nagaswamy, U., Muzny, D., Reid, J.G.,
Newsham, I., Wu,  Y., Lewis, L., Han, Y., Voight, B.F., Lim, E., Rossin, E., Kirby, A.,
Flannick, J., Fromer, M.,  Shakir, K., Fennell, T., Garimella, K., Banks, E., Poplin, R.,
Gabriel, S., Depristo, M.,  Wimbish, J.R., Boone, B.E., Levy, S.E., Betancur, C.,
Sunyaev, S., Boerwinkle, E., Buxbaum, J.D., Cook, E.H. Jr., Devlin, B., Gibbs, R.A.,
Roeder, K., Schellenberg, G.D., Sutcliffe, J.S., Daly, M.J., 2012. Patterns and rates
of exonic de novo mutations in autism spectrum disorders. Nature 485,
242–245.
Negoro, H., Sawada, M., Iida, J., Ota, T., Tanaka, S., Kishimoto, T., 2010. Prefrontal
dysfunction in attention-deﬁcit/hyperactivity disorder as measured by
near-infrared spectroscopy. Child Psychiatry Hum. Dev. 41, 193–203.
Nigg, J.T., Knottnerus, G.M., Martel, M.M.,  Nikolas, M.,  Cavanagh, K., Karmaus, W.,
Rappley, M.D., 2008. Low blood lead levels associated with clinically diagnosed
attention-deﬁcit/hyperactivity disorder and mediated by weak cognitive
control. Biol. Psychiatry 63, 325–331.
Nikolaidis, A., Gray, J.R., 2010. ADHD and the DRD4 exon III 7-repeat
polymorphism: an international meta-analysis. Soc. Cogn. Affect. Neurosci. 5,
188–193.
Norman, L.J., Carlisi, C., Lukito, S., Hart, H., Mataix-Cols, D., Radua, J., Rubia, K., 2016.
Structural and functional brain abnormalities in attention-deﬁcit/hyperactivity
disorder and obsessive-compulsive disorder: a comparative meta-analysis.
JAMA Psychiatry 73, 815–825.
O’roak, B.J., Vives, L., Girirajan, S., Karakoc, E., Krumm,  N., Coe, B.P., Levy, R., Ko, A.,
Lee,  C., Smith, J.D., Turner, E.H., Stanaway, I.B., Vernot, B., Malig, M.,  Baker, C.,
Reilly, B., Akey, J.M., Borenstein, E., Rieder, M.J., Nickerson, D.A., Bernier, R.,
Shendure, J., Eichler, E.E., 2012. Sporadic autism exomes reveal a highly
interconnected protein network of de novo mutations. Nature 485, 246–250.
O’shea, K.S., Mcinnis, M.G., 2015. Induced pluripotent stem cell (iPSC) models of
bipolar disorder. Neuropsychopharmacology 40, 248–249.
Oades, R.D., Lasky-Su, J., Christiansen, H., Faraone, S.V., Sonuga-Barke, E.J.,
Banaschewski, T., Chen, W.,  Anney, R.J., Buitelaar, J.K., Ebstein, R.P., Franke, B.,
Gill,  M.,  Miranda, A., Roeyers, H., Rothenberger, A., Sergeant, J.A., Steinhausen,
H.C., Taylor, E.A., Thompson, M.,  Asherson, P., 2008. The inﬂuence of serotonin-
and other genes on impulsive behavioral aggression and cognitive impulsivity
in  children with attention-deﬁcit/hyperactivity disorder (ADHD): ﬁndings
from a family-based association test (FBAT) analysis. Behav. Brain Funct. 4, 48.
Okamoto, K., Aoki, K., 1963. Development of a strain of spontaneously
hypertensive rats. Jpn. Circ. J. 27, 282–293.
Oldenhof, J., Vickery, R., Anaﬁ, M.,  Oak, J., Ray, A., Schoots, O., Pawson, T., Von
Zastrow, M.,  Van Tol, H.H., 1998. SH3 binding domains in the dopamine D4
receptor. Biochemistry 37, 15726–15736.
Ollendick, T.H., Jarrett, M.A., Grills-Taquechel, A.E., Hovey, L.D., Wolff, J.C., 2008.
Comorbidity as a predictor and moderator of treatment outcome in youth with
anxiety, affective, attention deﬁcit/hyperactivity disorder, and
oppositional/conduct disorders. Clin. Psychol. Rev. 28, 1447–1471.
Oner, O., Akin, A., Herken, H., Erdal, M.E., Ciftci, K., Ay, M.E., Bicer, D., Oncu, B.,
Bozkurt, O.H., Munir, K., Yazgan, Y., 2011. Association among SNAP-25 gene
DdeI and MnlI polymorphisms and hemodynamic changes during
methylphenidate use: a functional near-infrared spectroscopy study. J. Atten.
Disord. 15, 628–637.
Onnink, A.M., Zwiers, M.P., Hoogman, M.,  Mostert, J.C., Dammers, J., Kan, C.C.,
Vasquez, A.A., Schene, A.H., Buitelaar, J., Franke, B., 2015. Deviant white matter
structure in adults with attention-deﬁcit/hyperactivity disorder points to
aberrant myelination and affects neuropsychological performance. Prog.
Neuropsychopharmacol. Biol. Psychiatry 63, 14–22.
Onnink, A.M., Franke, B., Van Hulzen, K., Zwiers, M.P., Mostert, J.C., Schene, A.H.,
Heslenfeld, D.J., Oosterlaan, J., Hoekstra, P.J., Hartman, C.A., Vasquez, A.A., Kan,
C.C., Buitelaar, J., Hoogman, M., 2016. Enlarged striatal volume in adults with
ADHD carrying the 9-6 haplotype of the dopamine transporter gene DAT1. J.
Neural Transm. (Vienna) 123 (8), 905–915.
Oo, K.Z., Aung, Y.K., Jenkins, M.A., Win, A.K., 2016. Associations of 5HTTLPR
polymorphism with major depressive disorder and alcohol dependence: a
systematic review and meta-analysis. Aust. N. Z. J. Psychiatry 50 (9), 842–857.
Oortveld, M.A., Keerthikumar, S., Oti, M.,  Nijhof, B., Fernandes, A.C., Kochinke, K.,
Castells-Nobau, A., Van Engelen, E., Ellenkamp, T., Eshuis, L., Galy, A., Van
Bokhoven, H., Habermann, B., Brunner, H.G., Zweier, C., Verstreken, P., Huynen,
M.A., Schenck, A., 2013. Human intellectual disability genes form conserved
functional modules in Drosophila. PLoS Genet. 9, e1003911.
Oquendo, M.A., Hastings, R.S., Huang, Y.Y., Simpson, N., Ogden, R.T., Hu, X.Z.,
Goldman, D., Arango, V., Van Heertum, R.L., Mann, J.J., Parsey, R.V., 2007. Brain
serotonin transporter binding in depressed patients with bipolar disorder
using positron emission tomography. Arch. Gen. Psychiatry 64, 201–208.
Osafune, K., Caron, L., Borowiak, M.,  Martinez, R.J., Fitz-Gerald, C.S., Sato, Y., Cowan,
C.A., Chien, K.R., Melton, D.A., 2008. Marked differences in differentiation
propensity among human embryonic stem cell lines. Nat. Biotechnol. 26,
313–315.
PGC and iPSYCH ADHD working groups (in preparation).
Paloyelis, Y., Mehta, M.A., Faraone, S.V., Asherson, P., Kuntsi, J., 2012. Striatal
sensitivity during reward processing in attention-deﬁcit/hyperactivity
disorder. J. Am.  Acad. Child Adolesc. Psychiatry 51, 722–732, e729.
Pan, Y., Yao, J., Wang, B., 2014. Association of dopamine D1 receptor gene
polymorphism with schizophrenia: a meta-analysis. Neuropsychiatr. Dis.
Treat. 10, 1133–1139.
Pan, Y.Q., Qiao, L., Xue, X.D., Fu, J.H., 2015. Association between ANKK1
(rs1800497) polymorphism of DRD2 gene and attention deﬁcit hyperactivity
disorder: a meta-analysis. Neurosci. Lett. 590, 101–105.
Pang, Z.P., Yang, N., Vierbuchen, T., Ostermeier, A., Fuentes, D.R., Yang, T.Q., Citri, A.,
Sebastiano, V., Marro, S., Sudhof, T.C., Wernig, M.,  2011. Induction of human
neuronal cells by deﬁned transcription factors. Nature 476, 220–223.
Pappa, I., Mileva-Seitz, V.R., Bakermans-Kranenburg, M.J., Tiemeier, H., Van
Ijzendoorn, M.H., 2015. The magniﬁcent seven: a quantitative review of
M. Klein et al. / Neuroscience and Biobehavioral Reviews 80 (2017) 115–155 151
dopamine receptor d4 and its association with child behavior. Neurosci.
Biobehav. Rev. 57, 175–186.
Parikshak, N.N., Luo, R., Zhang, A., Won, H., Lowe, J.K., Chandran, V., Horvath, S.,
Geschwind, D.H., 2013. Integrative functional genomic analyses implicate
speciﬁc molecular pathways and circuits in autism. Cell 155, 1008–1021.
Park, L., Nigg, J.T., Waldman, I.D., Nummy, K.A., Huang-Pollock, C., Rappley, M.,
Friderici, K.H., 2005. Association and linkage of alpha-2A adrenergic receptor
gene polymorphisms with childhood ADHD. Mol. Psychiatry 10, 572–580.
Park, M.H., Kim, J.W., Yang, Y.H., Hong, S.B., Park, S., Kang, H., Kim, B.N., Shin, M.S.,
Yoo,  H.J., Cho, S.C., 2012. Regional brain perfusion before and after treatment
with methylphenidate may  be associated with the G1287A polymorphism of
the norepinephrine transporter gene in children with
attention-deﬁcit/hyperactivity disorder. Neurosci. Lett. 514, 159–163.
Park, S., Hong, S.B., Kim, J.W., Yang, Y.H., Park, M.H., Kim, B.N., Shin, M.S., Yoo, H.J.,
Cho, S.C., 2013. White-matter connectivity and methylphenidate-induced
changes in attentional performance according to alpha2A-adrenergic receptor
gene polymorphisms in Korean children with attention-deﬁcit hyperactivity
disorder. J. Neuropsychiatry Clin. Neurosci. 25, 222–228.
Park, S., Kim, B.N., Cho, S.C., Kim, J.W., Kim, J.I., Shin, M.S., Yoo, H.J., Han, D.H.,
Cheong, J.H., 2014. The metabotropic glutamate receptor subtype 7 rs3792452
polymorphism is associated with the response to methylphenidate in children
with attention-deﬁcit/hyperactivity disorder. J. Child Adolesc.
Psychopharmacol. 24, 223–227.
Pascoli, V., Valjent, E., Corbille, A.G., Corvol, J.C., Tassin, J.P., Girault, J.A., Herve, D.,
2005. cAMP and extracellular signal-regulated kinase signaling in response to
d-amphetamine and methylphenidate in the prefrontal cortex in vivo: role of
beta 1-adrenoceptors. Mol. Pharmacol. 68, 421–429.
Paul, D.S., Soranzo, N., Beck, S., 2014. Functional interpretation of non-coding
sequence variation: concepts and challenges. Bioessays 36, 191–199.
Payton, A., Holmes, J., Barrett, J.H., Hever, T., Fitzpatrick, H., Trumper, A.L.,
Harrington, R., Mcgufﬁn, P., O’donovan, M.,  Owen, M.,  Ollier, W.,  Worthington,
J.,  Thapar, A., 2001. Examining for association between candidate gene
polymorphisms in the dopamine pathway and attention-deﬁcit hyperactivity
disorder: a family-based study. Am.  J. Med. Genet. 105, 464–470.
Peper, J.S., Brouwer, R.M., Boomsma, D.I., Kahn, R.S., Hulshoff Pol, H.E., 2007.
Genetic inﬂuences on human brain structure: a review of brain imaging
studies in twins. Hum. Brain Mapp. 28, 464–473.
Pingault, J.B., Viding, E., Galera, C., Greven, C.U., Zheng, Y., Plomin, R., Rijsdijk, F.,
2015. Genetic and environmental inﬂuences on the developmental course of
attention-deﬁcit/hyperactivity disorder symptoms from childhood to
adolescence. JAMA Psychiatry 72, 651–658.
Plaisancie, J., Bouneau, L., Cances, C., Garnier, C., Benesteau, J., Leonard, S.,
Bourrouillou, G., Calvas, P., Vigouroux, A., Julia, S., Bieth, E., 2014. Distal 10q
monosomy: new evidence for a neurobehavioral condition? Eur. J. Med. Genet.
57, 47–53.
Plichta, M.M.,  Scheres, A., 2014. Ventral-striatal responsiveness during reward
anticipation in ADHD and its relation to trait impulsivity in the healthy
population: a meta-analytic review of the fMRI literature. Neurosci. Biobehav.
Rev. 38, 125–134.
Poelmans, G., Pauls, D.L., Buitelaar, J.K., Franke, B., 2011. Integrated genome-wide
association study ﬁndings: identiﬁcation of a neurodevelopmental network for
attention deﬁcit hyperactivity disorder. Am.  J. Psychiatry 168, 365–377.
Poelmans, G., Franke, B., Pauls, D.L., Glennon, J.C., Buitelaar, J.K., 2013. AKAPs
integrate genetic ﬁndings for autism spectrum disorders. Transl. Psychiatry 3,
e270.
Polanczyk, G., Rohde, L.A., 2007. Epidemiology of attention-deﬁcit/hyperactivity
disorder across the lifespan. Curr. Opin. Psychiatry 20, 386–392.
Polina, E.R., Rovaris, D.L., De Azeredo, L.A., Mota, N.R., Vitola, E.S., Silva, K.L.,
Guimaraes-Da-Silva, P.O., Picon, F.A., Belmonte-De-Abreu, P., Rohde, L.A.,
Grevet, E.H., Bau, C.H., 2014. ADHD diagnosis may  inﬂuence the association
between polymorphisms in nicotinic acetylcholine receptor genes and tobacco
smoking. Neuromolecular Med. 16, 389–397.
Posner, J., Park, C., Wang, Z., 2014. Connecting the dots: a review of resting
connectivity MRI  studies in attention-deﬁcit/hyperactivity disorder.
Neuropsychol. Rev. 24, 3–15.
Psaty, B.M., O’donnell, C.J., Gudnason, V., Lunetta, K.L., Folsom, A.R., Rotter, J.I.,
Uitterlinden, A.G., Harris, T.B., Witteman, J.C., Boerwinkle, E., Consortium, C.,
2009. Cohorts for heart and aging research in genomic epidemiology (CHARGE)
consortium: design of prospective meta-analyses of genome-wide association
studies from 5 cohorts. Circ. Cardiovasc. Genet. 2, 73–80.
Purcell, S.M., Moran, J.L., Fromer, M.,  Ruderfer, D., Solovieff, N., Roussos, P.,
O’dushlaine, C., Chambert, K., Bergen, S.E., Kahler, A., Duncan, L., Stahl, E.,
Genovese, G., Fernandez, E., Collins, M.O., Komiyama, N.H., Choudhary, J.S.,
Magnusson, P.K., Banks, E., Shakir, K., Garimella, K., Fennell, T., Depristo, M.,
Grant, S.G., Haggarty, S.J., Gabriel, S., Scolnick, E.M., Lander, E.S., Hultman, C.M.,
Sullivan, P.F., Mccarroll, S.A., Sklar, P., 2014. A polygenic burden of rare
disruptive mutations in schizophrenia. Nature 506, 185–190.
Quist, J.F., Barr, C.L., Schachar, R., Roberts, W.,  Malone, M.,  Tannock, R., Basile, V.S.,
Beitchman, J., Kennedy, J.L., 2000. Evidence for the serotonin HTR2A receptor
gene as a susceptibility factor in attention deﬁcit hyperactivity disorder
(ADHD). Mol. Psychiatry 5, 537–541.
Rahmim, A., Zaidi, H., 2008. PET versus SPECT: strengths, limitations and
challenges. Nucl. Med. Commun. 29, 193–207.
Ramos-Quiroga, J.A., Sanchez-Mora, C., Casas, M.,  Garcia-Martinez, I., Bosch, R.,
Nogueira, M.,  Corrales, M.,  Palomar, G., Vidal, R., Coll-Tane, M.,  Bayes, M.,
Cormand, B., Ribases, M.,  2014. Genome-wide copy number variation analysis
in adult attention-deﬁcit and hyperactivity disorder. J. Psychiatr. Res. 49,
60–67.
Ran, F.A., Hsu, P.D., Wright, J., Agarwala, V., Scott, D.A., Zhang, F., 2013. Genome
engineering using the CRISPR-Cas9 system. Nat. Protoc. 8, 2281–2308.
Rappley, M.D., 2005. Clinical practice. Attention deﬁcit-hyperactivity disorder. N.
Engl. J. Med. 352, 165–173.
Raznahan, A., Shaw, P.W., Lerch, J.P., Clasen, L.S., Greenstein, D., Berman, R.,
Pipitone, J., Chakravarty, M.M.,  Giedd, J.N., 2014. Longitudinal
four-dimensional mapping of subcortical anatomy in human development.
Proc. Natl. Acad. Sci. U. S. A. 111, 1592–1597.
Reif, A., Jacob, C.P., Rujescu, D., Herterich, S., Lang, S., Gutknecht, L., Baehne, C.G.,
Strobel, A., Freitag, C.M., Giegling, I., Romanos, M.,  Hartmann, A., Rosler, M.,
Renner, T.J., Fallgatter, A.J., Retz, W.,  Ehlis, A.C., Lesch, K.P., 2009. Inﬂuence of
functional variant of neuronal nitric oxide synthase on impulsive behaviors in
humans. Arch. Gen. Psychiatry 66, 41–50.
Reif, A., Nguyen, T.T., Weissﬂog, L., Jacob, C.P., Romanos, M., Renner, T.J.,
Buttenschon, H.N., Kittel-Schneider, S., Gessner, A., Weber, H., Neuner, M.,
Gross-Lesch, S., Zamzow, K., Kreiker, S., Walitza, S., Meyer, J., Freitag, C.M.,
Bosch, R., Casas, M.,  Gomez, N., Ribases, M.,  Bayes, M.,  Buitelaar, J.K., Kiemeney,
L.A.,  Kooij, J.J., Kan, C.C., Hoogman, M.,  Johansson, S., Jacobsen, K.K., Knappskog,
P.M., Fasmer, O.B., Asherson, P., Warnke, A., Grabe, H.J., Mahler, J., Teumer, A.,
Volzke, H., Mors, O.N., Schafer, H., Ramos-Quiroga, J.A., Cormand, B., Haavik, J.,
Franke, B., Lesch, K.P., 2011. DIRAS2 is associated with adult ADHD, related
traits, and co-morbid disorders. Neuropsychopharmacology 36, 2318–2327.
Reinhardt, M.C., Reinhardt, C.A., 2013. Attention deﬁcit-hyperactivity disorder,
comorbidities, and risk situations. J. Pediatr. (Rio. J) 89, 124–130.
Reinhardt, P., Schmid, B., Burbulla, L.F., Schondorf, D.C., Wagner, L., Glatza, M.,
Hoing, S., Hargus, G., Heck, S.A., Dhingra, A., Wu,  G.M., Muller, S., Brockmann,
K., Kluba, T., Maisel, M.,  Kruger, R., Berg, D., Tsytsyura, Y., Thiel, C.S., Psathaki,
O.E., Klingauf, J., Kuhlmann, T., Klewin, M.,  Muller, H., Gasser, T., Scholer, H.R.,
Sterneckert, J., 2013. Genetic correction of a LRRK2 mutation in human iPSCs
links parkinsonian neurodegeneration to ERK-dependent changes in gene
expression. Cell Stem Cell 12, 354–367.
Ribases, M.,  Hervas, A., Ramos-Quiroga, J.A., Bosch, R., Bielsa, A., Gastaminza, X.,
Fernandez-Anguiano, M.,  Nogueira, M.,  Gomez-Barros, N., Valero, S., Gratacos,
M.,  Estivill, X., Casas, M.,  Cormand, B., Bayes, M.,  2008. Association study of 10
genes encoding neurotrophic factors and their receptors in adult and child
attention-deﬁcit/hyperactivity disorder. Biol. Psychiatry 63, 935–945.
Ribases, M.,  Ramos-Quiroga, J.A., Hervas, A., Bosch, R., Bielsa, A., Gastaminza, X.,
Artigas, J., Rodriguez-Ben, S., Estivill, X., Casas, M.,  Cormand, B., Bayes, M.,  2009.
Exploration of 19 serotoninergic candidate genes in adults and children with
attention-deﬁcit/hyperactivity disorder identiﬁes association for 5HT2A, DDC
and MAOB. Mol. Psychiatry 14, 71–85.
Ribases, M.,  Ramos-Quiroga, J.A., Sanchez-Mora, C., Bosch, R., Richarte, V., Palomar,
G.,  Gastaminza, X., Bielsa, A., Arcos-Burgos, M.,  Muenke, M.,  Castellanos, F.X.,
Cormand, B., Bayes, M.,  Casas, M.,  2011. Contribution of LPHN3 to the genetic
susceptibility to ADHD in adulthood: a replication study. Genes Brain Behav.
10,  149–157.
Ribases, M.,  Ramos-Quiroga, J.A., Hervas, A., Sanchez-Mora, C., Bosch, R., Bielsa, A.,
Gastaminza, X., Lesch, K.P., Reif, A., Renner, T.J., Romanos, M.,  Warnke, A.,
Walitza, S., Freitag, C., Meyer, J., Palmason, H., Casas, M.,  Bayes, M.,  Cormand, B.,
2012. Candidate system analysis in ADHD: evaluation of nine genes involved in
dopaminergic neurotransmission identiﬁes association with DRD1. World J.
Biol. Psychiatry 13, 281–292.
Richards, J.S., Arias Vasquez, A., Franke, B., Hoekstra, P.J., Heslenfeld, D.J.,
Oosterlaan, J., Faraone, S.V., Buitelaar, J.K., Hartman, C.A., 2016.
Developmentally sensitive interaction effects of genes and the social
environment on total and subcortical brain volumes. PLoS One 11, e0155755.
Rivero, O., Sich, S., Popp, S., Schmitt, A., Franke, B., Lesch, K.P., 2013. Impact of the
ADHD-susceptibility gene CDH13 on development and function of brain
networks. Eur. Neuropsychopharmacol. 23, 492–507.
Rivero, O., Selten, M.M.,  Sich, S., Popp, S., Bacmeister, L., Amendola, E., Negwer, M.,
Schubert, D., Proft, F., Kiser, D., Schmitt, A.G., Gross, C., Kolk, S.M., Strekalova, T.,
Van Den Hove, D., Resink, T.J., Nadif Kasri, N., Lesch, K.P., 2015. Cadherin-13, a
risk gene for ADHD and comorbid disorders, impacts GABAergic function in
hippocampus and cognition. Transl. Psychiatry 5, e655.
Rohde, L.A., Roman, T., Szobot, C., Cunha, R.D., Hutz, M.H., Biederman, J., 2003.
Dopamine transporter gene, response to methylphenidate and cerebral blood
ﬂow in attention-deﬁcit/hyperactivity disorder: a pilot study. Synapse 48,
87–89.
Roman, T., Schmitz, M.,  Polanczyk, G.V., Eizirik, M.,  Rohde, L.A., Hutz, M.H., 2003. Is
the alpha-2A adrenergic receptor gene (ADRA2A) associated with
attention-deﬁcit/hyperactivity disorder? Am.  J. Med. Genet. B Neuropsychiatr.
Genet. 120B, 116–120.
Rommelse, N.N., Geurts, H.M., Franke, B., Buitelaar, J.K., Hartman, C.A., 2011. A
review on cognitive and brain endophenotypes that may  be common in autism
spectrum disorder and attention-deﬁcit/hyperactivity disorder and facilitate
the search for pleiotropic genes. Neurosci. Biobehav. Rev. 35, 1363–1396.
Rose, E.J., Donohoe, G., 2013. Brain vs behavior: an effect size comparison of
neuroimaging and cognitive studies of genetic risk for schizophrenia.
Schizophr. Bull. 39, 518–526.
Rubia, K., 2007. Neuro-anatomic evidence for the maturational delay hypothesis of
ADHD. Proc. Natl. Acad. Sci. U. S. A. 104, 19663–19664.
Ruocco, L.A., Treno, C., Gironi Carnevale, U.A., Arra, C., Boatto, G.,  Nieddu, M.,
Pagano, C., Illiano, P., Barbato, F., Tino, A., Carboni, E., Laviola, G.,  Lacivita, E.,
Leopoldo, M., Adriani, W.,  Sadile, A.G., 2014. Prepuberal stimulation of 5-HT7-R
152 M. Klein et al. / Neuroscience and Biobehavioral Reviews 80 (2017) 115–155
by LP-211 in a rat model of hyper-activity and attention-deﬁcit: permanent
effects on attention, brain amino acids and synaptic markers in the
fronto-striatal interface. PLoS One 9, e83003.
Russell, V., DE Villiers, A., Sagvolden, T., Lamm, M.,  Taljaard, J., 1995. Altered
dopaminergic function in the prefrontal cortex, nucleus accumbens and
caudate-putamen of an animal model of attention-deﬁcit hyperactivity
disorder–the spontaneously hypertensive rat. Brain Res. 676, 343–351.
Sanchez-Carmona, A.J., Albert, J., Hinojosa, J.A., 2016. Neural and behavioral
correlates of selective stopping: evidence for a different strategy adoption.
Neuroimage 139, 279–293.
Sanchez-Mora, C., Ribases, M.,  Casas, M.,  Bayes, M.,  Bosch, R., Fernandez-Castillo,
N., Brunso, L., Jacobsen, K.K., Landaas, E.T., Lundervold, A.J., Gross-Lesch, S.,
Kreiker, S., Jacob, C.P., Lesch, K.P., Buitelaar, J.K., Hoogman, M.,  Kiemeney, L.A.,
Kooij, J.J., Mick, E., Asherson, P., Faraone, S.V., Franke, B., Reif, A., Johansson, S.,
Haavik, J., Ramos-Quiroga, J.A., Cormand, B., 2011. Exploring DRD4 and its
interaction with SLC6A3 as possible risk factors for adult ADHD: a
meta-analysis in four European populations. Am.  J. Med. Genet. B
Neuropsychiatr. Genet. 156B, 600–612.
Sanchez-Mora, C., Cormand, B., Ramos-Quiroga, J.A., Hervas, A., Bosch, R., Palomar,
G.,  Nogueira, M.,  Gomez-Barros, N., Richarte, V., Corrales, M.,  Garcia-Martinez,
I.,  Corominas, R., Guijarro, S., Bigorra, A., Bayes, M.,  Casas, M., Ribases, M., 2013.
Evaluation of common variants in 16 genes involved in the regulation of
neurotransmitter release in ADHD. Eur. Neuropsychopharmacol. 23, 426–435.
Sanchez-Mora, C., Ramos-Quiroga, J.A., Bosch, R., Corrales, M.,  Garcia-Martinez, I.,
Nogueira, M.,  Pagerols, M.,  Palomar, G., Richarte, V., Vidal, R., Arias-Vasquez, A.,
Bustamante, M.,  Forns, J., Gross-Lesch, S., Guxens, M.,  Hinney, A., Hoogman, M.,
Jacob, C., Jacobsen, K.K., Kan, C.C., Kiemeney, L., Kittel-Schneider, S., Klein, M.,
Onnink, M.,  Rivero, O., Zayats, T., Buitelaar, J., Faraone, S.V., Franke, B., Haavik,
J.,  Johansson, S., Lesch, K.P., Reif, A., Sunyer, J., Bayes, M.,  Casas, M.,  Cormand, B.,
Ribases, M.,  2014. Case-control genome-wide association study of persistent
attention-deﬁcit hyperactivity disorder identiﬁes FBXO33 as a novel
susceptibility gene for the disorder. Neuropsychopharmacology 40 (4),
915–926.
Sanchez-Mora, C., Richarte, V., Garcia-Martinez, I., Pagerols, M.,  Corrales, M.,  Bosch,
R.,  Vidal, R., Viladevall, L., Casas, M.,  Cormand, B., Ramos-Quiroga, J.A., Ribases,
M.,  2015. Dopamine receptor DRD4 gene and stressful life events in persistent
attention deﬁcit hyperactivity disorder. Am.  J. Med. Genet. B Neuropsychiatr.
Genet., epub ahead of print.
Schadt, E.E., Buchanan, S., Brennand, K.J., Merchant, K.M., 2014. Evolving toward a
human-cell based and multiscale approach to drug discovery for CNS
disorders. Front. Pharmacol. 5, 252.
Schecklmann, M.,  Romanos, M.,  Bretscher, F., Plichta, M.M.,  Warnke, A., Fallgatter,
A.J., 2010. Prefrontal oxygenation during working memory in ADHD. J.
Psychiatr. Res. 44, 621–628.
Schecklmann, M.,  Ehlis, A.C., Plichta, M.M.,  Dresler, T., Heine, M.,  Boreatti-Hummer,
A.,  Romanos, M.,  Jacob, C., Pauli, P., Fallgatter, A.J., 2013. Working memory and
response inhibition as one integral phenotype of adult ADHD? A behavioral
and imaging correlational investigation. J. Atten. Disord. 17, 470–482.
Schizophrenia Working Group of The Psychiatric Genomics Consortium, Ripke, S.,
Neale, B.M., Corvin, A., Walters, J.T.R., Farh, K.H., Holmans, P.A., Lee, P.,
Bulik-Sullivan, B., Collier, D.A., Huang, H., Pers, T.H., Agartz, I., Agerbo, E., Albus,
M.,  Alexander, M.,  Amin, F., Bacanu, S.A., Begemann, M.,  Belliveau, R.A., Bene, J.,
Bergen, S.E., Bevilacqua, E., Bigdeli, T.B., Black, D.W., Bruggeman, R., Buccola,
N.G., Buckner, R.L., Byerley, W.,  Cahn, W.,  Cai, G., Campion, D., Cantor, R.M.,
Carr, V.J., Carrera, N., Catts, S.V., Chambert, K.D., Chan, R.C.K., Chan, R.Y.L., Chen,
E.Y.H., Cheng, W.,  Cheung, E.F.C., Chong, S.A., Cloninger, C.R., Cohen, D., Cohen,
N.,  Cormican, P., Craddock, N., Crowley, J.J., Curtis, D., Davidson, M.,  Davis, K.L.,
Degenhardt, F., del Favero, J., Demontis, D., Dikeos, D., Dinan, T., Djurovic, S.,
Donohoe, G., Drapeau, E., Duan, J., Dudbridge, F., Durmishi, N., Eichhammer, P.,
Eriksson, J., Escott-Price, V., Essioux, L., Fanous, A.H., Farrell, M.S., Frank, J.,
Franke, L., Freedman, R., Freimer, N.B., Friedl, M.,  Friedman, J.I., Fromer, M.,
Genovese, G., Georgieva, L., Giegling, I., Giusti-Rodríguez, P., Godard, S.,
Goldstein, J.I., Golimbet, V., Gopal, S., Gratten, J., De Haan, L., Hammer, C.,
Hamshere, M.L., Hansen, M.,  Hansen, T., Haroutunian, V., Hartmann, A.M.,
Henskens, F.A., Herms, S., Hirschhorn, J.N., Hoffmann, P., Hofman, A.,
Hollegaard, M.V., Hougaard, D.M., Ikeda, M.,  et al., 2014. Biological insights
from 108 schizophrenia-associated genetic loci. Nature 511, 421–427.
Schur, R.R., Draisma, L.W., Wijnen, J.P., Boks, M.P., Koevoets, M.G., Joels, M., Klomp,
D.W., Kahn, R.S., Vinkers, C.H., 2016. Brain GABA levels across psychiatric
disorders: a systematic literature review and meta-analysis of H-MRS studies.
Hum. Brain Mapp. 37 (9), 3337–3352.
Schweren, L.J., de Zeeuw, P., Durston, S., 2013. MR imaging of the effects of
methylphenidate on brain structure and function in
attention-deﬁcit/hyperactivity disorder. Eur. Neuropsychopharmacol. 23,
1151–1164.
Schweren, L.J., Hartman, C.A., Heslenfeld, D.J., Groenman, A.P., Franke, B.,
Oosterlaan, J., Buitelaar, J.K., Hoekstra, P.J., 2016. Age and DRD4 genotype
moderate associations between stimulant treatment history and cortex
structure in attention-deﬁcit/hyperactivity disorder. J. Am.  Acad. Child
Adolesc. Psychiatry 55, 877–885, e873.
Segal, D.S., Kuczenski, R., 1997. Repeated binge exposures to amphetamine and
methamphetamine: behavioral and neurochemical characterization. J.
Pharmacol. Exp. Ther. 282, 561–573.
Segurado, R., Bellgrove, M.A., Manconi, F., Gill, M.,  Hawi, Z., 2011. Epistasis between
neurochemical gene polymorphisms and risk for ADHD. Eur. J. Hum. Genet. 19,
577–582.
Seu, E., Lang, A., Rivera, R.J., Jentsch, J.D., 2009. Inhibition of the norepinephrine
transporter improves behavioral ﬂexibility in rats and monkeys.
Psychopharmacology (Berl.) 202, 505–519.
Shaw, P., Eckstrand, K., Sharp, W.,  Blumenthal, J., Lerch, J., Greenstein, D., Clasen, L.,
Evans, A., Giedd, J., Rapoport, J., 2007a. Attention-deﬁcit/hyperactivity disorder
is characterized by a delay in cortical maturation. Proc. Natl. Acad. Sci. 104,
19649–19654.
Shaw, P., Gornick, M.,  Lerch, J., Addington, A., Seal, J., Greenstein, D., Sharp, W.,
Evans, A., Giedd, J.N., Castellanos, F.X., Rapoport, J.L., 2007b. Polymorphisms of
the dopamine D4 receptor, clinical outcome, and cortical structure in
attention-deﬁcit/hyperactivity disorder. Arch. Gen. Psychiatry 64, 921–931.
Shaw, P., Malek, M., Watson, B., Sharp, W.,  Evans, A., Greenstein, D., 2012.
Development of cortical surface area and gyriﬁcation in
attention-deﬁcit/hyperactivity disorder. Biol. Psychiatry 72, 191–197.
Sheehan, K., Lowe, N., Kirley, A., Mullins, C., Fitzgerald, M.,  Gill, M.,  Hawi, Z., 2005.
Tryptophan hydroxylase 2 (TPH2) gene variants associated with ADHD. Mol.
Psychiatry 10, 944–949.
Shenhav, A., Botvinick, M.M.,  Cohen, J.D., 2013. The expected value of control: an
integrative theory of anterior cingulate cortex function. Neuron 79, 217–240.
Sheridan, S.D., Theriault, K.M., Reis, S.A., Zhou, F., Madison, J.M., Daheron, L., Loring,
J.F., Haggarty, S.J., 2011. Epigenetic characterization of the FMR1 gene and
aberrant neurodevelopment in human induced pluripotent stem cell models of
fragile X syndrome. PLoS One 6, e26203.
Shiffrin, N.D., Gruber, J., Glatt, S.J., Faraone, S.V., 2013. No association between MspI
allele of the ADRA2A polymorphism and ADHD: meta-analysis of family-based
studies. Psychiatr. Genet. 23, 174–175.
Shim, S.H., Hwangbo, Y., Kwon, Y.J., Jeong, H.Y., Lee, B.H., Hwang, J.A., Kim, Y.K.,
2010. A case-control association study of serotonin 1A receptor gene and
tryptophan hydroxylase 2 gene in attention deﬁcit hyperactivity disorder.
Prog. Neuropsychopharmacol. Biol. Psychiatry. 34, 974–979.
Shim, S.H., Hwangbo, Y., Yoon, H.J., Kwon, Y.J., Lee, H.Y., Hwang, J.A., Kim, Y.K.,
2015. Increased levels of plasma glial-derived neurotrophic factor in children
with attention deﬁcit hyperactivity disorder. Nord. J. Psychiatry 69, 546–551.
Shimada, K., Fujisawa, T.X., Takiguchi, S., Naruse, H., Kosaka, H., Okazawa, H.,
Tomoda, A., 2015. Ethnic differences in COMT genetic effects on striatal grey
matter alterations associated with childhood ADHD: a voxel-based
morphometry study in a Japanese sample. World J. Biol. Psychiatry, 1–7.
Shook, D., Brady, C., Lee, P.S., Kenealy, L., Murphy, E.R., Gaillard, W.D., Vanmeter,
J.W., Cook, E.H., Stein, J.R., Vaidya, M.,  2011. Effect of dopamine transporter
genotype on caudate volume in childhood ADHD and controls. Am.  J. Med.
Genet. B Neuropsychiatr. Genet. 156B, 28–35.
Sigurdardottir, H.L., Kranz, G.S., Rami-Mark, C., James, G.M., Vanicek, T.,
Gryglewski, G., Kautzky, A., Hienert, M.,  Traub-Weidinger, T., Mitterhauser, M.,
Wadsak, W.,  Hacker, M.,  Rujescu, D., Kasper, S., Lanzenberger, R., 2015. Effects
of  norepinephrine transporter gene variants on NET binding in ADHD and
healthy controls investigated by PET. Hum. Brain Mapp.
Simchon, Y., Weizman, A., Rehavi, M., 2010. The effect of chronic methylphenidate
administration on presynaptic dopaminergic parameters in a rat model for
ADHD. Eur. Neuropsychopharmacol. 20, 714–720.
Simchon-Tenenbaum, Y., Weizman, A., Rehavi, M.,  2015. Alterations in brain
neurotrophic and glial factors following early age chronic methylphenidate
and cocaine administration. Behav. Brain Res. 282, 125–132.
Simon, V., Czobor, P., Balint, S., Meszaros, A., Bitter, I., 2009. Prevalence and
correlates of adult attention-deﬁcit hyperactivity disorder: meta-analysis. Br. J.
Psychiatry 194, 204–211.
Smit, D.J., Boersma, M.,  Van Beijsterveldt, C.E., Posthuma, D., Boomsma, D.I., Stam,
C.J., de Geus, E.J., 2010. Endophenotypes in a dynamically connected brain.
Behav. Genet. 40, 167–177.
Sobanski, E., Bruggemann, D., Alm, B., Kern, S., Deschner, M.,  Schubert, T., Philipsen,
A.,  Rietschel, M.,  2007. Psychiatric comorbidity and functional impairment in a
clinically referred sample of adults with attention-deﬁcit/hyperactivity
disorder (ADHD). Eur. Arch. Psychiatry Clin. Neurosci. 257, 371–377.
Soderqvist, S., Mcnab, F., Peyrard-Janvid, M.,  Matsson, H., Humphreys, K., Kere, J.,
Klingberg, T., 2010. The SNAP25 gene is linked to working memory capacity
and maturation of the posterior cingulate cortex during childhood. Biol.
Psychiatry 68, 1120–1125.
Sokolova, E., Hoogman, M.,  Groot, P., Claassen, T., Vasquez, A.A., Buitelaar, J.K.,
Franke, B., Heskes, T., 2015. Causal discovery in an adult ADHD data set
suggests indirect link between DAT1 genetic variants and striatal brain
activation during reward processing. Am. J. Med. Genet. B Neuropsychiatr.
Genet., epub ahead of print.
Sollner, T., Whiteheart, S.W., Brunner, M.,  Erdjument-Bromage, H., Geromanos, S.,
Tempst, P., Rothman, J.E., 1993. SNAP receptors implicated in vesicle targeting
and fusion. Nature 362, 318–324.
Spencer, T.J., Biederman, J., Madras, B.K., Faraone, S.V., Dougherty, D.D., Bonab, A.A.,
Fischman, A.J., 2005. In vivo neuroreceptor imaging in
attention-deﬁcit/hyperactivity disorder: a focus on the dopamine transporter.
Biol.  Psychiatry 57, 1293–1300.
Spencer, T.J., Biederman, J., Faraone, S.V., Madras, B.K., Bonab, A.A., Dougherty, D.D.,
Batchelder, H., Clarke, A., Fischman, A.J., 2013. Functional genomics of
attention-deﬁcit/hyperactivity disorder (ADHD) risk alleles on dopamine
transporter binding in ADHD and healthy control subjects. Biol. Psychiatry 74,
84–89.
Stahl, S.M., 2003. Neurotransmission of cognition, part 3. Mechanism of action of
selective NRIs: both dopamine and norepinephrine increase in prefrontal
cortex. J. Clin. Psychiatry 64, 230–231.
M. Klein et al. / Neuroscience and Biobehavioral Reviews 80 (2017) 115–155 153
Stein, J.L., Hua, X., Lee, S., Ho, A.J., Leow, A.D., Toga, A.W., Saykin, A.J., Shen, L.,
Foroud, T., Pankratz, N., Huentelman, M.J., Craig, D.W., Gerber, J.D., Allen, A.N.,
Corneveaux, J.J., Dechairo, B.M., Potkin, S.G., Weiner, M.W.,  Thompson, P.,
ALZHEIMER’S Disease Neuroimaging, I., 2010. Voxelwise genome-wide
association study (vGWAS). Neuroimage 53, 1160–1174.
Stein, J.L., Medland, S.E., Vasquez, A.A., Hibar, D.P., Senstad, R.E., Winkler, A.M.,
Toro, R., Appel, K., Bartecek, R., Bergmann, O., Bernard, M., Brown, A.A., Cannon,
D.M., Chakravarty, M.M.,  Christoforou, A., Domin, M.,  Grimm,  O., Hollinshead,
M., Holmes, A.J., Homuth, G., Hottenga, J.J., Langan, C., Lopez, L.M., Hansell, N.K.,
Hwang, K.S., Kim, S., Laje, G., Lee, P.H., Liu, X., Loth, E., Lourdusamy, A.,
Mattingsdal, M., Mohnke, S., Maniega, S.M., Nho, K., Nugent, A.C., O’brien, C.,
Papmeyer, M.,  Putz, B., Ramasamy, A., Rasmussen, J., Rijpkema, M., Risacher,
S.L., Roddey, J.C., Rose, E.J., Ryten, M.,  Shen, L., Sprooten, E., Strengman, E.,
Teumer, A., Trabzuni, D., Turner, J., Van Eijk, K., Van Erp, T.G., Van Tol, M.J.,
Wittfeld, K., Wolf, C., Woudstra, S., Aleman, A., Alhusaini, S., Almasy, L., Binder,
E.B.,  Brohawn, D.G., Cantor, R.M., Carless, M.A., Corvin, A., Czisch, M.,  Curran,
J.E., Davies, G., de Almeida, M.A., Delanty, N., Depondt, C., Duggirala, R., Dyer,
T.D.,  Erk, S., Fagerness, J., Fox, P.T., Freimer, N.B., Gill, M., Goring, H.H., Hagler,
D.J., Hoehn, D., Holsboer, F., Hoogman, M.,  Hosten, N., Jahanshad, N., Johnson,
M.P., Kasperaviciute, D., Kent Jr., J.W., Kochunov, P., Lancaster, J.L., Lawrie, S.M.,
Liewald, D.C., Mandl, R., Matarin, M.,  Mattheisen, M.,  Meisenzahl, E., Melle, I.,
Moses, E.K., Muhleisen, T.W., et al., 2012. Identiﬁcation of common variants
associated with human hippocampal and intracranial volumes. Nat. Genet. 44,
552–561.
Stergiakouli, E., Hamshere, M.,  Holmans, P., Langley, K., Zaharieva, I., de, C.G.,
Psychiatric, G.C., Hawi, Z., Kent, L., Gill, M.,  Williams, N., Owen, M.J., O’donovan,
M., Thapar, A., 2012. Investigating the contribution of common genetic variants
to  the risk and pathogenesis of ADHD. Am.  J. Psychiatry 169, 186–194.
Sterley, T.L., Howells, F.M., Russell, V.A., 2013a. Evidence for reduced tonic levels of
GABA in the hippocampus of an animal model of ADHD, the spontaneously
hypertensive rat. Brain Res. 1541, 52–60.
Sterley, T.L., Howells, F.M., Russell, V.A., 2013b. Maternal separation increases
GABA(A) receptor-mediated modulation of norepinephrine release in the
hippocampus of a rat model of ADHD, the spontaneously hypertensive rat.
Brain Res. 1497, 23–31.
Sugita, S., Ichtchenko, K., Khvotchev, M.,  Sudhof, T.C., 1998. alpha-Latrotoxin
receptor CIRL/latrophilin 1 (CL1) deﬁnes an unusual family of ubiquitous
G-protein-linked receptors. G-protein coupling not required for triggering
exocytosis. J. Biol. Chem. 273, 32715–32724.
Swistowski, A., Peng, J., Liu, Q., Mali, P., Rao, M.S., Cheng, L., Zeng, X., 2010. Efﬁcient
generation of functional dopaminergic neurons from human induced
pluripotent stem cells under deﬁned conditions. Stem Cells 28, 1893–1904.
Szobot, C., Roman, T., Cunha, R., Acton, P., Hutz, M.,  Rohde, L.A., 2005. Brain
perfusion and dopaminergic genes in boys with attention-deﬁcit/hyperactivity
disorder. Am.  J. Med. Genet. B Neuropsychiatr. Genet. 132B, 53–58.
Szobot, C.M., Roman, T., Hutz, M.H., Genro, J.P., Shih, M.C., Hoexter, M.Q., Junior, N.,
Pechansky, F., Bressan, R.A., Rohde, L.A., 2011. Molecular imaging genetics of
methylphenidate response in ADHD and substance use comorbidity. Synapse
65,  154–159.
Takahashi, K., Tanabe, K., Ohnuki, M.,  Narita, M.,  Ichisaka, T., Tomoda, K.,
Yamanaka, S., 2007. Induction of pluripotent stem cells from adult human
ﬁbroblasts by deﬁned factors. Cell 131, 861–872.
Takeuchi, H., Tomita, H., Taki, Y., Kikuchi, Y., Ono, C., Yu, Z., Sekiguchi, A., Nouchi, R.,
Kotozaki, Y., Nakagawa, S., Miyauchi, C.M., Iizuka, K., Yokoyama, R., Shinada, T.,
Yamamoto, Y., Hanawa, S., Araki, T., Hashizume, H., Kunitoki, K., Sassa, Y.,
Kawashima, R., 2015. Cognitive and neural correlates of the 5-repeat allele of
the dopamine D4 receptor gene in a population lacking the 7-repeat allele.
Neuroimage 110, 124–135.
Tamm,  L., Menon, V., Ringel, J., Reiss, A.L., 2004. Event-related FMRI evidence of
frontotemporal involvement in aberrant response inhibition and task
switching in attention-deﬁcit/hyperactivity disorder. J. Am.  Acad. Child
Adolesc. Psychiatry 43, 1430–1440.
ter Huurne, N., Onnink, M., Kan, C., Franke, B., Buitelaar, J., Jensen, O., 2013.
Behavioral consequences of aberrant alpha lateralization in
attention-deﬁcit/hyperactivity disorder. Biol. Psychiatry 74, 227–233.
Thapar, A., Cooper, M.,  Eyre, O., Langley, K., 2013. What have we learnt about the
causes of ADHD? J. Child Psychol. Psychiatry 54, 3–16.
Thapar, A., Martin, J., Mick, E., Arias Vasquez, A., Langley, K., Scherer, S.W.,
Schachar, R., Crosbie, J., Williams, N., Franke, B., Elia, J., Glessner, J., Hakonarson,
H., Owen, M.J., Faraone, S.V., O’donovan, M.C., Holmans, P., 2015. Psychiatric
gene discoveries shape evidence on ADHD’s biology. Mol. Psychiatry 21 (9),
1202–1207.
The Network Pathway Analysis Subgroup of The Psychiatric Genomics Consortium,
2015. Psychiatric genome-wide association study analyses implicate neuronal,
immune and histone pathways. Nat. Neurosci. 18, 199–209.
Thomason, M.E., Dougherty, R.F., Colich, N.L., Perry, L.M., Rykhlevskaia, E.I., Louro,
H.M., Hallmayer, J.F., Waugh, C.E., Bammer, R., Glover, G.H., Gotlib, I.H., 2010.
COMT genotype affects prefrontal white matter pathways in children and
adolescents. Neuroimage 53, 926–934.
Thompson, P.M., Stein, J.L., Medland, S.E., Hibar, D.P., Vasquez, A.A., Renteria, M.E.,
Toro, R., Jahanshad, N., Schumann, G., Franke, B., Wright, M.J., Martin, N.G.,
Agartz, I., Alda, M.,  Alhusaini, S., Almasy, L., Almeida, J., Alpert, K., Andreasen,
N.C., Andreassen, O.A., Apostolova, L.G., Appel, K., Armstrong, N.J., Aribisala, B.,
Bastin, M.E., Bauer, M.,  Bearden, C.E., Bergmann, O., Binder, E.B., Blangero, J.,
Bockholt, H.J., Boen, E., Bois, C., Boomsma, D.I., Booth, T., Bowman, I.J., Bralten,
J.,  Brouwer, R.M., Brunner, H.G., Brohawn, D.G., Buckner, R.L., Buitelaar, J.,
Bulayeva, K., Bustillo, J.R., Calhoun, V.D., Cannon, D.M., Cantor, R.M., Carless,
M.A., Caseras, X., Cavalleri, G.L., Chakravarty, M.M.,  Chang, K.D., Ching, C.R.,
Christoforou, A., Cichon, S., Clark, V.P., Conrod, P., Coppola, G., Crespo-Facorro,
B.,  Curran, J.E., Czisch, M.,  Deary, I.J., de Geus, E.J., Den Braber, A., Delvecchio, G.,
Depondt, C., de Haan, L., de Zubicaray, G.I., Dima, D., Dimitrova, R., Djurovic, S.,
Dong, H., Donohoe, G., Duggirala, R., Dyer, T.D., Ehrlich, S., Ekman, C.J.,
Elvsashagen, T., Emsell, L., Erk, S., Espeseth, T., Fagerness, J., Fears, S., Fedko, I.,
Fernandez, G., Fisher, S.E., Foroud, T., Fox, P.T., Francks, C., Frangou, S., Frey,
E.M., Frodl, T., Frouin, V., Garavan, H., Giddaluru, S., Glahn, D.C., Godlewska, B.,
Goldstein, R.Z., Gollub, R.L., Grabe, H.J., et al., 2014. The ENIGMA Consortium:
large-scale collaborative analyses of neuroimaging and genetic data. Brain
Imag. Behav. 8, 153–182.
Tian, L., Jiang, T., Wang, Y., Zang, Y., He, Y., Liang, M.,  Sui, M.,  Cao, Q., Hu, S., Peng,
M.,  Zhuo, Y., 2006. Altered resting-state functional connectivity patterns of
anterior cingulate cortex in adolescents with attention deﬁcit hyperactivity
disorder. Neurosci. Lett. 400, 39–43.
Toren, P., Rehavi, M.,  Luski, A., Roz, N., Laor, N., Lask, M.,  Weizman, A., 2005.
Decreased platelet vesicular monoamine transporter density in children and
adolescents with attention deﬁcit/hyperactivity disorder. Eur.
Neuropsychopharmacol. 15, 159–162.
Turic, D., Langley, K., Mills, S., Stephens, M.,  Lawson, D., Govan, C., Williams, N., Van
Den Bree, M.,  Craddock, N., Kent, L., Owen, M.,  O’donovan, M.,  Thapar, A., 2004.
Follow-up of genetic linkage ﬁndings on chromosome 16p13: evidence of
association of N-methyl-D aspartate glutamate receptor 2A gene
polymorphism with ADHD. Mol. Psychiatry 9, 169–173.
Turic, D., Langley, K., Williams, H., Norton, N., Williams, N.M., Moskvina, V., Van
Den  Bree, M.B., Owen, M.J., Thapar, A., O’donovan, M.C., 2005. A family based
study implicates solute carrier family 1-member 3 (SLC1A3) gene in
attention-deﬁcit/hyperactivity disorder. Biol. Psychiatry 57, 1461–1466.
Tzang, R.F., Hsu, C.D., Liou, Y.J., Hong, C.J., Tsai, S.J., 2014. Family-based association
study of ciliary neurotrophic factor receptor and norepinephrine transporter
genes in attention-deﬁcit hyperactivity disorder. Psychiatr. Genet. 24, 118–119.
Urbach, A., Bar-Nur, O., Daley, G.Q., Benvenisty, N., 2010. Differential modeling of
fragile X syndrome by human embryonic stem cells and induced pluripotent
stem cells. Cell Stem Cell 6, 407–411.
Urban, A.E., Purmann, C., 2015. Using iPSCs and genomics to catch CNVs in the act.
Nat. Genet. 47, 100–101.
Vadodaria, K.C., Mertens, J., Paquola, A., Bardy, C., Li, X., Jappelli, R., Fung, L.,
Marchetto, M.C., Hamm, M.,  Gorris, M.,  Koch, P., Gage, F.H., 2015. Generation of
functional human serotonergic neurons from ﬁbroblasts. Mol. Psychiatry.
Valbonesi, S., Magri, C., Traversa, M.,  Faraone, S.V., Cattaneo, A., Milanesi, E.,
Valenti, V., Gennarelli, M.,  Scassellati, C., 2015. Copy number variants in
attention-deﬁcit hyperactive disorder: identiﬁcation of the 15q13 deletion and
its  functional role. Psychiatr. Genet. 25, 59–70.
Valera, E.M., Faraone, S.V., Murray, K.E., Seidman, L.J., 2007. Meta-analysis of
structural imaging ﬁndings in attention-deﬁcit/hyperactivity disorder. Biol.
Psychiatry 61, 1361–1369.
Vanderwert, R.E., Nelson, C.A., 2014. The use of near-infrared spectroscopy in the
study of typical and atypical development. Neuroimage 85 (Pt 1), 264–271.
van der Meer, D., Hartman, C.A., Richards, J., Bralten, J.B., Franke, B., Oosterlaan, J.,
Heslenfeld, D.J., Faraone, S.V., Buitelaar, J.K., Hoekstra, P.J., 2014. The serotonin
transporter gene polymorphism 5-HTTLPR moderates the effects of stress on
attention-deﬁcit/hyperactivity disorder. J. Child Psychol. Psychiatry 55 (12),
1363–1371.
van der Meer, D., Hoekstra, P.J., Zwiers, M.,  Mennes, M.,  Schweren, L.J., Franke, B.,
Heslenfeld, D.J., Oosterlaan, J., Faraone, S.V., Buitelaar, J.K., Hartman, C.A., 2015.
Brain correlates of the interaction between 5-HTTLPR and psychosocial stress
mediating attention deﬁcit hyperactivity disorder severity. Am.  J. Psychiatry
172,  768–775.
van der Meer, D., Hoekstra, P.J., Bralten, J., Van Donkelaar, M., Heslenfeld, D.J.,
Oosterlaan, J., Faraone, S.V., Franke, B., Buitelaar, J.K., Hartman, C.A., 2016.
Interplay between stress response genes associated with attention-deﬁcit
hyperactivity disorder and brain volume. Genes Brain Behav. 15, 627–636.
van der Voet, M.,  Nijhof, B., Oortveld, M.A., Schenck, A., 2014. Drosophila models of
early onset cognitive disorders and their clinical applications. Neurosci.
Biobehav. Rev. 46 (Pt 2), 326–342.
van der Voet, M.,  Harich, B., Franke, B., Schenck, A., 2016. ADHD-associated
dopamine transporter, latrophilin and neuroﬁbromin share a
dopamine-related locomotor signature in Drosophila. Mol. Psychiatry 21,
565–573.
van Diessen, E., Numan, T., Van Dellen, E., Van Der Kooi, A.W., Boersma, M.,
Hofman, D., Van Lutterveld, R., Van Dijk, B.W., Van Straaten, E.C., Hillebrand, A.,
Stam, C.J., 2015. Opportunities and methodological challenges in EEG and MEG
resting state functional brain network research. Clin. Neurophysiol. 126,
1468–1481.
van Ewijk, H., Heslenfeld, D.J., Zwiers, M.P., Buitelaar, J.K., Oosterlaan, J., 2012.
Diffusion tensor imaging in attention deﬁcit/hyperactivity disorder: a
systematic review and meta-analysis. Neurosci. Biobehav. Rev. 36, 1093–1106.
van Ewijk, H., Heslenfeld, D.J., Zwiers, M.P., Faraone, S.V., Luman, M.,  Hartman, C.A.,
Hoekstra, P.J., Franke, B., Buitelaar, J.K., Oosterlaan, J., 2014. Different
mechanisms of white matter abnormalities in attention-deﬁcit/hyperactivity
disorder: a diffusion tensor imaging study. J. Am. Acad. Child Adolesc.
Psychiatry 53, 790–799, e793.
van Ewijk, H., Bralten, J., Van Duin, E., Hakobjan, M.,  Hoogman, M.,  Oosterlaan, J.,
Franke, B., Female-speciﬁc association of NOS1 genotype with white matter
154 M. Klein et al. / Neuroscience and Biobehavioral Reviews 80 (2017) 115–155
microstructure in ADHD patients and controls. J. Child Psychol. Psychiatry, (in
revision).
van Hulzen, K.J., Scholz, C.J., Franke, B., Ripke, S., Klein, M.,  McQuillin, A.,
Sonuga-Barke, E.J., Kelsoe, J.R., Landen, M.,  Andreassen, O.A., Lesch, K.P., Weber,
H.,  Faraone, S.V., Arias-Vasquez, A., Reif, A., 2016. Genetic Overlap Between
Attention-Deﬁcit/Hyperactivity Disorder and Bipolar Disorder: Evidence From
Genome-wide Association Study Meta-analysis. Biol. Psychiatry.
van Pelt, S., Boomsma, D.I., Fries, P., 2012. Magnetoencephalography in twins
reveals a strong genetic determination of the peak frequency of visually
induced gamma-band synchronization. J. Neurosci. 32, 3388–3392.
van Rooij, D., Hartman, C.A., Van Donkelaar, M.M.,  Bralten, J., Von Rhein, D.,
Hakobjan, M.,  Franke, B., Heslenfeld, D.J., Oosterlaan, J., Rommelse, N., Buitelaar,
J.K., Hoekstra, P.J., 2015a. Variation in serotonin neurotransmission genes
affects neural activation during response inhibition in adolescents and young
adults with ADHD and healthy controls. World J. Biol. Psychiatry 16, 625–634.
van Rooij, D., Hoekstra, P.J., Bralten, J., Hakobjan, M.,  Oosterlaan, J., Franke, B.,
Rommelse, N., Buitelaar, J.K., Hartman, C.A., 2015b. Inﬂuence of DAT1 and
COMT variants on neural activation during response inhibition in adolescents
with attention-deﬁcit/hyperactivity disorder and healthy controls. Psychol.
Med. 45, 3159–3170.
van Rooij, D., Hoekstra, P.J., Mennes, M.,  Von Rhein, D., Thissen, A.J., Heslenfeld, D.,
Zwiers, M.P., Faraone, S.V., Oosterlaan, J., Franke, B., Rommelse, N., Buitelaar,
J.K.,  Hartman, C.A., 2015c. Distinguishing adolescents with ADHD from their
unaffected siblings and healthy comparison subjects by neural activation
patterns during response inhibition. Am.  J. Psychiatry 172, 674–683.
van Tol, H.H., Wu,  C.M., Guan, H.C., Ohara, K., Bunzow, J.R., Civelli, O., Kennedy, J.,
Seeman, P., Niznik, H.B., Jovanovic, V., 1992. Multiple dopamine D4 receptor
variants in the human population. Nature 358, 149–152.
Villemonteix, T., de Brito, S.A., Slama, H., Kavec, M.,  Baleriaux, D., Metens, T., Baijot,
S., Mary, A., Ramoz, N., Septier, M.,  Gorwood, P., Peigneux, P., Massat, I., 2015.
Structural correlates of COMT Val158Met polymorphism in childhood ADHD: a
voxel-based morphometry study. World J. Biol. Psychiatry 16, 190–199.
Villringer, A., Chance, B., 1997. Non-invasive optical spectroscopy and imaging of
human brain function. Trends Neurosci. 20, 435–442.
Voineagu, I., Wang, X., Johnston, P., Lowe, J.K., Tian, Y., Horvath, S., Mill, J., Cantor,
R.M., Blencowe, B.J., Geschwind, D.H., 2011. Transcriptomic analysis of autistic
brain reveals convergent molecular pathology. Nature 474, 380–384.
Volkow, N.D., Wang, G.J., Newcorn, J., Telang, F., Solanto, M.V., Fowler, J.S., Logan, J.,
Ma,  Y., Schulz, K., Pradhan, K., Wong, C., Swanson, J.M., 2007. Depressed
dopamine activity in caudate and preliminary evidence of limbic involvement
in  adults with attention-deﬁcit/hyperactivity disorder. Arch. Gen. Psychiatry
64, 932–940.
von Rhein, D., Cools, R., Zwiers, M.P., van der Schaaf, M.,  Franke, B., Luman, M.,
Oosterlaan, J., Heslenfeld, D.J., Hoekstra, P.J., Hartman, C.A., Faraone, S.V., van
Rooij, D., van Dongen, E.V., Lojowska, M.,  Mennes, M.,  Buitelaar, J., 2015.
Increased neural responses to reward in adolescents and young adults with
attention-deﬁcit/hyperactivity disorder and their unaffected siblings. J. Am.
Acad. Child Adolesc. Psychiatry 54, 394–402.
Waider, J., Araragi, N., Gutknecht, L., Lesch, K.P., 2011. Tryptophan hydroxylase-2
(TPH2) in disorders of cognitive control and emotion regulation: a perspective.
Psychoneuroendocrinology 36, 393–405.
Walitza, S., Renner, T.J., Dempﬂe, A., Konrad, K., Wewetzer, C., Halbach, A.,
Herpertz-Dahlmann, B., Remschmidt, H., Smidt, J., Linder, M., Flierl, L., Knolker,
U.,  Friedel, S., Schafer, H., Gross, C., Hebebrand, J., Warnke, A., Lesch, K.P., 2005.
Transmission disequilibrium of polymorphic variants in the tryptophan
hydroxylase-2 gene in attention-deﬁcit/hyperactivity disorder. Mol. Psychiatry
10, 1126–1132.
Wallis, D., Arcos-Burgos, M.,  Jain, M.,  Castellanos, F.X., Palacio, J.D., Pineda, D.,
Lopera, F., Stanescu, H., Pineda, D., Berg, K., Palacio, L.G., Bailey-Wilson, J.E.,
Muenke, M.,  2009. Polymorphisms in the neural nicotinic acetylcholine
receptor alpha4 subunit (CHRNA4) are associated with ADHD in a genetic
isolate. Atten. Deﬁc. Hyperact. Disord. 1, 19–24.
Wallis, D., Hill, D.S., Mendez, I.A., Abbott, L.C., Finnell, R.H., Wellman, P.J., Setlow, B.,
2012. Initial characterization of mice null for Lphn3, a gene implicated in
ADHD and addiction. Brain Res. 1463, 85–92.
Walther, D.J., Peter, J.U., Bashammakh, S., Hortnagl, H., Voits, M.,  Fink, H., Bader, M.,
2003. Synthesis of serotonin by a second tryptophan hydroxylase isoform.
Science 299, 76.
Wang, E., Ding, Y.C., Flodman, P., Kidd, J.R., Kidd, K.K., Grady, D.L., Ryder, O.A.,
Spence, M.A., Swanson, J.M., Moyzis, R.K., 2004. The genetic architecture of
selection at the human dopamine receptor D4 (DRD4) gene locus. Am.  J. Hum.
Genet. 74, 931–944.
Wang, M., Zhong, Z., Zhong, Y., Zhang, W.,  Wang, H., 2015a. The zebraﬁsh period2
protein positively regulates the circadian clock through mediation of retinoic
acid receptor (RAR)-related orphan receptor alpha (Roralpha). J. Biol. Chem.
290, 4367–4382.
Wang, P., Lin, M.,  Pedrosa, E., Hrabovsky, A., Zhang, Z., Guo, W.,  Lachman, H.M.,
Zheng, D., 2015b. CRISPR/Cas9-mediated heterozygous knockout of the autism
gene CHD8 and characterization of its transcriptional networks in
neurodevelopment. Mol. Autism 6, 55.
Weber, P., Lutschg, J., Fahnenstich, H., 2005. Cerebral hemodynamic changes in
response to an executive function task in children with attention-deﬁcit
hyperactivity disorder measured by near-infrared spectroscopy. J. Dev. Behav.
Pediatr. 26, 105–111.
Weber, H., Scholz, C.J., Jacob, C.P., Heupel, J., Kittel-Schneider, S., Erhardt, A.,
Hempel, S., Schmidt, B., Kiel, T., Gessner, A., Lesch, K.P., Reif, A., 2014. SPOCK3, a
risk gene for adult ADHD and personality disorders. Eur. Arch. Psychiatry Clin.
Neurosci. 264, 409–421.
Weber, H., Kittel-Schneider, S., Heupel, J., Weissﬂog, L., Kent, L., Freudenberg, F.,
Alttoa, A., Post, A., Herterich, S., Haavik, J., Halmoy, A., Fasmer, O.B., Landaas,
E.T.,  Johansson, S., Cormand, B., Ribases, M.,  Sanchez-Mora, C., Ramos-Quiroga,
J.A.,  Franke, B., Lesch, K.P., Reif, A., 2015. On the role of NOS1 ex1f-VNTR in
ADHD-allelic, subgroup, and meta-analysis. Am.  J. Med. Genet. B
Neuropsychiatr. Genet., epub ahead of print.
Wen, Z., Nguyen, H.N., Guo, Z., Lalli, M.A., Wang, X., Su, Y., Kim, N.S., Yoon, K.J., Shin,
J.,  Zhang, C., Makri, G., Nauen, D., Yu, H., Guzman, E., Chiang, C.H., Yoritomo, N.,
Kaibuchi, K., Zou, J., Christian, K.M., Cheng, L., Ross, C.A., Margolis, R.L., Chen, G.,
Kosik, K.S., Song, H., Ming, G.L., 2014. Synaptic dysregulation in a human iPS
cell model of mental disorders. Nature 515, 414–418.
Whittle, S., Simmons, J.G., Dennison, M.,  Vijayakumar, N., Schwartz, O., Yap, M.B.,
Sheeber, L., Allen, N.B., 2014. Positive parenting predicts the development of
adolescent brain structure: a longitudinal study. Dev. Cogn. Neurosci. 8, 7–17.
Wilens, T.E., Biederman, J., Faraone, S.V., Martelon, M.,  Westerberg, D., Spencer, T.J.,
2009. Presenting ADHD symptoms, subtypes, and comorbid disorders in
clinically referred adults with ADHD. J. Clin. Psychiatry 70, 1557–1562.
Williams, J., Sagvolden, G., Taylor, E., Sagvolden, T., 2009a. Dynamic behavioural
changes in the Spontaneously Hyperactive Rat: 1. Control by place, timing, and
reinforcement rate. Behav. Brain Res. 198, 273–282.
Williams, J., Sagvolden, G., Taylor, E., Sagvolden, T., 2009b. Dynamic behavioural
changes in the spontaneously hyperactive rat: 2. control by novelty. Behav.
Brain Res. 198, 283–290.
Williams, J., Sagvolden, G., Taylor, E., Sagvolden, T., 2009c. Dynamic behavioural
changes in the Spontaneously Hyperactive Rat: 3. Control by reinforcer rate
changes and predictability. Behav. Brain Res. 198, 291–297.
Williams, N.M., Zaharieva, I., Martin, A., Langley, K., Mantripragada, K., Fossdal, R.,
Stefansson, H., Stefansson, K., Magnusson, P., Gudmundsson, O.O., Gustafsson,
O.,  Holmans, P., Owen, M.J., O’donovan, M.,  Thapar, A., 2010. Rare chromosomal
deletions and duplications in attention-deﬁcit hyperactivity disorder: a
genome-wide analysis. Lancet 376, 1401–1408.
Williams, N.M., Franke, B., Mick, E., Anney, R.J., Freitag, C.M., Gill, M.,  Thapar, A.,
O’donovan, M.C., Owen, M.J., Holmans, P., Kent, L., Middleton, F., Zhang-James,
Y., Liu, L., Meyer, J., Nguyen, T.T., Romanos, J., Romanos, M., Seitz, C., Renner, T.J.,
Walitza, S., Warnke, A., Palmason, H., Buitelaar, J., Rommelse, N., Vasquez, A.A.,
Hawi, Z., Langley, K., Sergeant, J., Steinhausen, H.C., Roeyers, H., Biederman, J.,
Zaharieva, I., Hakonarson, H., Elia, J., Lionel, A.C., Crosbie, J., Marshall, C.R.,
Schachar, R., Scherer, S.W., Todorov, A., Smalley, S.L., Loo, S., Nelson, S., Shtir, C.,
Asherson, P., Reif, A., Lesch, K.P., Faraone, S.V., 2012. Genome-wide analysis of
copy number variants in attention deﬁcit hyperactivity disorder: the role of
rare variants and duplications at 15q13.3. Am. J. Psychiatry 169, 195–204.
Willsey, A.J., Sanders, S.J., Li, M.,  Dong, S., Tebbenkamp, A.T., Muhle, R.A., Reilly, S.K.,
Lin,  L., Fertuzinhos, S., Miller, J.A., Murtha, M.T., Bichsel, C., Niu, W.,  Cotney, J.,
Ercan-Sencicek, A.G., Gockley, J., Gupta, A.R., Han, W.,  He, X., Hoffman, E.J., Klei,
L.,  Lei, J., Liu, W.,  Liu, L., Lu, C., Xu, X., Zhu, Y., Mane, S.M., Lein, E.S., Wei, L.,
Noonan, J.P., Roeder, K., Devlin, B., Sestan, N., State, M.W.,  2013. Coexpression
networks implicate human midfetal deep cortical projection neurons in the
pathogenesis of autism. Cell 155, 997–1007.
Winkler, A.M., Kochunov, P., Blangero, J., Almasy, L., Zilles, K., Fox, P.T., Duggirala,
R.,  Glahn, D.C., 2010. Cortical thickness or grey matter volume? The
importance of selecting the phenotype for imaging genetics studies.
Neuroimage 53, 1135–1146.
Womersley, J.S., Dimatelis, J.J., Russell, V.A., 2015. Proteomic analysis of maternal
separation-induced striatal changes in a rat model of ADHD: the
spontaneously hypertensive rat. J. Neurosci. Methods 252, 64–74.
Wu,  J., Xiao, H., Sun, H., Zou, L., Zhu, L.Q., 2012. Role of dopamine receptors in
ADHD: a systematic meta-analysis. Mol. Neurobiol. 45, 605–620.
Wu,  Z., Yang, L., Wang, Y., 2014. Applying imaging genetics to ADHD: the promises
and the challenges. Mol. Neurobiol. 50 (2), 449–462.
Wu,  Z.M., Bralten, J., Cao, Q.J., Hoogman, M., Zwiers, M.P., An, L., Sun, L., Yang, L.,
Zang, Y.F., Franke, B., Wang, Y.F., 2016. White matter microstructural
alterations in children with ADHD: categorical and dimensional perspectives.
Neuropsychopharmacology 42 (2), 572–580.
Xiao, T., Xiao, Z., Ke, X., Hong, S., Yang, H., Su, Y., Chu, K., Xiao, X., Shen, J., Liu, Y.,
2012. Response inhibition impairment in high functioning autism and
attention deﬁcit hyperactivity disorder: evidence from near-infrared
spectroscopy data. PLoS One 7, e46569.
Xu, X., Brookes, K., Sun, B., Ilott, N., Asherson, P., 2009. Investigation of the
serotonin 2C receptor gene in attention deﬁcit hyperactivity disorder in UK
samples. BMC  Res. Notes 2, 71.
Yang, J.-W., Jang, W.-S., Hong, S.D., Ji, Y.I., Kim, D.H., Park, J., Kim, S.W., Joung, Y.S.,
2008. A case-control association study of the polymorphism at the promoter
region of the DRD4 gene in Korean boys with attention deﬁcit-hyperactivity
disorder: evidence of association with the – 521 C/T SNP. Prog.
Neuro-Psychopharmacol. Biol. Psychiatry 32, 243–248.
Yang, L., Neale, B.M., Liu, L., Lee, S.H., Wray, N.R., Ji, N., Li, H., Qian, Q., Wang, D., Li,
J., Faraone, S.V., Wang, Y., Psychiatric, G.C.A.S., Doyle, A.E., Reif, A.,
Rothenberger, A., Franke, B., Sonuga-Barke, E.J., Steinhausen, H.C., Buitelaar,
J.K., Kuntsi, J., Biederman, J., Lesch, K.P., Kent, L., Asherson, P., Oades, R.D., Loo,
S.K., Nelson, S.F., Faraone, S.V., Smalley, S.L., Banaschewski, T., Arias Vasquez,
A., Todorov, A., Charach, A., Miranda, A., Warnke, A., Thapar, A., Neale, B.M.,
Cormand, B., Freitag, C., Mick, E., Mulas, F., Middleton, F.,
Hakonarsonhakonarson, H., Palmason, H., Schafer, H., Roeyers, H., Mcgough,
J.J.,  Romanos, J., Crosbie, J., Meyer, J., Ramos-Quiroga, J.A., Sergeant, J., Elia, J.,
M. Klein et al. / Neuroscience and Biobehavioral Reviews 80 (2017) 115–155 155
Langely, K., Nisenbaum, L., Romanos, M.,  Daly, M.J., Ribases, M.,  Gill, M.,
O’donovan, M.,  Owen, M.,  Casas, M.,  Bayes, M.,  Lambregts-Rommelse, N.,
Williams, N., Holmans, P., Anney, R.J., Ebstein, R.P., Schachar, R., Medland, S.E.,
Ripke, S., Walitza, S., Nguyen, T.T., Renner, T.J., Hu, X., 2013. Polygenic
transmission and complex neuro developmental network for attention deﬁcit
hyperactivity disorder: genome-wide association study of both common and
rare variants. Am.  J. Med. Genet. B Neuropsychiatr. Genet. 162B, 419–430.
Yoncheva, Y.N., Somandepalli, K., Reiss, P.T., Kelly, C., di Martino, A., Lazar, M.,
Zhou, J., Milham, M.P., Castellanos, F.X., 2016. Mode of anisotropy reveals
global diffusion alterations in attention-deﬁcit/hyperactivity disorder. J. Am.
Acad. Child Adolesc. Psychiatry 55, 137–145.
Yu, J., Vodyanik, M.A., Smuga-Otto, K., Antosiewicz-Bourget, J., Frane, J.L., Tian, S.,
Nie,  J., Jonsdottir, G.A., Ruotti, V., Stewart, R., Slukvin, I.I., Thomson, J.A., 2007.
Induced pluripotent stem cell lines derived from human somatic cells. Science
318,  1917–1920.
Zang, Y.F., He, Y., Zhu, C.Z., Cao, Q.J., Sui, M.Q., Liang, M.,  Tian, L.X., Jiang, T.Z., Wang,
Y.F.,  2007. Altered baseline brain activity in children with ADHD revealed by
resting-state functional MRI. Brain Dev. 29, 83–91.
Zayats, T., Athanasiu, L., Sonderby, I., Djurovic, S., Westlye, L.T., Tamnes, C.K., Fladby,
T., Aase, H., Zeiner, P., Reichborn-Kjennerud, T., Knappskog, P.M., Knudsen, G.P.,
Andreassen, O.A., Johansson, S., Haavik, J., 2015. Genome-wide analysis of
attention deﬁcit hyperactivity disorder in Norway. PLoS One 10, e0122501.
Zhang, Y.S., Pak, C., Han, Y., Ahlenius, H., Zhang, Z.J., Chanda, S., Marro, S., Patzke, C.,
Acuna, C., Covy, J., Xu, W.,  Yang, N., Danko, T., Chen, L., Wernig, M.,  Sudhof, T.C.,
2013. Rapid single-step induction of functional neurons from human
pluripotent stem cells. Neuron 78, 785–798.
Zhao, L., Lin, Y., Lao, G., Wang, Y., Guan, L., Wei, J., Yang, Z., Ni, P., Li, X., Jiang, Z., Li,
T., Hao, X., Lin, D., Cao, L., Ma,  X., 2015. Association study of dopamine receptor
genes polymorphism with cognitive functions in bipolar I disorder patients. J.
Affect. Disord. 170, 85–90.
Zhou, K., Dempﬂe, A., Arcos-Burgos, M.,  Bakker, S.C., Banaschewski, T., Biederman,
J.,  Buitelaar, J., Castellanos, F.X., Doyle, A., Ebstein, R.P., Ekholm, J., Forabosco, P.,
Franke, B., Freitag, C., Friedel, S., Gill, M.,  Hebebrand, J., Hinney, A., Jacob, C.,
Lesch, K.P., Loo, S.K., Lopera, F., Mccracken, J.T., Mcgough, J.J., Meyer, J., Mick, E.,
Miranda, A., Muenke, M.,  Mulas, F., Nelson, S.F., Nguyen, T.T., Oades, R.D.,
Ogdie, M.N., Palacio, J.D., Pineda, D., Reif, A., Renner, T.J., Roeyers, H.,  Romanos,
M.,  Rothenberger, A., Schafer, H., Sergeant, J., Sinke, R.J., Smalley, S.L.,
Sonuga-Barke, E., Steinhausen, H.C., Van Der Meulen, E., Walitza, S., Warnke, A.,
Lewis, C.M., Faraone, S.V., Asherson, P., 2008. Meta-analysis of genome-wide
linkage scans of attention deﬁcit hyperactivity disorder. Am.  J. Med. Genet. B
Neuropsychiatr. Genet. 147B, 1392–1398.
Zhu, J., Lee, K.P., Spencer, T.J., Biederman, J., Bhide, P.G., 2014. Transgenerational
transmission of hyperactivity in a mouse model of ADHD. J. Neurosci. 34,
2768–2773.
Zhuang, X., Oosting, R.S., Jones, S.R., Gainetdinov, R.R., Miller, G.W., Caron, M.G.,
Hen, R., 2001. Hyperactivity and impaired response habituation in
hyperdopaminergic mice. Proc. Natl. Acad. Sci. U. S. A. 98, 1982–1987.
Zimmer, L., 2009. Positron emission tomography neuroimaging for a better
understanding of the biology of ADHD. Neuropharmacology 57, 601–607.
Zimmermann, A.M., Jene, T., Wolf, M.,  Gorlich, A., Gurniak, C.B., Sassoe-Pognetto,
M.,  Witke, W.,  Friauf, E., Rust, M.B., 2015. Attention-deﬁcit/hyperactivity
disorder-like phenotype in a mouse model with impaired actin dynamics. Biol.
Psychiatry 78, 95–106.
Zuo, L., Saba, L., Lin, X., Tan, Y., Wang, K., Krystal, J.H., Tabakoff, B., Luo, X., 2015.
Signiﬁcant association between rare IPO11-HTR1A variants and attention
deﬁcit hyperactivity disorder in Caucasians. Am. J. Med. Genet. B
Neuropsychiatr. Genet. 168, 544–556.
